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RECOVERY FROM COMMUNITY ACQUIRED PNEUMONIA.   
A PhD Thesis by Daniel Gower Wootton 
Aims 
To measure symptomatic recovery over a year among an adult cohort 
recruited from hospital with community acquired pneumonia (CAP).  To 
measure the host recovery mechanism efferocytosis and the diversity of 
the bacterial microbiota in sputum and relate these to individual 
characteristics of subjects in the cohort. 
Methods 
Patients with CAP were recruited from two hospitals in Liverpool, (UK) 
and were followed-up for one year.  The CAP-sym questionnaire was 
completed at multiple time-points in order to create a statistical model 
of symptomatic recovery.  DNA was extracted from acute sputum 
samples and 16S rRNA sequencing revealed the diversity of bacteria in 
sputum.  At one month into recovery subjects volunteered for 
bronchoalveolar lavage and rates of efferocytosis were measured by co-
culturing ex-vivo alveolar macrophages with apoptotic autologous 
neutrophils.  
Results 
The 169 subjects recruited with CAP were found to have high levels of 
socio-economic deprivation, smoking and COPD and the median age 
was 64 years.  A non-linear, longitudinal, statistical model of symptoms 
found that smoking impaired recovery but people tended to describe 
better recovery as they got older.  Efferocytosis was impaired by 
smoking but improved by statins and these effects were modified by 
body mass index.  Those with prior pulmonary disease had lower 
bacterial diversity in their sputum and in this cohort a species from the 
genus Haemophilus was dominant.   
Conclusion 
This work proves the principal that modelling CAP-sym scores can be 
used to investigate factors associated with differential recovery from 
CAP.  It highlights the detrimental effects of smoking on both recovery 
and efferocytosis.   This is the first study to show that the bacterial 
diversity of CAP sputum is influenced by prior lung disease.  The 
translational outcomes are the potential for trials of statins as pro-
recovery agents and to study modified empirical antibiotics for those 
with CAP and prior-lung disease. 
ABSTRACT.   
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1 INTRODUCTION AND LITERATURE REVIEW 
1.1 Defining Community Acquired Pneumonia 
1.1.1 What is Pneumonia? 
The term pneumonia is old.  In the 5th Century BC Hippocrates is 
said to have referred to it as ‘a disease of the ancients’.[1]  
Hippocrates was using the term in a clinical context and defined 
its features:- 
“… if fever be acute, and if there be pains on either side, or in both, 
and…if cough be present, and the sputa expectorated be of a blond 
or livid colour…” [1] 
For practicing clinicians today, pneumonia remains a syndromic, 
clinical diagnosis based upon a combination of signs, symptoms, 
and where available, radiological findings.  It describes a patient 
with an acute lower respiratory tract infection, positive 
examination findings and associated systemic features such as 
fever.  Post-mortem examination of lungs from patients who have 
died with this syndrome reveals the distal airways and lung 
parenchyma filled with an inflammatory infiltrate that is 
predominantly neutrophilic.[2]  This has led to the expansion of 
the term pneumonia to include the pathological finding of distal 
airway and parenchymal inflammation in general, including non-
infective inflammation - for example ‘eosinophilic pneumonia’, 
‘cryptogenic organising pneumonia’ and ‘non-specific interstitial 
pneumonia’.[3]  The pneumonic infiltrate can sometimes be seen 
on a plain chest x-ray (CXR) or computed tomography (CT) scan 
where it is associated with a new set of terminology based on its 
extent and anatomical distribution.[4,5]    
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1.1.2 What is Community acquired pneumonia? 
A patient with pneumonia who has not had a recent hospital 
admission is described as having community acquired pneumonia 
(CAP).  The site of acquisition is relevant as it distinguishes this 
syndrome from others such as hospital acquired pneumonia 
(HAP) and ventilator acquired pneumonia (VAP).  CAP includes 
those who have aspirated a large volume of oropharyngeal 
contents or vomitus.[6]  This phenomenon is thought to be 
common in the elderly and in those with neurological deficit.[7]  
Most studies of CAP exclude patients where aspiration 
pneumonia is strongly suspected but in routine clinical practice it 
is difficult to verify when pneumonia has developed as a 
consequence of aspiration.  In the United States of America 
another entity, Health Care Associated Pneumonia (HCAP), is 
recognised.[8]  This is pneumonia which develops in a patient who 
resides in a nursing home or other healthcare institution where 
the use of antibiotics is common.  Neither the UK British Thoracic 
Society (BTS) guidelines nor the recent National Institute of 
Clinical Excellence (NICE) pneumonia guidelines recognise HCAP 
as a separate phenomenon as the evidence for a different 
spectrum of organisms and or outcome is weak; these patients are 
treated as CAP. [9,10]  Defining the various pneumonia 
syndromes above enables the clinician to empirically target 
therapy towards a particular spectrum of aetiological agents that 
are associated with each.  Definitions of CAP differ across 
national guidelines and within individual guidelines there may be 
several definitions applicable to different clinical settings – for 
example primary and secondary care.  For the purposes of this 
thesis the ‘in hospital’ definition of CAP found in the BTS 
Guidelines for the management of CAP will be used and are 
reproduced in figure 1.1.[6]    
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CAP in hospital has been defined as: 
1 Symptoms and signs consistent with an acute lower respiratory tract 
infection*  
2 Associated with new radiographic shadowing for which there is no other 
explanation (e.g. not pulmonary oedema or infarction). 
3 The illness is the primary reason for hospital admission and is managed 
as pneumonia. 
4 The patient has not been in hospital in the last 10 days. 
*An acute lower respiratory tract infection is defined as: 
1 Cough and at least one other lower respiratory tract symptom (e.g. 
chest pain).   
2 New focal chest signs on examination.   
3 At least one systemic feature (either a symptom complex of sweating, 
fevers, shivers, aches and pains and/or temperature of 38˚C or more). 
 
1.1.3 Imprecision associated with the definition of CAP 
The BTS definition of CAP requires the identification of a new 
infiltrate on a CXR but it is recognised that levels of inter-user 
agreement in the interpretation of CXRs can be low and that this 
reduces the precision of the diagnosis of CAP (see figures 1.2, 1.3, 
1.4 and 1.5).[11]   Moreover, although the term CAP has become 
widely adopted into clinical practice it has not yet been recognised 
by The World Health Organisation (WHO) International 
Classification of Diseases (ICD).  The most up to date iteration of 
this document, WHO ICD-10, includes 18 major codes which are 
further sub-divided into 42 sub-codes for infective pneumonia.[12]   
Community acquired pneumonia does not easily map to any single 
one of these ICD-10 codes and this can cause inconsistencies when 
institutions and researchers try to assess the incidence of CAP.   
Figure 1.1 BTS in-hospital definition of CAP 
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Figure 1.2 PASS subject admission CXR Figure 1.3 Repeat CXR at follow up one month later 
These are examples of relatively straightforward chest x-rays in the context of a patient with a clinical syndrome consistent with CAP.  
The acute film on the left shows diffuse opacification throughout the right lung field.  The recovery film at one month reveals good 
resolution.  These films would likely produce high levels of agreement among reporting clinicians. 





Figure 1.4 Patient screened for PASS Figure 1.5 CT slice through the thorax of the same patient 
The film on the left is more ambiguous than figure 1.2.  This patient had a clinical syndrome compatible with CAP but pleuritic chest 
pain and hypoxia were prominent.  A CT pulmonary angiogram excluded pulmonary embolus and revealed left basal consolidation 
behind the heart, in the x-rays ‘blind spot’. 
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1.2 Epidemiology of Hospitalised CAP in the UK 
1.2.1 Incidence 
In the UK, between 5 and 11 of every 1000 adults develop 
community acquired pneumonia (CAP) each year.[6]  In 1992/3 
the National Health Service (NHS) treated 16.3 million episodes 
of lower respiratory tract infection (LRTI) and classified 261000 
(1.6%) as CAP of which 32% was admitted hospital.[13]  Between 
1997/8 and 2004/5 the annual, age-standardised incidence of 
admission to hospital with CAP increased by 34% from 1.48 to 
1.98 per 1000 of the UK population.[14] 
1.2.2 Seasonality 
Pneumonia is a disease of the cold winter months and the UK 
peak is normally around the weeks surrounding Christmas / New 
Year.[15]  This trend is not restricted to the UK and a strong 
relationship with climate and in particular ambient air 
temperature has been demonstrated.  In Japan, for every 1°C fall 
in temperature the rates of CAP increased by 0.03%.[16]         
1.2.3 Age 
CAP is a disease of the extremes of age.  It is common in children 
under the age of 5 and incidence increases exponentially in adults 
for every decile above 55 years.[17,18]  In the UK whilst the 
incidence of CAP hospitalisation has increased across all adult 
age groups the greatest increase (39%) has been in the most 
elderly (>85 years).[14]  In the year 2009/10 the mean age of 
adults admitted to UK hospitals with CAP was 71 years.[19]  
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1.2.4 Comorbidity 
Pneumonia is an illness associated phenomenon.  It is strongly 
associated with a wide range of comorbidities and in most cases a 
pre-existing chronic condition or recently acquired comorbidity 
(such as viral respiratory tract infection) can be identified.[20]  As 
might be expected pneumonia rates are high among those with 
inherited or acquired immune deficiency.[21]  However, in 
addition to this a range of other chronic conditions predispose to 
pneumonia in particular pre-existing chronic lung disease and 
smoking.[22]   
Patients recovering from CAP are at a significantly increased risk 
of death for at least the next year when compared to control 
patients.[23]  This risk seems to be greatest in the elderly and is 
associated with comorbidity, [24-26]  in particular there is a 
widely reported increased risk of cardiovascular morbidity and 
mortality following CAP.[27]      
1.2.5 Aetiology and antimicrobial treatment 
Current evidence suggests that, in adults, CAP is most frequently 
caused by bacteria and because of this patients are given 
antibiotics.[6]  This is clearly an effective strategy as CAP 
mortality rates following the development of penicillin fell 
dramatically.[28]  To be most effective antibiotics need to be given 
as soon as possible and this does not leave enough time to 
determine which bacteria are causing the pneumonia.  Traditional 
diagnostic tests require culturing a clinical specimen, isolating 
the causative species and then determining which antibiotic it is 
susceptible to.  This process currently takes 2-3 days.  Therefore, 
at the time of commencing treatment the antibiotic choice is 
‘empirical’, that is a best guess based on the most likely causative 
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organism.  To help clinicians choose the most suitable empirical 
antibiotic, guidelines are drawn-up with various options for 
particular patient groups and circumstances.  These guidelines 
are based on studies that have described the incidence of bacteria 
cultured from large numbers of people with CAP (see Table 1.1).  
Large prospective studies of CAP aetiology in the UK have 
demonstrated the importance of Streptococcus pneumoniae as the 
commonest causative organism of CAP.  However, these studies 
only achieve a confirmed microbiological diagnosis in up to 50% of 
patients.[29]  In routine clinical practice the causative organism 
of CAP is determined in less than 15% of hospital cases.[29,30]  
There are a number of reasons why detection rates are so low in 
CAP.  Cultures of bacteria may be impaired if patients have 
recently taken antibiotics. Some bacteria are technically more 
difficult to culture and therefore we are only able to grow 1% of 
bacterial species that can be detected by molecular testing.[31,32]. 
As a consequence of these factors we have an incomplete 
understanding of the range of bacteria that cause CAP.  The 
resulting empirical use of combination broad-spectrum antibiotics 
is associated with complications that are avoidable with more 
targeted therapy.[33]  In the last 10 years antigen detection tests 
have become widely available for detecting Streptococcus 
pneumoniae and Legionella pneumophila in urine.  These tests 
are very specific. The Legionella antigen test is much more 
sensitive than culture alone and the pneumococcal antigen test, 
when combined with culture of blood and sputum detects some 
additional cases of pneumococcal disease.[34]  In the UK these 
antigen tests are now recommended for all severe CAP cases.   
Recently developed multiplex quantitative polymerase chain 
reaction (qPCR) tests have the potential to markedly improve the 
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speed and precision of microbiological diagnosis in CAP.[35]  
Several of these platforms include a range of bacterial and viral 
qPCR based techniques.[36]  If these techniques could be made 
more rapid then pre-treatment aetiological diagnosis would allow 
the use of targeted antibiotic therapy resulting in decreased 
antibiotic resistance and reduced antibiotic-related 
complications.[37,38]  However, these qPCR platforms are limited 
to the detection of specific agents that are believed, a priori to be 
potential pathogens and do not help determine the full range of 
potential pathogens in an individual.  There is a need for studies 
to look again at the aetiological agents in CAP using the 
comprehensive tools used in microbiome studies to determine 
what may account for the large number of culture negative cases 
in order to validate current treatment guidelines (see 1.6).   
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Aetiological Agent Mean % (95% CI) 
Streptococcus pneumoniae 39 (36.1 to 41.8) 
Haemophilus influenzae 5.2 (4.0 to 6.6) 
Legionella spp. 3.6 (2.6 to 4.9) 
Staphylococcus aureus 1.9 (1.2 to 2.9) 
Moraxella catarrhalis 1.9 (0.6 to 4.3) 
Gram-negative enteric bacteria 1.0 (0.5 to 1.7) 
Mycoplasma pneumoniae 10.8 (9.0 to 12.6) 
Chlamydophila pneumoniae 13.1 (9.1 to 17.2) 
Chlamydophila psittaci 2.6 (1.7 to 3.6) 
Coxiella burnetii 1.2 (0.7 to 2.1) 
All viruses 12.8 (10.8 to 14.7) 
Influenza A and B 10.7 (8.9 to 12.5) 
Mixed 14.2 (12.2 to 16.3) 
Other 2 (1.3 to 3) 
None 30.8 (28.1 to 33.5) 




1.3 Outcome following CAP 
1.3.1 Choice of outcome measure matters 
Following an episode of CAP a range of outcomes can be measured 
against which we can prognosticate or assess the efficacy of 
interventions.  Each has its own inherent strengths, weaknesses 
and applicability.  Various studies have sought to link patient 
characteristics to a range of outcomes.  However few of the 
traditional outcome measures used have been rigorously validated 
in CAP.  Barlow et al. argued strongly for the inclusion of patient 
based outcome measures in studies of CAP and for more rigour 
when matching outcome measures to the design of studies.[39]  
The above is based on data presented in the BTS CAP 
guidelines [6] and comprises data from 5 UK studies and a 
total of 1137 patients.  
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1.3.2 Clinical cure 
Therapeutic trials of antimicrobials have commonly used clinical 
cure as an end-point.  Clinical cure is determined by a clinician.  
It has no consistent definition.  It generally implies that the 
clinician felt there was no longer a requirement for antibiotic.  It 
is highly likely to be subject to significant inter and intra-clinician 
variation and it is not clear exactly which domains it is 
measuring.[40]  As an example of its application, a recent 
antibiotic randomised controlled trial used clinical cure as its 
primary outcome measure of efficacy.[41]  Clinical cure was not 
defined in the publication, but the protocol which is available as 
an online supplement, defines clinical cure as “Total resolution of 
all signs and symptoms of pneumonia, or improvement to such an 
extent that further antimicrobial therapy is not necessary”.[42]  
This definition of cure is ambiguous and open to a range of 
interpretations. 
1.3.3 Clinical stability 
Several authors have proposed formal physiological criteria for 
clinical stability that include factors such as resolution of pyrexia 
and hypoxia.[43]  Clinical stability has then been used to make 
practical clinical decisions such as switching from intra-venous to 
oral antibiotics and the duration of antibiotics.[43,44]  Clinical 
stability as a concept has been shown to be safe and the use of 
this endpoint is now incorporated into guidelines although criteria 
vary depending on the application.[10] 
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1.3.4 Mortality 
CAP mortality rates in the UK are amongst the highest in Europe 
and each year 34,000 patients die.[6]  The 2009/10 British 
Thoracic Society (BTS) audit of CAP demonstrated an in-patient 
mortality of 21% for CAP managed in UK hospitals.[19]  Of the 
7% admitted to intensive care over 50% die.[6,19]  However, these 
results confirm that most patients hospitalised for CAP survive 
their initial infective insult to be discharged back to the 
community.  Moreover mortality in the 70% of CAP treated in the 
community is <1%.[6]  Therefore mortality may be a useful 
outcome in certain populations where death rates are high – for 
example the very elderly or those admitted to intensive care – but 
for less severe CAP in hospital and for those managed in the 
community the event rate is low and using mortality as the 
primary outcome measure would provide no information as to the 
clinical course of those who survived.      
1.3.5 Health Economics of UK CAP 
In 1992/3 the annual direct healthcare costs of CAP were 
estimated at £440 million and this figure will have increased with 
the increase in CAP hospital admission rates.[13,14]  Although 
only 32% of patients with CAP are admitted to hospital they 
account for 96% of the total NHS CAP expenditure.[13]  The 
health and economic consequences of CAP extend beyond the 
period of acute management.    Many patients will not return to 
work for days or weeks following a period of hospitalisation with 
CAP.  Others will have been carers and will be too frail to return 
to caring necessitating periods of respite for their dependents.  
Few studies have taken into account these post-discharge costs. 
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1.3.6 Length of stay 
Length of stay is an important measure for hospital managers 
and commissioners since a night in a hospital bed is so expensive.  
However, length of stay is influenced by many factors that are not 
directly related to the severity or aetiology of the CAP or to the 
quality of care received.[45]  Most CAP occurs in the winter when 
the NHS invariably has a hospital bed crisis and clinicians face a 
huge pressure to discharge patients as soon as possible.  
Moreover, due to regional differences in demographics and 
socioeconomic factors some hospitals will be more affected than 
others by discharge delays due to lack of availability of residential 
and nursing home places.            
1.3.7 Readmissions 
A significant number of patients are re-admitted to hospital 
following an episode of pneumonia. A Spanish study found that 
2.5% of patients were re-admitted within 30 days with pneumonia 
related problems and 4.6% were readmitted with non-pneumonia 
related problems.[46].  In a study specifically designed to capture 
medium and long-term morbidity associated with re-admission, 
Johstone et al. found 2% of their cohort were re-admitted with 
pneumonia within 30 days of hospital discharge and a further 9% 
by one year.[24]  In addition to these re-admissions there were a 
significant number of non-pneumonia re-admissions.  Adamuz 
and colleagues looked not only at re-admissions to hospital but 
contact with healthcare in general following a CAP discharge.[47]  
They found that within 30 days of discharge 17% of patients 
presented to primary care with ongoing symptoms.  10% of 
patients presented to emergency departments with pneumonia 
related symptoms, 9% with non-pneumonia symptoms and 2% 
with a combination of pneumonia and non-pneumonia symptoms.  
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3% of patients were re-admitted due to pneumonia, 4% due to 
non-pneumonia illnesses and 1.6% with a combination of 
pneumonia and non-pneumonia problems.  Rates of re-admission 
are difficult to compare across countries with different healthcare 
systems and even vary within regions of the UK due to the 
availability of out-of-hours primary care provision.  However 
these studies demonstrate that despite being well enough to be 
discharged, for some patients, CAP is associated with substantial 
ongoing morbidity.  
1.3.8 Patient based CAP outcomes 
It is now widely accepted that a key component of healthcare 
delivery is the involvement of patients in decision making and 
management of their conditions.[48]  Patients’ experiences and 
expectations are now understood to be vital metrics of quality 
care.[49]  Patients receiving a diagnosis of community acquired 
pneumonia (CAP) often ask “how long will it take to get better?”  
The literature reveals that answering this question is more 
difficult that it might seem.  The British Lung Foundation (BLF) 
advice leaflet on pneumonia suggests patients should not expect 
to feel back to normal for several weeks or months following CAP 
– but does not suggest who might take weeks or who might take 
months.[50]  Bruns et al. assessed recovery at 10 and 28 days 
following an episode of CAP of moderate severity.  Their measures 
of recovery were chest x-ray (CXR) resolution (assessed by a 
radiologist), clinical recovery (assessed by a doctor) and patient 
reported recovery (assessed by using a symptom score).[51]  They 
found discrepancies between all measures of recovery.  Doctors 
declared the patients ‘recovered’ long before the patients’ 
symptom score demonstrated they actually felt better.  CXR 
resolution lagged behind doctor defined recovery but CXR 
    15 
 
abnormalities were deemed resolved at a stage when many 
patients had yet to recover their symptom scores.  Each of these 
modalities, clinical assessment, radiology and symptom 
evaluation has a role to play in the assessment of patients 
following pneumonia.  Chest x-rays (CXRs) are performed with 
the aim of screening for an underlying pathology, such as lung 
cancer, or for identifying pneumonia associated complications 
such as empyema.  Clinical assessment, supported by bio-markers 
can be used to inform acute management decisions such as 
duration of antibiotic therapy or day of safe discharge.[52]  But 
only symptom scoring has been formally validated as an outcome 
measure in community acquired pneumonia (CAP).[39]   
1.4 Symptomatic recovery from CAP 
1.4.1 Validity of symptom questionnaires 
A number of studies have used patient based techniques to assess 
symptomatic recovery from CAP.  In a prospective study of LRTI 
in the community 35% of patients took longer than 7 days to 
return to normal activity.[53]  Other groups suggest thirty 
percent of patients have not regained normal function after four 
weeks.[54,55]  The validity of a healthcare outcome is determined 
by the application of the techniques of psychometrics to 
healthcare – sometimes referred to as clinimetrics.[56]  This 
involves testing an outcome measure for its responsiveness (can it 
detect change in a patient’s condition), reliability (e.g. same result 
from two different observers) and validity (does the outcome 
measure what it purports to measure).  In the studies that have 
investigated symptomatic recovery from CAP most have used 
scoring systems that have not been validated.[39]  However there 
are two scoring systems which measure symptomatic recovery 
from CAP that have been psychometrically validated: the ‘CAP 
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SCORE’ developed by a group from the Netherlands and the 
‘CAP-sym questionnaire’ developed in the UK.[57,58]. 
1.4.2 The CAP SCORE 
The CAP SCORE is divided into two sections and can be 
decomposed to give an overall CAP SCORE and two sub-scores for 
respiratory symptoms and well-being.  The respiratory section 
enquires about 3 symptoms – shortness of breath, cough and 
sputum production.  The well-being section has two questions – 
‘fitness’ and ‘general state of health’.  The questionnaire uses 
mixed methods – the fitness question is a visual Likert scale and 
the other questions require the patient to choose one of several 
possible answers.  When the numerical values for each question 
are summed the lower the CAP SCORE the worse a patient is 
feeling.  During the validation study of this score the authors 
noted that the well-being scores took longer to improve than the 
respiratory component.[57]  They also noted a lack of correlation 
between CAP SCORE and either the severity of CXR abnormality 
or speed of resolution of CXR findings.  A follow-on study showed 
that resolution of respiratory symptoms in a cohort with CAP 
preceded the resolution of general well-being.  The mean value of 
respiratory symptoms for the group had returned to baseline by 
14 days where as the well-being mean took six months to 
normalise.[59]  No statistically significant associations were found 
between patient characteristics and recovery defined as >80% of 
the pre-morbid score.  One major criticism of this study of 
recovery is that patients who deteriorated in the first 3 days of 
treatment were excluded meaning this is a study of patient pre-
destined to do well. 
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1.4.3 The CAP-sym questionnaire 
The community acquired pneumonia (CAP) symptom (sym) 
questionnaire stands out among all other pneumonia symptom 
tools for the rigor applied during its design and validation.[60]  A 
long-list of component questions was created by trained 
interviewers formally consulting 33 patients, drawn from the US 
and France, at a number of stages during pneumonia treatment.  
The resulting list of symptoms was then forwards and backwards 
translated by linguistic experts into 13 languages (English plus 12 
others).  The 18 question CAP-sym questionnaire was then tested 
within a randomised controlled pneumonia treatment trial among 
556 patients from 13 countries.  Validation used gold standard 
psychometric techniques.  The final validated score consists of 18 
questions which are asked by the study team member and it can 
be completed in about 2 minutes.  A shorter version including just 
12 of the 18 questions has very similar performance 
characteristics to the full version.  Of note, during the validation 
of the CAP-sym questionnaire it was compared to a generic health 
questionnaire (SF-36) and was found to be more responsive to 
changes in the clinical state of patients with pneumonia.      
1.5 The Pathophysiology of CAP 
1.5.1 Host pathogen interactions 
The factors associated with differential recovery from CAP are not 
clear however it is likely both host and pathogen factors play a 
part.[61,62]  On the host side the resolution of the acute 
inflammation associated with CAP is essential for good recovery.  
Kruger et al. demonstrated that peak levels of several 
inflammatory and stress related biomarkers predicted mortality 
at 28 days.[63]  Yende et al. showed that the acute phase cytokine 
IL-6 is elevated in many patients at the time of discharge 
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following CAP and that there was a correlation between IL-6 level 
and adverse events in the subsequent 3 months.[64]  From the 
pathogen side it is clear that the pneumonia syndrome a patient 
experiences is influenced by the causative organism.  For example 
the CAPNETZ cohort produced a number of papers describing in 
detail the similarities and differences between clinical 
characteristics and outcome among a large number of CAP cases 
of defined aetiology.  They found that CAP caused by Mycoplasma 
pneumoniae was more likely to occur in younger patients, was a 
much less severe condition (lower severity scores, commonly out-
patients) and the mean C-reactive protein level was a third of that 
in CAP caused by other confirmed pathogens.[65]  In contrast, 
CAP caused by Legionella pneumophila was indistinguishable 
from CAP of other causes.[66]  CAP associated with Streptococcus 
pneumoniae was more severe, more frequently treated in hospital 
and associated with higher rates of complications such as pleural 
effusions than the syndrome associated with other proven 
pathogens.[67]     
1.5.2 Quiescent immune homeostasis in the healthy lung 
(see figure 1.6) The distal regions of healthy lungs contain very 
few neutrophils and each alveolus contains on average one 
resident alveolar macrophage.[68]  Alveolar macrophages are the 
principle phagocyte in the distal airway but also play a vital role 
as the interface between the innate and adaptive immune 
system.[69]  In particular, via direct contact with the alveolar 
epithelium, they are the effectors of epithelial regulation of 
immune activation state in the lung.[70]  When the alveolar 
epithelium is in an unthreatened homeostatic resting state, 
alveolar macrophages are subject to tonic inhibition in comparison 
to those in other anatomical sites.[71]  This is desirable as the 
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lung is constantly challenged by antigen.  There are on average 
190,000 airborne bacteria per cubic metre of the low earth 
atmospheric air that we breathe, although this concentration 
varies in response to climatic, topographical and human 
geographical factors between 104 and 107/m-3.[72]  Our lower 
airway is in unbroken mucosal continuity with the mouth and 
nasopharynx which harbour very high concentrations of bacteria.  
Gleeson et al. showed that if you infuse radio-labelled technetium 
into the nose of normal people during normal sleep, the next 
morning a gamma camera will demonstrate isotope throughout 
the lung parenchyma of at least 50% of subjects.[73]  Bacteria 
therefore continuously reach the lung via the air we breathe, by 
direct outgrowth across mucosal surfaces and by low-volume 
aspiration of nasopharyngeal secretions.  If all of these bacterial 
challenges were to elicit a full blown immune response then the 
resulting continuous inflammation would make gas-exchange 
impossible.  Anatomical features such as airway bifurcations and 
mechanical features such as the mucociliary escalator reduce the 
total burden of bacteria that reach the lung.  Moreover, bacteria 
that do reach the airway find it an inhospitable environment.  The 
lumen of the airway is rendered nutritionally barren by the action 
of various host scavenger molecules – a defence strategy referred 
to as nutritional immunity.[74]  The mucosal lining fluid is 
suffused with multiple soluble antimicrobial compounds which 
are either directly toxic or inhibit bacterial growth; examples 
include lactoferrin[75], lysozyme [76], phospholipase A2 [77], 
defensins and cathelicidins [78] collectins and surfactant 
proteins[79].  Having run the gauntlet of these defences, bacteria 
that reach the lung encounter alveolar macrophages, which 
although subject to T-regulatory cell suppression and inhibition 
by the epithelium, remain active phagocytes.[80] 





homeostasis in the 
lower airway 
 
Wootton DG et al.  The pathophysiology of pneumococcal pneumonia.  In: Chalmers JD, Aliberti S, Pletz M, eds. European Respiratory Society Monograph: Community-Acquired 
Pneumonia. 63rd Edn. European Respiratory Society, 2014; 42-63  Reproduced with permission of the European Respiratory Society © 
A healthy alveolar epithelium is vital to the maintenance of innate immune homeostasis in the lung. A: Alveolar lining fluid is 
nutritionally barren and replete with antimicrobial compounds. B: Bacteria are lysed by secreted innate factors such as lysozyme, 
phospholipase-A2 and surfactant proteins (SP) A and D. C: Induction of an anti-inflammatory phenotype in alveolar macrophages. 
Phagocytic functions are maintained but the ability to present antigen and secrete pro-inflammatory cytokines is suppressed by 
surfactant proteins, granulocyte-macrophage colony-stimulating factor, interleukin-10 and transforming growth factor-b, and the 
CD200 and signal regulatory protein alpha (SIRPα ) interactions. 
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1.5.3 Macrophage / epithelial interactions in the early 
development of CAP  
Most of the time, for most people, the innate-host defence defeats 
the constant tide of bacterial intruders into the airway.  The 
earliest events surrounding the switch from quietly dealing with 
bacteria to the development of the inflammatory ‘total war’ seen 
in pneumonia are unclear.  Most of the bacteria that cause 
pneumonia are frequent visitors to the lung and why they should 
be tolerated most of the time but cause potentially fatal disease 
on other occasions is debated.[81]  Bacterial density seems to 
matter.  Many bacteria have the ability to phenotypically switch 
to a more virulent form when they quorum sense their population 
is thriving.[82]  Virulence often means tissue damage as bacteria 
attempt to gain access to nutrients by lysing host cells.[83]  Tissue 
damage is a potent inducer of innate immune activation via the 
release of damage-associated molecular pattern (DAMPs) 
molecules.[84]  Early in the development of pneumonia DAMPs 
are spilled by damaged alveolar epithelium.[85]  These soluble 
DAMPs are macrophage activators.  Moreover macrophages, 
previously suppressed by CD200 interactions whilst anchored to 
intact epithelium, become highly susceptible to activation when 
released from damaged cells.[86]      
1.5.4 Macrophage neutrophil interactions in CAP 
(see figure 1.7) With the removal of epithelial restraints, alveolar 
macrophages become activated in the presence of bacteria and 
rapidly escalate the production of pro-inflammatory cytokines.[87]  
In particular they are responsible for the early burst of 
chemokines, such as CXCL8, which lead to the ingress of 
neutrophils from alveolar capillaries.[88]  Once neutrophils 
numbers build, paracrine effects result in positive feedback loops 
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which lead luminal neutrophils to become the major producers of 
cytokine and chemokine in the lung.  Alongside the recruitment of 
neutrophils from the circulation, this chemokine production leads 
to the influx of tissue macrophages from the lung 
parenchyma.[89]  In addition to their key role in the initiation of 
the pneumonic inflammatory response, alveolar macrophages 
have an equally vital role in tempering and eventually resolving 
inflammation.  In particular they act as a check on neutrophil 
numbers and activation state. [90]   
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Figure 1.7 The 
evolution of an 
acute inflammatory 
response that 




Wootton DG et al.  The pathophysiology of pneumococcal pneumonia.  In: Chalmers JD, Aliberti S, Pletz M, eds. European Respiratory Society Monograph: Community-Acquired 
Pneumonia. 63rd Edn. European Respiratory Society, 2014; 42-63  Reproduced with permission of the European Respiratory Society © 
Pneumococcal pneumonia is the result of overwhelming numbers of pneumococci provoking an inflammatory response orchestrated by 
alveolar macrophages that have been unrestrained by a damaged, activated epithelium. A: Pneumolysin breaches the cell walls 
releasing damage-associated molecular patterns. B: Macrophages recognise opsonised pneumococci and non-opsonised pneumococci via 
Toll-like receptor-2 and platelet activating factor receptor interactions with the pneumococcal cell wall constituents. C: Pneumolysin 
recognition leads to activation of the NLRP3 inflammasome. D: Activated neutrophils translocate across the endothelium and 
epithelium into the alveolar lumen. E: Macrophages present antigen to dendritic cells and migrate to regional lymph nodes. The red 
arrows represent inflammatory cytokine and chemokine (e.g. CXCL8) release by activated macrophages and epithelium. 
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1.5.5 Efferocytosis  
If bacterial replication and metabolism are arrested by antibiotics 
then neutrophils can reduce the numbers of bacteria to safe 
levels.  Neutrophils are terminally differentiated and they 
eventually enter a process of programmed cell death called 
apoptosis.[91]  As a consequence, during pneumonia the lung is 
filled with cellular debris such as hyaluronan and dead and dying 
neutrophils.[92]  Clearing this dead ‘self’ material is the job of 
alveolar macrophages and is called efferocytosis.[93]  As they 
apoptose neutrophils release DAMPs such as ADP which act as 
macrophage chemo-attractants.[94]  Macrophages recognise 
apoptotic cells and material destined for efferocytosis via a range 
of receptors.  Many apoptotic ligands and phagocyte efferocytotic 
receptors have been described.[91]  CD44 is a receptor for 
degradation fragments of hyaluronan which is the main 
component of human extra-cellular matrix. [92]  CD44 is 
expressed at uniquely high levels on macrophages and is crucial 
in the recognition of apoptotic neutrophils in mice. [95]  
Phosphatidylserine (PS) is a constituent of cell walls that is 
usually hidden on the inner surface.  During apoptosis the 
enzyme phospholipid translocase stops functioning and PS is 
exposed on the outer wall leaflet where it can be recognised by 
macrophage scavenger receptors.[91]   
1.5.6 Efferocytosis is defective in chronic inflammatory lung 
conditions  
Efferocytosis is vital in the resolution of inflammation in the 
lung.[96]  Not only does efferocytosis reduce the numbers of 
potentially damaging neutrophils but the act of efferocytosis 
induces an anti-inflammatory phenotype on the macrophage 
itself.[97]  This results in increased levels of several anti-
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inflammatory factors including transforming growth factor-β 
(TGF-β).[98]  Therefore following an episode of pneumonia the 
effectiveness of efferocytosis may be associated with the rate and 
extent of symptom resolution.  Efferocytosis can be measured ex-
vivo by culturing alveolar macrophages with a labelled apoptotic 
challenge then observing either microscopically or by flow 
cytometry the proportion of macrophages that contain the 
apoptotic cells.[99]  In several chronic inflammatory lung 
conditions efferocytosis has been shown to be defective and 
therapeutic intervention to improve efferocytosis has been 
suggested.[100]  Azithromycin has been shown to improve 
efferocytosis of apoptosed bronchial epithelial cells by alveolar 
macrophages taken from patients with chronic obstructive 
pulmonary disease (COPD).[101]  Statins have been shown to 
improve the efferocytosis of apoptotic neutrophils by alveolar 
macrophages from patients with COPD.[102]  If rates of 
efferocytosis were demonstrated to vary among patients 
recovering from CAP, and if these differences could be linked to 
symptomatic recovery, then this would raise the possibility that 
pro-resolution treatment aimed at enhancing efferocytosis could 
be trialled.  
1.6 The lung microbiome and its relationship with 
CAP 
1.6.1 Sequencing the 16S rRNA gene to identify bacteria 
As discussed above a defining feature of community acquired 
pneumonia (CAP) is its infectious aetiology.  Despite this, even 
the most rigorous contemporary attempts to describe the 
microbiological epidemiology of CAP achieve positive pathogen 
identification in only 50% of cases.  The identification of bacteria 
in a sample using culture is hampered by our limited ability to 
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culture the majority of bacterial species.[103]  An alternative to 
culture is to identify the presence of bacteria in a sample by 
detecting ‘bacteria only’ genes.  The three main branches of life, 
Eukarya (which includes among others humans and fungi) 
Archacea, and Bacteria can be separated by differences in the 
gene that encodes for ribosomal RNA.[104]   Ribosomes are split 
into two sub-units and each contains a length of RNA.  Ribosomal 
RNA (rRNA) is measured by the Svedberg unit (S) which is a 
measure of sedimentation rate. The rRNA found in the bacterial 
small ribosomal subunit is 16 Svedbergs (16S).[105]  Ribosomal 
RNA plays a fundamental role and the gene that encodes 
bacterial rRNA, the 16S rRNA gene, is highly conserved.  
However within the 16S rRNA gene are regions which are 
variable and sequence differences in these variable regions are 
approximately species specific.[106]  If universal primers, which 
cover the variable region of the 16S rRNA gene, are used in a PCR 
reaction and the products sequenced, then by referencing online 
sequence data-bases the bacteria in a sample can be identified.   
1.6.2 Microbiome and microbiota 
The methodology above has been used to describe the bacteria 
present in a wide range of environmental niches.[107]  Related 
molecular techniques can identify fungi and viruses and the 
complete range of microorganisms in a sample is referred to as 
the microbiota.  The relationships between the constituents of a 
microbiota, how they react and adapt to specific characteristics, is 
largely a function of their genes and the totality of genes in a 
sample has been termed the “microbiome”.  This nomenclature is 
not universally adhered to and many general articles use the 
terms microbiota and microbiome interchangeably.  Since 2008 
the Human Microbiome Project (HMP) has sought to describe the 
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range and interactions of bacteria from selected anatomical sites 
such as the skin, gut and female reproductive tract of healthy 
individuals.[108]  Perturbations in the microbome between health 
and select disease states (e.g. type II diabetes and inflammatory 
bowel disease) have also been studied by the HMP.  Importantly, 
at the time the Human Microbiome Project was conceived the 
lower respiratory tract was not included as a site for investigation 
largely due to controversy surrounding the paradigm of the 
healthy lung’s bacterial sterility and the invasive methods 
required for obtaining samples.  As an example of the output of 
the Human Microbiome Project figure 1.8 demonstrates the 
current understanding of the bacterial ecology of human skin. 
 







Figure 1.8 The microbiota of human skin 
Publically available image reproduced from the Unites 





In the above schematic diagram it can be seen that different 
bacterial phyla thrive in different anatomical niches.  It should 
be noted that differences at the taxonomic level of phylum are 
profound and bacteria of the phylum firmicutes are as different 
from bacteria of the phylum actinobacteria, as a sponge 
(kingdom Animalia, phylum porifera) is from an elephant 
(kingdom Animalia, phylum chordata). 
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1.6.3 The microbiota of the healthy lung 
As mentioned above, the lung is constantly challenged by 
bacteria.  Bowers et al. described the range of bacteria recovered 
from the air of US Mid-Western Cities.[109]  They filtered the air 
and using bead beating and methods optimised for soil samples 
they extracted the DNA and sequenced variable regions of the 16S 
rRNA gene using the Roche 454 FLX platform (described in detail 
in chapter 5).  They found a strong seasonal signal with winter 
bacterial concentrations being on average 52% lower than in the 
Summer.  Summer samples were dominated by soil and plant 
derived bacteria.  Samples from the winter months, when the soil 
is less moist and plants have fewer leaves, were dominated by 
bacteria derived from dog faeces!  Since we breathe 6 or more 
litres of this air a minute the fact that some of these bacteria 
reach the lung is not controversial.  However, determining 
whether any of the bacteria that reach the lung by inhalation or 
aspiration take up residence there, establishing a community 
adapted to the lung as a niche, is more difficult to prove.  
Charlson et al. used an elaborate and rigorous methodology to 
sample the length of the healthy airway whilst minimising the 
impact of oral contamination of the samples.[110]  By analysing 
bronchoalveolar lavage (BAL) samples they consistently found 
bacteria in the lung.  However, the bacteria detected in BAL were 
numerically smaller in quantity (3 orders of magnitude lower) and 
compositionally indistinguishable from mouth samples.  Moreover 
within subject comparisons of paired samples (e.g. oral, upper-
airway and BAL) were always more closely related than was 
sample type (e.g. BAL) compared between subjects.  The summary 
conclusions were that a) there are bacteria in the lung in health, 
b) they are derived from the upper respiratory tract and mouth c) 
they are not established residents but transients.  This last 
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observation is important and is based on the long established 
environmental observation that community composition is 
exquisitely sensitive to even the smallest differences between 
niches suggesting that, since the lung is physiochemically 
different from the mouth, any established lung microbiome would 
be clearly distinguishable from a mouth microbiome in the same 
individual.            
1.6.4 The microbiota of chronic stable lung disease 
Hilty et al. compared the bacterial microbiota of BAL obtained 
from patients with COPD, asthma and healthy controls.[111]  The 
healthy samples contained a similar pattern of bacteria to the 
Charlson study described above with the bacterial phyla 
Firmicutes (including the genera Staphylococcus and 
Streptococcus) and Bacteroides (in particular the genus 
Prevotella) dominating.  However there were very distinct 
differences in the patients with airways disease.  Both asthma 
and COPD were characterised by a comparative increase in the 
abundance of Proteobacteria (including the genera Haemophilus 
and Neisseria).  Importantly, this paper also demonstrated that in 
health oral samples and lung samples were similar but in disease 
the lung samples diverged from the oral samples.  This suggests 
that environmental changes in the lung in the context of lung 
disease are associated with the emergence of a distinct, resident, 
colonising bacterial microbiota. 
Erb-Downward et al.  conducted a similar study to investigate the 
bacterial microbiota of healthy non-smokers, ‘healthy’ smokers 
and patients with spirometrically proven COPD.[112]   They used 
quantitative PCR of the 16S rRNA gene to compare levels of 
bacteria across conditions and found no statistically significant 
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differences.  However, when they investigated the range of 
bacteria their findings were similar to the two studies previously 
mentioned.  BAL from healthy smokers diverged from the oral 
samples suggesting that even before the establishment of COPD 
smoking had altered the lower airway environment in such a way 
as to promote the establishment of a distinct, adapted microbiota.  
BAL from patients with COPD had reduced bacterial diversity 
which was associated with the dominance of a particular genus – 
most commonly Pseudomonas or Haemophilus. 
1.6.5 Microbiota of respiratory samples in acute lung disease 
Huang et al. analysed the bacterial microbiota in tracheal 
aspirates from 8 patients who had been intubated and ventilated 
for “exacerbation of COPD”.[113]  They found a range of bacteria 
in these samples but the patients had been intubated for an 
average of 10 days at the time of sampling and had received on 
average 18 days of antibiotic.  Therefore it is not possible to draw 
any inferences as to the causal relationship between the 
microbiota and the exacerbation from this study.  It is interesting 
to note however that despite large quantities of antibiotic bacteria 
remained detectable in culture negative lung samples.  Fodor et 
al.  conducted a longitudinal analysis of self-expectorated sputum 
from 23 patients with cystic fibrosis.[114]  The samples were 
taken at exacerbation (pre-antibiotic) during treatment and then 
during stability.  They found that CF sputum was dominated by 
Pseudomonas and Burkholderia but changed very little before 
during or after antibiotic.  They also showed that mouthwash 
samples were nearly identical to sputum samples highlighting 
again than the lower respiratory tract is likely challenged by, and 
in disease states colonised by, oral flora.   
    32 
 
1.7 What are the gaps in the literature? 
1.7.1 Recovery from CAP 
Only two studies have used validated, pneumonia specific, patient 
based tools to describe symptom patterns in CAP.  Each study 
used a different tool meaning each has been tested only once.  
Given the current drive to personalise medicine and involve 
patients more closely in the optimisation of processes of care it 
would seem vital to re-use these tools in a contemporary cohort.  
Moreover, it is likely that symptoms, particularly when 
systematically quantified, will detect more subtle perturbations in 
a patient’s condition than blunt outcomes such as mortality or 
length of stay.    
1.7.2 Efferocytosis and CAP  
To date there are no studies exploring the relationship between 
patient factors, efferocytosis and symptom recovery following 
pneumonia.  Yet since efferocytosis plays such a vital role in 
returning the lung to its neutrophil free homeostatic state, it 
seems highly likely that differential rates of efferocytosis will 
affect levels of inflammation in the lung and therefore respiratory 
and systemic symptoms.  This is a cellular mechanism that has 
already been shown to be amenable to therapeutic manipulation 
and this raises the possibility that, if it is found to be deficient in 
some patients recovering from CAP, treatment trials could be 
designed. 
1.7.3 Sputum microbiota of CAP    
The aetiological cause of a significant proportion of CAP is 
unknown.  16S rRNA sequencing is a powerful tool for the 
detection of bacteria in clinical specimens and has less inherent 
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bias than platforms which target specific bacteria.  This technique 
has begun to reveal the patterns of microbiota in the lung and 
how they vary with disease state.  The bacterial microbiota in 
sputum from patients with CAP is unknown and may provide a 
deeper insight into the bacterial aetiology of CAP.  
1.8 Thesis aim 
To explore how efferocytosis and sputum microbiota vary 
depending on the clinical characteristics of patients with CAP and 
to relate these to symptomatic recovery. 
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2 PASS METHODS 
2.1 Introduction 
The Pneumonia Aetiology and Severity Study (PASS) was funded 
by a Doctoral Research Fellowship from the National Institute of 
Health Research (NIHR) awarded to the author.  This chapter is 
derived from the PASS protocol and describes how the study was 
carried out.  The protocol incorporated elements of the ethics 
submission which was made via the Integrated Research Ethics 
Service (IRAS).  Sections of the protocol pertaining to background 
and rationale have been incorporated into chapter 1.  Chapter 3 
will describe the clinical results of PASS and chapters 4, 5, 6 will 
describe the methodology and results for each of the experimental 
components.  Study documents referred to below such as 
information sheets, case record folders, consent forms and the 
CAP-sym questionnaire appear in appendix 1.  PASS was 
approved by the North Wales Research Ethics Committee 
(Central and East) (NHS REC Number 10/WNo03/40).  It was 
adopted to the National Institute of Health Research, Local 
Clinical Research Network (NIHR LCRN) portfolio and sponsored 
by the Research and Development department of Aintree 
University Hospital NHS Foundation Trust.   
2.2 Objectives  
PASS aimed to prospectively recruit a representative cohort of 
hospitalised adult patients with CAP in order to describe recovery 
over one year and investigate host and pathogen factors that may 
affect recovery. 
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2.3 Study design 
2.3.1 Hospitals 
The patients who volunteered for the PASS study were recruited 
from two acute hospitals in Liverpool.  Aintree University 
Hospital NHS Trust (AUH) and the Royal Liverpool University 
Hospital (RLUH) provide acute secondary care services to the 
Liverpool Local Authority.  Patients requiring acute care are 
taken or directed to the hospital that is geographically nearest 
their location at the time of illness, with AUH serving 
predominantly the North of the City (Sefton and Knowsley) and 
RLUH the South (Liverpool).  Both hospitals see a large number 
of CAP cases each year with AUH recording 1572 cases of 
pneumonia (predominantly CAP) in the year 2013.[115].  The 
hospitals are operationally very similar.  Both have an accident 
and emergency department (A+E), medical admissions unit 
(MAU) and Intensive care unit (ITU).  One difference between the 
hospitals is that the Royal Liverpool has an Infectious Diseases 
department that, following initial stabilisation and assessment on 
MAU, provides ongoing in-patient care for a small proportion of 
CAP admitted to the RLUH.  CAP patients who fall under the 
care of the Infectious Diseases department tend to be younger 
with less co-morbidity or have a history of recent travel or 
immune suppression.  
2.3.2 Liverpool 
Liverpool is a large city in the North West of England and has one 
of the most populous metropolitan areas in the UK [116] with a 
population that grew from 445,200 to 469,700 during the period of 
recruitment.  Based on the UK Government Index of Multiple 
Deprivation (IMD statistics (2004 and 2010 reports), at the time 
this study recruited, Liverpool Local Authority was the most 
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deprived in England.[117]  A quarter of the 100 most deprived 
wards in England were in Liverpool.  17.5% of Liverpool’s wards 
were in the bottom 1% for the IMD domain “health deprivation 
and disability” with 61.9% being in the bottom 10%.[117]  The 
North West of England has the highest rates of lower respiratory 
tract infection and the third highest rates of CAP in the UK.[118]  
This is in part explained by the association between rates of CAP 
and the IMD.  Rates of CAP in the UK are 70% higher in the 
highest (most deprived) quintile of IMD compared to the 
lowest.[118]  
2.3.3 Rationale for the study design 
In order to study how patients recover from CAP it was important 
to have assessments at a number of time-points.  Recovery was 
measured against a perceived baseline level of symptoms.  Since it 
was not possible to identify patients who would develop 
pneumonia in advance the earliest we could recruit them was on 
presentation to hospital.  At that time-point the best 
approximation of patients’ pre-pneumonia (in health) symptoms 
was derived from patient recall and was best quantified using a 
structured, pneumonia specific questionnaire such as the CAP-
sym score (see 1.4.3).  Previous studies have reported the validity 
of this approach.[57]  Since the time to full recovery is variable we 
extended follow-up to a point where a large proportion of patients 
were expected to have recovered.  Not all patients would have 
been fully back to their pre-pneumonia level of symptoms by six 
months and therefore follow-up was for one year.  In order to 
study the mechanisms behind delayed recovery it was important 
to determine what was happening in the lung.  The cells in the 
lung are not easily accessible and only small numbers are 
obtained from sputum samples.  Surgical biopsies of lung tissue 
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would have been scientifically valid specimens but unacceptable 
ethically due to the risk and discomfort involved.  
Bronchoscopically obtained specimens therefore represented the 
best compromise of risk, discomfort and validity.  See figure 2.1 
for a schematic representation of the study design. 
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2.4 CAP case-definition 
Radiological evidence of a new pulmonary infiltrate compatible 
with the presence of acute pneumonia (where the author was the 
final arbiter with regards to ambiguous x-rays), plus TWO of the 
following symptoms, signs or investigations consistent with a 
diagnosis of CAP and no alternative clinical explanation e.g. 
pulmonary oedema, pulmonary embolism: 
Symptoms 
 Cough. 
 Production of purulent or mucopurulent sputum. 
 Dyspnoea or tachypnoea.  
 Pleuritic chest pain 
Signs 
 Pyrexia (within 24 h before recruitment), defined as 
temperature ≥38°C OR hypothermia, defined as a 
temperature <35°C. 
 Respiratory examination findings suggestive of pulmonary 
consolidation (dullness to percussion, crepitations, or 
bronchial breath sounds). 
Investigations 
 White blood cell (WBC) count >10,000/mm3 OR >15% 
immature neutrophils (bands) OR leukopaenia with a total 
WBC count <4500/mm3. 
 Hypoxaemia (PaO2 < 8kPa or oxygen saturation <90% while 
the subject was breathing room air). 
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2.5 Inclusion criteria 
 Unselected adolescents (16-18 years) and adults (>18 years) 
with CAP (as defined in 2.4 above) as their primary diagnosis 
after medical admission. 
 Recruitment possible within 24 hours of the first dose of 
antibiotic.  
2.6 Exclusion criteria 
 Previous admission to hospital within the last 14 days*.  
 Non-pneumonic exacerbations of COPD (no new radiological 
change). 
 Dementia of a level preventing CAP-sym completion. 
 Primary lung cancer or any malignancy metastatic to the 
lungs.  
 Advanced malignancy under ongoing care. 
 Known bronchiectasis or cystic fibrosis. 
 Immunocompromised patients: 
o Immunosuppressive therapy including cancer 
chemotherapy and long-term corticosteroid treatment at an 
equivalent daily dose of prednisolone 40mg or greater. 
o Solid organ, bone marrow or stem cell transplant 
recipients. 
o Known infection with human immunodeficiency virus. 
 Concurrent haemodialysis, haemofiltration, peritoneal 
dialysis, or plasmapheresis. 
 Requires invasive ventilation.   
 Requires acute renal replacement therapy. 
*BTS guidelines suggest 10 days excludes hospital acquired 
pneumonia. This is based on weak evidence and some hospital 
contacts are ambiguous (out-patient and A+E visits). We extended 
to 14 days to ensure all cases would be regarded as community 
acquired.   
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2.7 Study Procedures 
2.7.1 Identification of potential study subjects 
The study team was in regular communication with the bed 
managers and the nursing and medical coordinators in A+E and 
in the Medical Admissions Unit.  Via regular education and 
dissemination events and through day to day interaction with the 
study team, these coordinators were fully aware of the research 
study, its aims, objectives and processes.  As a result of their 
unique overview of the patients admitted to the hospitals these 
individuals were best placed to generate a list of potential 
subjects for the study.  This list was discussed with the study 
team at pre-arranged time-points throughout a recruiting day or 
by phoning or bleeping a study team member to alert them to a 
potential recruit.  The assistance and feedback of these 
coordinating members of the clinical team was essential to the 
study and they were included in the ‘User Group’ who will meet at 
regular intervals throughout the study to discuss its running, 
feedback and improvements. 
2.7.2 Initial approach to potential subjects 
The first approach to a patient identified as a possible subject 
occurred as soon as the study team become aware of a possible 
diagnosis of CAP.  Practically this meant after the patient had 
seen the admitting doctor, had a chest x-ray (CXR) and a decision 
had been made to manage community acquired pneumonia.  The 
latest a patient was approached regarding the study was 22 hours 
after administration of the first dose of in-hospital antibiotic for 
CAP.  The first approach to a patient regarding the study was by 
a doctor or nurse from the study team.  The medical notes, blood 
tests and CXR were reviewed by the study team to assess the 
suitability of the patient against the inclusion and exclusion 
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criteria.  The study representative then introduced themselves.  It 
was essential at this point for the study representative to gauge 
the clinical stability of the patient, form an opinion about capacity 
and assess the appropriateness of the environment for the initial 
interview.  The study was explained and the patient information 
leaflet (PIL) reviewed with the patient.  At the end of this process, 
and once any questions had been answered either consent was 
obtained or the patient declined to participate or an agreed length 
of time was provided for the patient to consider and discuss the 
study with their advocates. 
2.7.3 Consent 
The same member of the study team who carried out the initial 
approach returned to the patient to answer any further questions 
and written informed consent was obtained, assuming the patient 
had capacity.  We sought to obtain assent on behalf of those 
subjects deemed not to have capacity and the process for doing so 
is explained below.  All those involved in obtaining consent were 
GCP trained and had experience of the consent process in both 
clinical and research settings.  Moreover, from prior clinical 
experience all study members involved in consent were 
accustomed to making decisions about patient capacity.   
The process of consent had the following pattern: 
 An introductory conversation took place between the study 
team member and the potential study subject.  During this 
conversation the team member began to judge the degree of 
capacity the patient had and the best style of language, spoken 
volume and vocabulary to use in the description of the study. 
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 A description of the study occurred with frequent summaries 
and requests for recall and understanding of the information.  
Particular focus was placed on the potential risks and benefits 
of the study.  Emphasis on the implications of not participating 
was given and recall of this was sought – in particular that 
non-participation would have in no way altered the standard, 
duration or personnel involved in the care that would 
otherwise be provided by the NHS then or in the future.   
 Questions were invited. 
 The study information leaflet was provided and its contents 
demonstrated. 
 Patients were encouraged to consider whether the presence of 
a confidant – friend, carer, relative or member of the clinical 
team – would have helped them consider the decision making 
and consent process.  Where support from such a person was 
sought care was taken for the explanation of the study to be 
repeated in this individual’s presence.  The study team was 
mindful of the need to ensure that these individuals merely 
helped facilitate a decision rather than directly influencing or 
coercing a decision from the patient.  
 An agreed period of reflection (normally in the order of 1-2 
hours) was offered before the study team member returned. 
 Upon return the study team member invited questions and 
gently tested recall of important information relevant to 
consent. 
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Figure 2.1 The Pneumonia 
Aetiology and Severity Study 
Design 
The backbone of the study was a 
longitudinal record of subjects’ 
symptom burden.  This was 
measured and recorded using 
the CAP-sym questionnaire.  
This enabled the level of 
symptoms to be plotted for each 
subject at each timepoint in 
order to infer different patterns 
of recovery and explore clinical 
associations. 
At each visit, from admission to 
one year’s follow-up a range of 
procedures and measures were 
taken. 
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2.7.4 Consent in the context of lack of capacity 
We sought to include patients who lacked capacity and in doing so 
adhered to the procedures set out in the National Patient Safety 
Agency document, “Information and Consent Forms Guidance for 
Researchers and Reviewers” with particular reference to sections 
8.0 and 37.[119]   
Advice regarding the patient’s wishes were obtained from a 
suitable advocate in the following hierarchy: 
 Direct discussion with accompanying next of kin 
 Telephone conversation with next of kin. 
 Direct conversation with accompanying adult. 
 Telephone conversation with relative, friend or GP. 
If following a single phone call we were unable to contact anyone 
able to provide advice regarding the patient’s wishes the patient 
was not recruited.  Persons able and willing to provide advice 
were asked to sign the ‘Consultee Declaration Form’.  If the 
patient regained capacity during the study we sought their 
consent and asked them to sign a consent form. 
2.7.5 Initial study visit and procedures 
a. Following consent the patient was allocated a study identifier 
code.   These non-sequential 4 figure codes were created prior 
to the onset of recruitment by random number generating 
software.  A case record folder (CRF) was created for the 
subject into which study related data and notes were hand 
written. 
b. Clinical Review.  Following consent a study team member 
completed clinical review which took the form of a structured 
history and examination.  The history included a review of the 
patients symptoms and duration, their past medical history, 
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prior medication use and social history.  The examination 
focussed on the respiratory system and the primary presenting 
complaint.  The aim of this clinical review was to obtain 
patient related information that was comparable between 
subjects and could be used to test for associations with 
recovery. 
c. CAP-sym.  Next the CAP-sym questionnaire was completed.  
Once the CAP-sym questionnaire had been completed to reflect 
the patient’s acute symptoms it was repeated to reflect how 
the patient felt 30 days prior to admission.  This pre-
pneumonia CAP-sym score was used as a baseline with which 
to judge recovery. 
d. Blood.  Verbal consent was obtained for a venous blood sample. 
Where possible this venous sample was combined with the 
initial routine clinical blood sampling.  However in some 
instances these routine bloods may have already been drawn 
and a second blood draw was necessary.  Blood was used for a 
range of diagnostics related to pneumonia including blood 
cultures to determine the causal organism.  Spun serum was 
stored for serological diagnosis of influenza infection and 
measurement of pro-calcitonin.   
e. Sputum.  We then asked all patients for expectorated sputum 
samples.  The sputum specimen was placed on wet water ice 
and transferred to the -80 freezer for storage prior to 
subsequent batched DNA extraction.  In Many cases this 
resulted in two sputum samples being taken; a sample 
collected by the study team as above andanother being sent to 
the hospital microbiology lab for routine identification of 
causal organisms at the discretion of the clinical team.. 
f. Communication 
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Following the conclusion of the initial visit outlined above we 
discussed methods for contacting the study team prior to their 
next visit.  Attention was drawn to the telephone numbers and 
email addresses in the study information leaflet and the 
ability to contact the team via subject’s clinical team.  We 
placed a sticker into the clinical and nursing notes to identify 
the patient as a study subject.  This sticker included contact 
details for the study team.  All samples were labelled to 
identify the patient as a study subject and this facilitated 
study standard operating procedures (SOPs) to be enacted in 
the laboratory.  Any laboratory results that become available 
that had clinical relevance to the subject were communicated 
to the subject’s clinical team in a timely fashion.   
The study did not influence or participate in the in-patient care.  
This remained at the discretion of and the responsibility of the 
named clinician and their team.  No further study procedures 
were performed on patients who triggered exclusion criteria 
between recruitment and subsequent time-points (e.g. through 
admission to intensive care unit for invasive ventilation). 
However, specimens and data obtained to that point will be used 
for analysis unless consent for its use was withdrawn. 
2.7.6 Second study visit (48 hours post recruitment) 
At 48 hours following recruitment another study visit occurred.  
Verbal consent was obtained for blood to be drawn.  A structured 
clinical review was undertaken and the CAP-sym score was 
repeated.  The subject had the opportunity to ask any questions 
and information about any results obtained from initial tests was 
provided.   
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2.7.7 Third (pre-hospital-discharge) study visit 
Having been informed of discharge planning the subjects were 
seen immediately prior to discharge.  If a subject’s clinical team 
planned to discharge the subject before 48 hours had elapsed 
following enrolment then the clinical team contacted the study 
team to enable a study visit to take place prior to discharge.  
Subjects had a structured clinical review and a CAP-sym score at 
this visit.  Subjects were not routinely seen by the study team 
again until follow up.  Therefore at this visit we spent time 
ensuring the subjects were aware of the procedures for contacting 
the study team and the arrangements for the follow-up clinic one 
month post-admission.   
We discussed research brochoscopy with the subject.  If a subject 
volunteered for the research bronchoscopy this took place shortly 
after the one month follow-up clinic. The rationale and 
practicalities of the bronchoscopy were explained and a separate 
study information leaflet was provided.  The subject was asked to 
provide written consent to the bronchoscopy.  The subject had a 
follow up visit scheduled prior to the brochoscopy and this 
provided an opportunity for further questions to be asked and for 
the subject to change their mind.   
2.7.8 Loss to follow-up 
Subjects were asked if they were happy to receive a phone call as 
a reminder prior to a study follow-up visit.  They were also asked 
for permission to try to contact them or their GP to clarify reasons 
for failure to attend a follow-up visit. 
    49 
 
2.7.9 Fourth study visit (one month post recruitment) 
During the in-patient stay the study subject’s clinical care was the 
responsibility of the admitting clinical team.  However, all 
subjects were then followed up as out-patients by the study team 
who provided the dual function of clinical care and study 
investigators.  Subjects were seen by a study doctor in a dedicated 
pneumonia clinic.  Prior to seeing the study doctor a number of 
procedures occurred:   
a. Chest X-ray 
All study subjects had a chest x-ray to assess pneumonia 
resolution.  This was part of routine clinical practice. 
b. Clinical samples 
Subjects were asked to provide expectorated sputum and a 
sample of venous blood. 
c. Clinical Review 
A structured clinical review took place and a CAP-sym 
questionnaire was completed.   
d. Bronchoscopy consent check 
As is clinically routine when assessing patients post 
pneumonia, particular focus was placed on detecting 
symptoms or signs suggestive of underlying health problems – 
most notably lung malignancy.  It was likely that a proportion 
of the study subjects would have been told that a 
bronchoscopy and further tests were clinically advised due to 
their signs and symptoms.  It was made clear to the subject 
which tests were being suggested clinically and which were 
study tests not required as part of routine clinical assessment.  
Those subjects who required a bronchoscopy on clinical 
grounds were asked to provide consent for a lavage to be 
taken if the initial bronchoscopic visualisation of the airways 
    50 
 
was normal.  If the airways were not normal or if procedures 
other than inspection were needed on clinical grounds then 
the lavage was not performed.  All subjects were then asked to 
return for a final study visit at six months post enrolment.   
2.7.10 Fifth study visit - bronchoscopy 
All bronchoscopies were carried out at Aintree University 
Hospital in the Elective Care Centre which has a dedicated 
bronchoscopy suite.  They occurred as soon as was practically 
possible following the one month follow-up visit.  PASS 
bronchoscopies occurred on Tuesday mornings between 8 and 9am 
prior to the routine clinical bronchoscopy list.  Subjects were 
asked to fast for 4 hours before hand and not to drink fluids for 2 
hours of the procedure.  Subjects were asked to arrive for the test 
30 minutes before the scheduled procedure time.  They were met 
by a study nurse and endoscopy nurse and went through standard 
procedures and checks used for all bronchoscopies performed in 
the Aintree University Hospital endoscopy suite.  Following the 
procedure the subjects were recovered into the endoscopy recovery 
room and were monitored as per standard procedures.  It was 
anticipated most subjects would be able to leave after two hours of 
recovery.  In the event that a subject was unwell and required 
admission this would have followed standard procedures and the 
subject would be have been looked after by the relevant admitting 
team (i.e. not the study team).  However, fortunately no PASS 
subjects required admission.  The pre-bronchoscopy checks, a copy 
of the bronchoscopy report and recovery details were filed in the 
hospital notes.  During the bronchoscopy visit subjects also had a 
venesection to provide blood for the extraction of neutrophils for 
the efferocytosis assay (see table in section 7).  We phoned all 
subjects 48 hours after their bronchoscopy for feedback.   
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2.7.11 Sixth study visit (six months post recruitment) 
The sixth study visit at 6 months was identical to the forth.  
However, another x-ray was only requested when this was 
clinically indicated.  Extra x-rays, over and above routine clinical 
care, were not requested.   
2.7.12 One year phone call and / or visit 
Subjects were asked if they would accept a phone call to their 
General Practitioner and themselves one year after their original 
admission (if the GP call identified that that the subject had died 
since their last visit the subject’s home was not contacted).  
During the call to the patient they were asked to confirm if they 
were still happy to attend for a last visit.  The purpose of this visit 
was to complete a final CAP-sym score and to ask about health 
events that had occurred since the 6 month follow up visit.  At the 
end of this final contact all subjects were reminded about how to 
contact the study team and were advised about plans for 
dissemination of study results. 
2.8 Laboratory Testing 
2.8.1 Biochemistry, haematology and microbiology samples 
All routine samples were processed by the hospital laboratories.  
Study subject samples were labelled with an extra sticker to 
identify them as belonging to a study and this triggered the study 
SOPs for sample handling.  This SOP directed excess sample to be 
labelled with a study number and frozen for storage.  Samples 
were stored for potential future testing in ethically approved 
research relevant to the study aims.  Since the laboratory staff 
had no idea of the recovery status of study subjects there was no 
opportunity for bias at this stage in the study.  
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2.8.2 Efferocytosis assay 
Bronchoalveolar lavage samples were labelled with a study code 
and used immediately in the efferocytosis assay.  This involved 
the safe transfer of samples to the laboratories at the Clinical 
Sciences Unit of Aintree University Hospital.   
2.8.3 16S rRNA analysis 
Sputum samples were deep frozen very soon after receipt.  
Samples were subsequently defrosted in batches, the DNA 
extracted and purified and transported to The National Heart 
Lung Institute, Imperial College London.  Here the author, under 
the supervision of Imperial scientists, conducted the 16S rRNA 
PCRs prior to sending the samples for sequencing. 
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*Only if clinically indicated 
 
Table 2.1 Summary of PASS Subject Sampling 














Full blood count (3 ml) X   X  X   
Biochemistry and pro-calcitonin (5 ml) X X  X  X   
Clotting profile (6 ml) X X  X  X   
Serum glucose (4 ml) X        
Blood culture (20 ml x 2) X        
HIV and influenza serology (5 ml) X   X  X   
Whole blood for DNA extraction (10 ml) X        
Whole blood for RNA expression (5 ml) X   X  X   
Whole blood for neutrophil extraction 36 ml     X  X  
Maximum total blood volumes (ml) 78 11  24 36 ml 24 36 ml  
Volume extra to routine clinical care(ml) 15 6  24 36 ml 24 36 ml  
Respiratory tract specimens  
BAL fluid (200 ml instilled)     X  X  
Sputum – Microbiology and 16S rRNA 
sequencing 
X   X  X   
CXR         
 X   X  X*   
CAP-SYM score         
 X X X X  X  X 
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2.9 Safety considerations 
2.9.1 Venesection 
The study protocol required a total blood donation over one year of 
94 mls in excess to that which was clinically indicated with 10 mls 
extra being drawn on admission. This volume was within safe 
limits.  For individual participants, the required blood donation 
was minimised by the use of results of investigations performed 
on samples obtained by the clinical team.   
2.9.2 Research bronchoscopy with BAL 
Flexible bronchoscopy is a safe procedure with a published 
complication rate of 0.12-0.5% and a minor complication rate of 
0.8%.[120]  Major complications of flexible bronchoscopy include 
respiratory depression, pneumonia, pneumothorax, 
bronchospasm, cardio-respiratory arrest, arrhythmias and 
pulmonary oedema. Minor complications include discomfort, 
vasovagal reactions, fever, nausea and vomiting. 
Broncheoalveolar lavage (BAL) involved the instillation and 
removal by gentle hand suction of 200 ml of warm sterile saline.  
BAL can induce a post-BAL acute phase response which peaks at 
24 hours.  This can be measured in up to 30% of individuals but is 
often asymptomatic and seems to be related to volume of fluid and 
number of lobes lavaged. [121,122]  
Efferocytosis has been shown to be influenced by factors such as 
smoking and COPD and these comorbidities affect all regions of 
the lung.  It was therefore postulated that rates of efferocytosis 
would be relatively uniform throughout the lung and that 
differences in efferocytosis between individuals would be greater 
than differences between lung lobes.  Local practice was to 
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perform research bronchoscopy in the “sat up, face to face” 
position in which the middle lobe bronchus was positioned in a 
favourable way for aspiration of lavage fluid.[123]  For these 
reasons we lavaged the middle lobe, rather than targeting the 
recently pneumonic lobe, as good sample yield was key to the 
success of the experiment and for patient comfort and safety.   
2.10 Ethical considerations 
2.10.1 Purpose and design  
The biological plausibility and prior evidence to support the 
scientific rationale behind this study were considered in chapter 1 
of this thesis.  Since the key cell involved in resolution of 
inflammation caused by pneumonia is the alveolar macrophage 
the best way to obtain these is by bronchoalveolar lavage (BAL).  
The British Thoracic Society describes bronchoscopy as safe and 
our group has published a large series of research bronchoscopies 
with extremely low rates of adverse events.[123,124]   
2.10.2 Recruitment 
It was important that this study recruited a representative group 
of patients so that its results had the widest possible applicability.  
As described in 2.3.1, 2.3.2. and 2.4.1  the hospitals, region and 
study processes employed by PASS were chosen to maximise 
recruitment.  Since one of the study aims was to identify the 
organisms responsible for CAP it was important to obtain samples 
from as many patients as possible before antibiotics have had 
time to influence the results.  For this reason we attempted to 
complete the consent process before twenty four hours had 
elapsed following the first dose of antibiotic.  This put pressure on 
the study team, but not patients who were offered time to read 
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the study information in private and to discuss joining the study 
with family, friends or other confidants. 
2.10.3 Inclusion / exclusion  
The diagnosis of CAP is inherently subjective (see 1.2) but we took 
particular care to ensure that this cohort would be considered 
representative of CAP and comparable with similar studies.  
Whilst it was recognised that children represent an important 
group of patients at risk of pneumonia and that many children 
suffer significant health problems following pneumonia, the CAP-
sym (Community Acquired Pneumonia – Symptom) score has not 
been validated for use with children and so they were excluded.  
CAP is important in the elderly and hence we had no upper age 
limit to recruitment.  Due to underlying chronic illness some 
subjects were not able to participate in the bronchoscopy studies 
but age per-se was not an exclusion criterion.  It would have been 
ideal to include primary care in this study since 70% of CAP cases 
are managed in the community but for logistical and financial 
purposes we restricted this initial study to hospital patients.  It 
was our intention to subsequently include a primary care study in 
a larger programme grant to validate PASS findings in that 
population.   
2.10.4 Consent 
The consent process was carefully thought out and adhered to as 
in 2.7.3.  A common clinical feature of community acquired 
pneumonia is the development of confusion.  Confusion occurs 
across all age groups but is particularly common in the elderly in 
whom community acquired pneumonia is itself more common.  We 
therefore included patients whose presentation included acute 
confusion and this will enable the results to be extrapolated into 
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normal clinical practice.  As a consequence this study was 
reviewed and approved by a research ethics committee convened 
specifically to consider studies involving lack of capacity.   
2.10.5 Conflict of interest  
There was no financial conflict of interest in this study.  The 
author who was also the lead investigator received a salary from 
the Fellowship awarded to support the study and no other 
financial remuneration.  Subjects received small sums of money 
as reimbursement and to compensate for their time.  These are 
laid out in the patient information leaflet (PIL) (appendix 1) and 
were approved by the research ethics committee.   
2.10.6 Use of tissue samples in future research 
We stored excess samples for future work relating to this topic.  
This was made clear to the patients prior to consent and was 
articulated clearly in the PIL.  If subjects objected to their 
samples being stored for use in the future, they were destroyed 
and this in no way precluded them from ongoing participation in 
the study.     
2.11 Confidentiality and data management 
The NHS Code of Confidentiality was followed at all times: 
Case record folder (CRF) 
Information contained within the source documents was 
transcribed into Case Record Folders (CRFs).  CRFs contained no 
patient identifiable information and were identified by the pre-
generated study codes only.  The CRFs remain at the study sites 
and will be kept there for 3 years after the study closure.  
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On-site computer data base 
Data from the CRFs was entered into a study computer data-base.  
The data-base is only accessible via University networked 
nomputers.  The data base is password protected.  To access a 
subject’s data the study identifier code is required. 
 
2.12 Data handling 
All clinical and laboratory data was transcribed from the CRFs 
and source documents by the author and entered into excel 
spreadsheets.  Data in individual spreadsheets was linked across 
to other spreadsheets by the four digit study number.  The data 
for the CAP-sym scores – which amounted to over 1100 rows of 
data was double entered by the author and a research admin 
assistant. 
2.13 Statistical analysis 
All statistical analysis was performed by the author in the R 
computing environment using R studio over R versions 2.13.2 
through to 3.1.3.  Statistical supervision and tutorage was 
supplied by Professor Peter Diggle initially at Lancaster 
University and latterly at University of Liverpool.  Individual 
analysis plans are articulated in each of the results chapters 3-6.  
In chapter 5 I am particularly grateful for the additional input of 
Dr Graeme Hickey (Clinical Lecturer in Statistics University of 
Liverpool) for his thoughts and advice on compositional analysis.  
All subjects who were recruited were included in the analyses in 
the manner of an intention to treat group.  Where patients 
dropped out prior to completion of the study their data to the 
point of drop-out remained in the analysis.  
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3 PASS CLINICAL RESULTS  
3.1 Introduction 
The Pneumonia Aetiology and Severity Study (PASS) opened for 
recruitment at Aintree University Hospital (AUH) on the 7th 
February 2011 followed by the Royal Liverpool University 
Hospital (RLUH) on 10th December 2012.  Both sites closed on 
March 29th 2013.  During this period 169 subjects from across 
Liverpool consented to join the study (figure 3.1.) The PASS 
cohort was used to address the experimental questions posed by 
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3.2 Results 
3.2.1 Screening and Recruitment 
4739 patients were screened for eligibility for PASS.  76% of 
screened cases had an alternative primary diagnosis (figure 3.2).  
25% of those identified by the study as being treated for CAP were 
deemed eligible and the majority of eligible patients volunteered 
to join PASS.  Key reasons for being in-eligible despite having 
CAP included:-  
 more than 24 hours had elapsed since hospital antibiotics 
commenced.  
 advanced dementia such that the CAP-sym questionnaire 
would not be available at any time point. 
 CAP that was so severe either mechanical ventilation had 
been or was expected to be instigated or the patient was 
being managed palliatively. 
As a result of this screening process 169 subjects were recruited to 
PASS and their subsequent rates of retention within the study 
can be seen in the study flowchart figure 3.3. 
3.2.2 Seasonality 
Weekly patterns of recruitment can be seen in figure 3.4.  Winter 
recruitment peaks were observed and these were associated with 
peaks in national notifications of ‘Influenza Like Illness (ILI)’ to 
the Health Protection Agency (now Public Health England 
(PHE)).   
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Figure 3.2 PASS screening flowchart 
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Figure 3.3 PASS flowchart 
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Peaks in recruitment of PASS subjects corresponded with winter peaks in influenza like illness (ILI) peaks.  The ILI counts 
represent counts per 100000 population.  ILI data courtesy of Public Health England. 
 
Figure 3.4 PASS weekly recruitment, flu rates and national ILI rates 
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3.2.3 Demographic details 
The demographics of the PASS cohort are presented in table 3.1.  
The age and sex distribution of the PASS cohort were similar to 
the contemporary British Thoracic Society Audit of UK 
Community Acquired Pneumonia (CAP).[125]  The age 
distribution of PASS subjects was also compared to the largest 
reported cohort of patients hospitalised with CAP, the CAPNETZ 
cohort (see figure 3.5).[18]  In both PASS and CAPNETZ each 
successive age centile contributes a greater proportion of CAP 
patients followed by a decline at the upper extreme of the age 
range.  In PASS the decline occurs in the decile 80-90 years which 
is younger than in CAPNETZ where the proportion of cases 
increased until 90-100 years.  The Ethnicity of PASS subjects was 
almost entirely white British; one Polish, one Brazilian and one 
















  Mean, range, (SD) 
 
64, 16-98, (18) 
 
68, 16-102, (20) 
Male, n (%) 






166 (98.2) NA 
2 (1.2) 
1 (0.6) 
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3.2.4 Socioeconomic status 
The IMD is a summary measure of socioeconomic status that is 
used in epidemiological studies and incorporates individual 
metrics of deprivation relating to seven sub-domains:- health, 
education, housing, income, crime, employment and living 
environment.  IMD scores are available for 32,482 Lower Super 
Output Areas (LSOAs) in the UK.[126]  Each LSOA is a small 
geographical area containing 400 houses (an estimated average of 
1500 individuals).  All UK post-codes map to a LSOA.  Each UK 
resident can therefore be assigned an IMD score by cross-
referencing their post-code with LSOAs and the associated IMD.  
Two individuals’ IMD can be compared either by the raw value 
where low IMD indicates less deprived and high IMD more 
deprived or the position of the IMD score in the rank order of all 
IMD scores for the 32,482 LSOAs in the UK.  If rank is considered 
then 1st is most deprived and 32482nd is least deprived.  Using 
residential postcodes, we were able to reference the Index IMD 
score for each subject in PASS.  One PASS subject was not 
assigned an IMD score as they were resident in Wales which has 
a different method of calculating IMD.  Figure 3.6 shows the 
proportion of PASS subjects that were drawn from each centile of 
the national rankings.  Proportions of PASS subjects in each 
group are compared to the proportion of LSOAs in Liverpool that 













The 32,482 UK Lower Super Output Areas (LSOAs) were ranked 
from 1 (most deprived) to 32,482 (least deprived).  The ranks 
were then divided into centiles.  The plot displays the percentage 
of PASS subjects that fell into each centile (blue bars) compared 
to the percentage of all Liverpool LSOAs that fall into each 
centile.  PASS recruited subjects from all but the least deprived 
10% of the UK population but was dominated by subjects from 
the most deprived 10%. 
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3.2.5 Comorbidities 
Subjects in PASS had high rates of co-morbidity (see table 3.2). In 
particular 39% of PASS subjects were active smokers and a 
further 20% were ex-smokers having abstained for at least 12 
months.  53.4% of subjects had some form of prior-pulmonary 
disease (41% COPD and 12.4% other lung disease).   
Table 3.2 PASS comorbidities 
* incomplete data available for these variables 
Diabetes n= 168 
BMI n=126 




Individual comorbidities PASS  n=169 
COPD n (%) 70 (41.0) 
Chronic lung disease other than COPD n (%) 21 (12.4) 
Congestive cardiac failure n (%) 23 (13.6) 
Dementia n (%) 2 (1.2) 
Diabetes* n (%) 28 (16.7) 
BMI, median(IQR) * 26 (22-30) 
Hepatic disease n (%) 5 (3.0) 
Renal disease n (%) 14 (8.3) 
Lived in nursing/residential care, n (%)  8 (4.7) 
Smoking status* n (%)  
  Active smoker 63 (39.0) 
  Ex-smoker 66 (41.0) 
  Never smoker 32 (20.0) 
Influenza infection* n (%) 18(16.8) 
Infection Markers 
Pyrexial, n (%) 90 (53.0) 
Neutrophil count, median (IQR) 9.9 (7.1-14.8) 
CRP (mg/ml), median (IQR) 145 (61-248) 
Pro-calcitonin* (ng/ml) median (IQR) 
  >0.25 n (%) 
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3.2.6 Clinical Characteristics at Presentation 
(Table 3.2) Half (53%) of PASS subjects had a temperature 
>37.5°C recorded during the first 24 hours of their admission to 
hospital.  Self-expectorated sputum was sent to the microbiology 
lab from 67/169 (40%) subjects.  Median values of blood neutrophil 
counts and C-reactive protein were above the normal range and 
140/169 (82.8%) of subjects had one of either pyrexia, raised 
neutrophils or raised pro-calcitonin demonstrating that the 
majority of the cohort had evidence of a systemic inflammatory 
response.  The Confusion, Urea, Respiratory Rate, Blood pressure 
and age >65 (CURB65) score is a risk stratification index which 
predicts mortality at 30 days following CAP.[127]  The 
distribution of CURB65 scores for PASS subjects can be seen in 
table 3.3.  The pattern was very similar to that reported by the 
BTS audit of CAP in the UK.  However, within the 3-5 group 
there were notable differences between PASS and the distribution 
of severity seen in UK hospitals.   None of the PASS subjects had 
a CURB score of 5 and only 4 (2.4%) subjects had a CURB65 score 
of 4.   
 Table 3.3 PASS CURB65 Scores 
  




0-1 79 (46.7) 1655 (46.4) 
2 50 (29.6) 952 (26.7) 
3-5 40 (23.7) 934 (26.2) 
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3.2.7 Antibiotics and vaccination 
18/169 (11%) of subjects had received an at least one dose of 
antibiotic in the community before presenting to hospital.  
Information was provided by general practitioners about the 
vaccination status of 119/169 (70.4%) of PASS subjects.  92% of 
those for whom we had information were, according to NHS 
vaccination guidelines, “at risk” from influenza.  55% of those had 
been vaccinated in the season during which they had been 
admitted with CAP and 85% had been vaccinated against 
influenza at some point in their lives.  76% of those for whom we 
had information were eligible (at risk group) for pneumococcal 
vaccination and 82% of those had received the vaccine. 
3.2.8 Bacterial Aetiology of CAP 
155/169 (92%) of PASS subjects had blood cultured in the NHS 
microbiology laboratories to investigate for a bacterial cause for 
their pneumonia.  67/169 (39.6%) of PASS subjects had a sputum 
sample cultured.   Overall 156/169 (92%) of subjects had at least 
one of either a sputum sample or blood culture sent (table 3.4).  
1/28 patients tested was diagnosed with legionella pneumonia on 
the basis of a positive urinary antigen test.  Using these three 
diagnostic modalities 28/156 (18%) had potentially pathogenic 
bacteria reported from their samples.  Yeasts and upper 
respiratory tract flora, and “mixed coliforms” where reported in 
sputum, were not regarded as the aetiological cause of CAP. 
3.2.9 Influenza infection 
107/169 (63%) of subjects had paired acute and convalescent 
serum samples available for measurement of antibody responses 
to circulating influenza viruses.  18 of these 107 subjects (16.8%) 
had met the Public Health England diagnostic criteria of a four-
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fold rise in influenza specific IgG titres, suggestive of acute 
influenza infection at the time of presentation with CAP and 
recruitment to PASS.   
 Table 3.4 PASS blood and sputum cultures 
 
3.2.10 Mixed infection 
Two PASS subjects grew Streptococcus pneumoniae in the blood 
and were serologically positive for influenza virus. One grew 
Haemophilus influenzae in the sputum and was serologically 








Negative 139 (89.7) 47 (70.1) 
Streptococcus pneumoniae 8 (5.2) 0 
Escherishia coli 2 (1.3) 0 
Klebsiella pneumoniae 2 (1.3) 1 (1.5) 
Streptococcus dysgalactiae equisimilis 1 (0.6) 0 
Staphylococcus aureus 1 (0.6) 0 
Lactococcus lactis 1 (0.6) 0 
Diptheroid bacilli 1 (0.6) 0 
Haemophilus influenzae 0 6 (9.0) 
Coliforms 0 3 (4.5) 
Yeasts 0 3 (4.5) 
Upper Respiratory tract flora 0 3 (4.5) 
Pseudomonas spp. 0 4 (6.0) 
Total 155 (99.9) 67 (100.1) 
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3.2.11 Clinical outcomes 
(Table 3.5) On average PASS subjects spent one day longer in 
hospital (6 days) than patients in the 2010/11 BTS pneumonia 
audit of UK CAP (5 days).  PASS subjects and BTS audit patients 
were equally likely to be re-admitted to hospital within 30 days 
(9%).  In-patient mortality was three times lower in PASS than in 
the BTS audit (7.7% vs 20.4%) and only one PASS subject (0.6%) 
died in the 30 days following discharge compared to 3.8 % in the 
BTS audit. In addition to the 13 in-patient deaths and the one 
early discharge death, a further 12 PASS subjects had died by 1 
year from admission.  In-patient mortality among the PASS 
cohort increased with age and followed the same pattern as in 
previous reported studies including the CAPNETZ cohort (Figure 
3.7). 
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Length of stay  
  Median, range (SD) 
 
6, 0-58, (7.8) 
 
5, 0-62, (9.0) 
Re-admission within 30 days of 





In hospital mortality, n (%) 13 (7.7) 730 (20.4) 






Death post discharge n (%) 13/156 (8.0) NA 
Total one year mortality, n (%) 26(15.0) NA 
Cause of in hospital death n (%)   
  CAP 
  Sepsis 
  Myocardial infarction 
  Respiratory failure 







Cause of death  
post discharge n (%) 
  CAP 
  HAP 
  Gastric cancer 
  Lung cancer 
  Interstitial lung disease 










  Unknown 3 (23.0)  
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3.2.12 Charlson co-morbidity scores in PASS 
Patients’ pre-existing chronic illnesses were used to calculate the 
revised version of the Charlson co-morbidity index.[128]  This 
index can be used to estimate the magnitude of a patient’s risk of 
death during a hospital admission that is attributable to 
comorbidity.  Comorbidity is defined as pre-existing conditions 
other than the primary diagnosis.  It is calculated by summing a 
weighted score for each of the 12 comorbidities that have been 
shown to be most closely associated with in-patient mortality 
(Figure 3.8).  In patient mortality rates for PASS subjects in 












Comorbidity Weighted score 
Chronic pulmonary disease 
Rheumatologic disease 
Renal disease 
Diabetes with chronic complications 
Congestive cardiac failure 
Dementia 
Hemiplegia or paraplegia 
Any malignancy 
Mild liver disease 
Moderate or severe liver disease 
Aids 
Metastatic solid tumour  














Figure 3.8 The Charlson comorbidity index 
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per score  
n (%) 





of mortality per 
score  
n (%) 
0 56 (33.1) 2 (3.6) 15 (1.2) 
1 69 (40.8) 4 (5.8) 38 (3.1) 
2 18 (10.7) 4 (22.2) 84 (6.8) 
3 17 (10.1) 3 (17.6) 115 (9.2) 
4 6 (3.6) 0 168 (13.6) 
5 2 (1.2) 0 226 (18.3) 
≥6 1 (0.6) 0 247 (20) 
Each of 12 comorbidities is assigned a weighted score and a 
subject’s Charlson index is the sum of those scores.  The risk of 
in-patient death rises as scores increase from 0 to a maximum 
of 24. 
 
PASS mortality data is compared with the mortality rates of 
patients in an Australian cohort which was used in the 
validation of the revised Charlson index. The validation study 
used large cohorts from 6 developed nations and the Australian 
cohort has been chosen here as the Australian health care 
system is the closest match to the NHS. 
 
The highest Charlson score in PASS was 6.  The proportion of 
PASS subjects with scores 0-6 is shown along with the 
proportion of each group who died during admission.   
 
The absence of PASS deaths in the Chalrson categories 4,5 and 
6 is almost certainly an artefact of low numbers of subjects in 
these groups.  
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3.3 Discussion  
3.3.1 Summary of Results 
The PASS study recruited a cohort of 169 patients with CAP.  The 
cohort was predominantly composed of older, socially deprived, 
white, British patients who often had COPD.  PASS subjects had 
many similarities with previously published CAP cohorts and, 
where differences existed, they could be explained by the study 
design, or reflected idiosyncrasies of the local population (see 
below).   
3.3.2 What were the strengths of this work? 
3.3.2.1 Strict case definition 
The diagnosis of CAP is subjective.  In particular determining the 
presence or absence of pneumonic consolidation on the CXR is 
prone to both intra and inter-user inconsistencies.[11]  As this 
was a prospective study we were able to carefully assess each 
subject’s eligibility and since the author acted as the final arbiter 
of eligibility for each subject, inter-user variability was reduced.    
3.3.2.2 Wide screen 
It was important to recruit a representative cohort and in order to 
do this we needed to ensure we screened the highest proportion of 
patients who presented with possible CAP.  This generated an 
enormous amount of work, particularly in the summer months 
where cases were rare, but as a result we considered the majority 
of cases of CAP that fell within our recruiting window.   
3.3.2.3 Comprehensive characterisation  
The cohort was characterised in detail such that similarities and 
differences with other cohorts could be clearly elucidated.  We 
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focussed on factors that have been or may be associated with 
outcome such as socioeconomic status, co-morbidity, markers of 
inflammation, severity scoring and risk-stratification.  As a result 
we were able to demonstrate similarities with other work and 
explain differences where they existed. 
3.3.2.4 Socioeconomic status  
The inclusion of socioeconomic status as a clinical variable is 
novel among UK adult cohort studies of CAP and enabled us to 
exclude the possibility of any related bias that may have 
influenced outcomes.  43% of PASS subjects were drawn from 
areas which have the highest level (lowest centile) of social 
deprivation in the UK.  The distribution of Index of Multiple 
Deprivation (IMD) scores for PASS patients was very similar to 
the distribution of IMD scores assigned to all the Liverpool Lower 
Super Output Areas (LSOAs) that would be served by our two 
recruiting hospitals.  This suggests PASS recruits were 
representative of the local population and that there was no 
obvious bias in PASS towards recruiting from any particular 
socioeconomic group.   
3.3.3 What were the limitations of this work? 
3.3.3.1 Pause in recruitment 
Active recruitment was suspended between May and September 
2011 as there were inadequate numbers of staff to conduct the 
study effectively.  During this period, only potential subjects 
identified by NHS colleagues were screened and, since there were 
very few pneumonia cases presenting to the hospital, this 
effectively meant recruitment stopped (see figure 3.1 central 
panel).  Following the addition of a nurse to the study team, active 
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case finding resumed in October 2011.  Due to the small number 
of cases recruited prior to this pause no formal statistical 
comparison was been made with the main body of subjects; 
however, no clear differences could be seen and the recruitment 
criteria were identical before and after.     
3.3.3.2 In-eligible patients with CAP 
Three quarters of patients being managed as CAP by the 
hospitals could not join the study as they failed to meet the PASS 
inclusion criteria.  The most common reason for this was the 
identification of the patient after 24 hours had elapsed since their 
first dose of in-hospital antibiotics.  ‘Late’ identification of 
patients was a manifestation of the complexity of hospital 
pathways, and in many instances a late clinical diagnosis.  Late 
clinical diagnoses occur where a patient is not immediately 
recognised as having CAP – but occult infection is included in the 
differential diagnosis and antibiotics are administered.  As test 
results arrive and more senior clinicians review the case, or 
opinions on the CXR change, the diagnosis becomes crystallised as 
CAP but by that point a study’s opportunity to recruit may have 
passed.  Another frequent reason for a patient being unavailable 
for recruitment within 24 hours is admission at the weekend.  
Most of the time PASS was unable to recruit after 1600 on Friday 
evening and this meant all patients admitted from then to 
midway through Sunday would be ineligible.  Another common 
reason for ineligibility was dementia of a level that meant the 
CAP-sym questionnaire could not be completed.  A less frequent 
but important reason for ineligibility were patients who were 
expected to die shortly after admission or who were rapidly 
intubated and ventilated. 
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Ineligibility for the reasons listed above may have influenced our 
results.  Although the time and day of presentation is unlikely to 
have affected the findings of the CAP-sym analysis, efferocytosis 
or microbiota studies – dementia and severe disease requiring 
ITU care may have done.  Patients with dementia may have been 
more likely to aspirate and or have Gram negative pneumonias.  
Patients with severe disease may have had a higher incidence of 
pneumococcal disease.   
3.3.3.3 Duration of illness and prior treatment 
This was, as far as possible, a pragmatic cohort designed to be 
representative of CAP in an acute UK hospital.  As such a 
proportion of subjects were several days into their disease episode 
at the time or recruitment.  Some patient’s route to hospital was 
to see the GP, be diagnosed with lower respiratory tract infection, 
attend for an outpatient CXR then at GP follow-up they were 
referred to hospital due to ongoing symptoms.  The initial CAP-
sym score may therefore not always have captured the initial 
trajectory of symptoms.  Since some patients had been pre-treated 
with antibiotics in the community prior to enrolment this will 
undoubtedly have affected the microbiological identification of the 
casual organism by culture and will also have had an impact on 
the microbiota identified.  However, all patients met the case 
definition of CAP at recruitment and were prescribed in-hospital 
antibiotic suggesting they had ongoing symptoms of acute 
infection. This is reinforced by the high levels of CRP and pro-
calcitonin measured in this group suggesting that a large 
proportion of the cohort were still in an acute inflammatory state 
at enrolment.  
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3.3.3.4 Ethnicity 
A striking feature of the PASS cohort was its ethnic uniformity 
with 98% of subjects being white British.  The ethnic distribution 
is PASS is however a very close reflection of the local population.  
In Liverpool local health authority 84.8% of people report being 
white British, 2.6% as white other and 1.8% as Black African.  In 
Knowsley local health authority, which is directly in the 
catchment of University Hospital Aintree, 96.1% of people are 
white British, 0.2% are Black African and 0.7% white Other.[129]  
This distribution of ethnicity is very different to many areas of the 
UK including central Manchester which is only 30 miles away.  
Ethnicity may impact on the incidence, severity, recovery and, 
mortality from pneumonia via cultural associations and 
mechanistic effects.  For example dietary differences can 
significantly affect the gut microbiota which in turns affects 
immunity at distant sites such as the lung.[130]  Differences in 
Vitamin D levels have had been linked to incidence and outcomes 
in pneumonia and patients from different ethnic backgrounds can 
have profound differences in vitamin D metabolism due to 
dietary, skin pigmentation and microbiome effects.[131]   
3.3.3.5 Socioeconomic status 
The socioeconomic profile of the PASS cohort was heavily biased 
towards the lowest end of the socioeconomic spectrum of England.  
Since the incidence of CAP is 70% higher among the most 
deprived quintile of England’s population than among the least 
deprived, patterns of admission for CAP may be different in other 
areas.[118]   Since low socioeconomic status is associated with 
higher comorbidity and worse outcomes in many diseases this 
may reduce the generalisability of these findings to more affluent 
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populations.  Future multi-site studies could investigate this by 
clustering sites based on socioeconomic data. 
3.3.4 Comparison with other published work 
3.3.4.1 Comorbidities 
Smoking is known to be a major risk factor for invasive 
pneumococcal disease and CAP.[22]  Despite this, recent UK 
cohort studies of CAP have not reported rates of smoking.[132]  
80% of PASS subjects were either active smokers or ex-smokers.  
This compares with 64.3% in a similar Spanish CAP cohort.[133]  
The high rate of smoking in the PASS cohort reflects the local 
population where Liverpool Local Health Authority has a smoking 
prevalence of 29% and Knowsley 32% both of which are 
significantly higher than the UK average of 20%.[134] 
COPD was very common among PASS Subjects with 41% 
reporting this condition.  This compares to a UK rate of 19% in 
the 2010/2011 BTS CAP audit and 9.41% in the German 
CAPNETZ cohort.   The high prevalence in PASS is likely a 
reflection of the very high rates in the local population.  The UK 
prevalence of COPD in men over 16 years has been estimated to 
be 4.49% and in women is 2.82%.[135]  Of 323 UK Local Health 
Authorities Knowsley has a predicted COPD rate of 7.0% in Men 
and 4.85% in Women which are the third and second highest rates 
in the UK respectively.  Liverpool and Sefton Local Health 
Authorities are also both in the top 5% of all UK health 
authorities for both male and female COPD rates. 
The revised Charlson co-morbidity index has been validated using 
data from 6 developed nation databases.  The index estimates the 
mortality risk attributable to diagnoses other than the primary 
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reason for admission.  72% of PASS subjects had Charlson scores 
of 0,1 or 2 - the lower end of the spectrum of mortality risk 
associated with comorbidity.  PASS subjects followed the 
predictable trend towards increasing mortality as the index 
increased through 0, 1 and 2.  There was however a higher 
mortality in these four groups compared to the Australian 
comparator cohort and this is probably explained by the high 
mortality associated with CAP.    
3.3.4.2 Aetiological diagnosis 
Rates of aetiological diagnosis in CAP vary widely in the 
literature.  This is likely to be due to variation in the samples 
taken, the range of assays used and to variation in the inclusion 
criteria between cohorts.  Moreover, some studies are designed 
with aetiological diagnosis as the primary aim whereas others, 
like ours, are pragmatic and simply report the results of clinical 
microbiological testing.  The 2009 BTS guidelines summarise 5 
UK studies which focussed on aetiological diagnosis of CAP and 
report rate of pathogen identification between 66.5%-71.9%.[6]  A 
recent systematic review of European studies investigating the 
aetiological causes of CAP revealed rates of pathogen 
identification of between 73.3 and 12.7%.[136]  PASS relied on 
routine microbiological testing undertaken by the hospitals on 
behalf of the patients in this study.  The hospitals perform 
sputum and blood cultures on the basis of local guidelines and in 
addition they offered urine antigen testing for Legionella spp. in 
more severe CAP cases.  Of note neither hospital offers urine 
pneumococcal antigen testing.  In addition to the routine clinical 
samples PASS aimed to take a blood culture and send serum for 
flu serology on all patients.  Using these 4 modalities bacteria 
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were identified as the sole cause in 25 patients, flu in 15 patients, 
and 3 had mixed flu and bacterial infections.  Overall 43/169 
(25.4%) had a positive aetiological diagnosis.  This places PASS at 
the lower end of aetiological confirmation studies and at the 
higher end of pragmatic studies and this is not surprising given 
its pragmatic design and the fact that molecular diagnostics were 
not used.  
The top four pathogens identified in PASS were Influenza virus, 
Streptococcus pneumoniae, Haemophilus influenzae and 
Pseudomonas aeruginosa.  This is different to the rank order of 
pathogens summarised in the BTS guidelines (table 1.1).[6]  The 
top four in the BTS summary were Steptococcus pneumoniae, 
Chlamydia pneumonia, Mycoplasma pneumoniae then Influenza 
virus.  The prominence of Haemophilus spp. and Pseudomonas 
spp. in our cohort likely reflects the high rates of COPD and 
smoking.[137,138]  
Rates of detection of Influenza in PASS were within the range 
reported in previous studies.  However, influenza virus has a 
complex relationship with CAP and assertions regarding causality 
are difficult.  Viral pneumonia has long been recognised as an 
entity and Influenza viruses are commonly felt to be the leading 
cause of “virus only” pneumonia.[139]  However, Influenza virus 
is closely linked to the pathophysiology of CAP caused by bacteria, 
and sequential or mixed infections, as detected in three PASS 
patients, are common.[20]  As part of the CAPNETZ programme 
of research a study was conducted to evaluate the impact of 
seasonal influenza vaccination on CAP.[140]  That study used rt-
PCR to detect Influenza virus in respiratory specimens and found 
that positivity rates fell in the winter in response to vaccination 
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and were higher in the summer between rounds of vaccination.  
Patients who developed winter CAP but had received seasonal 
Influenza vaccination fared better across a range of outcomes.  
However, their overall PCR detection rates were low at 3-6%.   
The investigators concluded that this low influenza detection rate 
was likely an under-estimate of the number of influenza related 
CAP cases.   They suggested that influenza infection which led to 
secondary bacterial CAP was unlikely to be detectable by PCR at 
the time of the presentation with CAP.   As molecular techniques 
improve it is clear that many other viruses are also capable of 
influencing the development and course CAP and when we factor 
in the recent shifts in our understanding of the bacteria present 
in the lung it becomes more difficult to clearly define viral from 
bacterial from mixed infections.  
3.3.4.3 Outcomes 
PASS aimed to describe outcomes over one year and mortality 
rates were remarkably similar to a comparable Spanish study 
that also sought to quantify and understand mortality also over 
one year.   That study recorded an in-patient mortality of 8.6%, a 
post-discharge mortality of 7.2% and total one year mortality of 
15.2%; equivalent figures for PASS were 7.7%, 8.3% and 
15.3%.[133]  Both PASS and the Spanish cohort excluded patients 
with immune-suppression but the Spanish cohort included most 
other comorbidities including patients with cancer.  The 7.7% in-
patient mortality in PASS was much lower than in either the 
recent UK based BTS audit of CAP (20.4%) or the German 
CAPNETZ cohort (17.43%).  Both of those cohorts included “all 
comers” with CAP and in particular CAPNETZ demonstrated that 
the highest rates of in-patient mortality were among those who 
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had active malignancy (27.65%).  PASS excluded those with active 
malignancy and also excluded those who were managed 
palliatively, ventilated acutely, or had advanced dementia; 
comorbidities that are associated with significantly increased 
mortality.  Interestingly, the most recent prospective cohort study 
of CAP in the UK reported 30 day mortality of 7.5% which is 
similar to PASS at 8.3%.[132]  That study had similar 
recruitment criteria to PASS in that it excluded thoracic 
malignancy (PASS excluded all active malignancy) and those who 
were not actively treated.  The exclusion of these severely ill 
patients from PASS ought to be reflected in the CURB65 scores 
yet PASS CURB65 scores looked very similar to the BTS audit 
range.  However, the BTS audit summaries collapse CURB65 
scores of 3-5 into a single group.  The rationale for that was that 
any score of 3 and above should be regarded as severe indicating 
the patient should be considered for level 2-3 care (high 
dependency or Intensive care).  Grouping the scores however, 
masks important differences in likely outcome; CURB-65 scores of 
3, 4 and 5 are associated with 30 day mortality rates of 17%, 
41.5% and 57% respectively.[127]  The lack of any score 5s will 
have reduced the overall in-patient and 30 day mortality in PASS.   
3.3.5 Implications 
The effort spent on clinical characterisation and the rich set of 
clinical samples obtained from the cohort allowed experimental 
hypotheses to be tested in the context of known clinical 
phenotypes.  This cohort was a true reflection of hospital CAP in 
our area and the results will be relevant to regions with similar 
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4 WHICH FACTORS ARE ASSOCIATED WITH 
EFFEROCYTOSIS IN PATIENTS RECOVERING FROM 
CAP? 
4.1 Introduction 
4.1.1 Efferocytosis and inflammatory lung disease 
Efferocytosis is the phagocytosis of autologous apoptotic cells (see 
1.6.5).  It is an essential mechanism for returning a site of 
inflammation to its homeostatic state.  In the lung the key effector 
of efferocytosis is the alveolar macrophage.  In health these are 
the most abundant leukocytes in the alveolar space and are (in 
addition to multiple other roles) professional phagocytes.  The 
effectiveness of macrophage efferocytosis has been studied in 
patients with a number of inflammatory lung conditions.  In 
patients with chronic obstructive pulmonary disease (COPD) 
efferocytosis has been shown to be impaired in comparison to 
healthy individuals. [100]  In Cystic fibrosis (CF), non-CF 
bronchiectasis and Idiopathic Pulmonary Fibrosis (IPF), similar 
results have been observed.[141,142] 
4.1.2 Efferocytosis and recovery from pneumonia 
Pneumonia involves pathology in which efficient efferocytosis 
could be expected to be vital for recovery.  The pathophysiology of 
pneumonia is characterised by the recruitment of large numbers 
of neutrophils into alveolar spaces.[20]  This influx is necessary 
and beneficial in terms of pathogen removal by neutrophil 
phagocytosis. However, once the pathogen threat has been 
overcome their presence is a risk to the delicate architecture of 
the gas exchanging structures of the lung.  Removal of 
neutrophils by alveolar macrophage efferocytosis is therefore a 
key process in the resolution of pneumonia.  In addition to the 
87 
 
    87 
 
benefits of removing pro-inflammatory cells, the act of 
efferocytosis has the effect of inducing a pro-resolution phenotype 
on the macrophage with a reduction in the production of 
inflammatory cytokines and an increase in TGF-β production. 
[143]  In mice, during resolution of pneumonia, the efferocytosis of 
neutrophils by alveolar macrophages leads to the secretion of 
hepatocyte growth factor that promotes resolution of 
inflammation. [144] Therefore in the process of understanding 
human recovery from pneumonia, determining if clinically 
significant differences in rates of efferocytosis exist, and 
identifying patient characteristics that are associated with 
impaired efferocytosis, are key steps towards testing possible pro-
resolution, pro-recovery interventions.   Rates of efferocytosis and 
factors that affect this in patients recovering from pneumonia 
have not been previously published.   
4.2 Aim 
To determine the association(s) between observed clinical 
characteristics and efferocytosis in patients recovering from 
community acquired pneumonia (CAP).  
4.3 Hypothesis 
Patients recovering from CAP will display different rates of 
alveolar macrophage efferocytosis that can be predicted by 
observed parameters. 
In order to address this hypothesis alveolar macrophages were 
obtained from Pneumonia Aetiology and Severity Study (PASS) 
subjects who were recovering from CAP and we measured their 
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4.4 Methods 
4.4.1 Subjects and bronchoscopy 
Eligibility, consent, the bronchoscopy procedure and the initial 
processing of bronchoscopy samples are described in sections 2.4, 
2.7.3 and 2.7.10 respectively.  For standard operating procedures 
(SOPs) for the processing of bronchoalveolar lavage (BAL), culture 
of macrophages, separation of neutrophils and the ex-vivo 
efferocytosis experiment (see appendix 2).  Briefly, eligible 
volunteers had bronchoscopy performed one month following 
enrolment into the study.  BAL of the middle lobe was performed 
with 200 ml warm saline which was removed by gentle syringe 
suction.[123] 
4.4.2 Alveolar macrophages 
Alveolar macrophages were derived by centrifugation of fresh 
BAL samples and were confirmed as the dominant population by 
cytospin.  The macrophages were washed and suspended at 1x106 
cells/ml in Iscove’s Modified Dubecco’s Medium (IMDM) 
supplemented with 10% pooled human AB serum (same lot used 
for all experiments) and antibiotics to prevent bacterial and 
fungal growth.  This has previously been described as optimal for 
supporting uncontaminated macrophage growth.[145]  500µl 
(0.5x106 cells) of the macrophage suspension was placed in as 
many wells as possible, (avoiding the outside rows) of a 48 well 
cell culture plate and then incubated for 4 hours at which point 
the media was replaced with antibiotic free media.  The culture 
plates used had a temperature sensitive coating which promoted 
macrophage adhesion at 37˚C but caused macrophages to detach 
at 20˚C (NuncTM, UpCellTM Thermo Scientific).  These plates were 
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chosen as they facilitate maximum macrophage recovery with the 
least amount of cellular damage.[146] 
4.4.3 Autologous neutrophils 
After two hours recovery in the endoscopy unit (during which time 
the bronchoscopy specimens were processed) 36 ml whole blood 
was collected into EDTA bottles from subjects who had undergone 
bronchoscopy. The blood was placed over Polymorphprep™ 
density gradient and spun (see figure 4.1).  This resulted in the 
separation of the whole blood into several layers containing 
different components.  The granulocyte layer (predominantly 
neutrophils) was removed, added to Hepes buffered saline and 
spun to pellet the cells.  Erythrocyte contamination of the 
granulocyte pellet was lysed and the cells washed, re-suspended 
in serum free IMDM and counted.  A cytospin was prepared to 
check that viable neutrophils were the dominant cell population.  
The neutrophil preparation was now divided into two centrifuge 
tubes, spun and both pellets re-suspended in 5 ml serum free 
IMDM.  One neutrophil aliquot was stained green with 
CellTracker™ Green and the other aliquot was left unstained.  
The stained and unstained neutrophil preparations were made up 
to 1x106 cells/ml with IMDM +5% AB serum in cell culture flasks 
and the degree of apoptosis was assessed by flow cytometry (see 
below).  Both culture flasks, containing stained and unstained 
neutrophils were incubated at 37˚C in 5% CO2.  After 20 hours 
incubation the neutrophils were harvested from their flasks, 
washed and counted.  The unstained and stained neutrophils 
were independently re-suspended at 5x106 cells/ml in IMDM + 
10% AB serum.  A cytospin was made of the unstained 
neutrophils to visually confirm features of apoptosis and the 
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PMT=photomultiplier tube.  Note the version used for these 
experiments was set up with a blue and red laser only 
Figure 4.1 Separation of neutrophils from whole blood 
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4.4.4 Measuring neutrophil apoptosis using flow-cytometry  
Four small neutrophil aliquots were washed and suspended in 
annexin binding buffer (a source of Ca2+).  One of the aliquots was 
then stained with annexin V – APC, another with 7-
Aminoactinomycin D (7AAD) and a third with both.  The last 
aliquot was left unstained.  The cells were all acquired on a 
CyanAn-ADPTM benchtop flow cytometer (see figure 4.2 previous 
page) using Summit software version 4.3.02 (Beckman Coulter).  
Figure 4.4 describes the gating strategy for the flow-cytometric 
method for measuring apoptosis.   
4.4.5 Efferocytosis assay 
The media was removed from the macrophages and 500µl of the 
appropriate challenge was added to each well i.e. unstained 
neutrophils, stained neutrophils or media alone.  The macrophage 
plate was then placed back in the incubator.   After 90 minutes, 
during which time efferocytosis took place, the media was 
removed and the macrophage monolayer washed gently to remove 
some of the remaining un-ingested neutrophils (see figure 4.3 for 
an image of the cells in co-culture).  The macrophages from each 
well were then removed to individual centrifuge tubes.  The 
macrophages were washed once, pelleted and re-suspended in 
100µl phosphate buffered saline (PBS).  To quench extracellular 
autofluorescence (see figure 4.5) 100µl crystal violet was added to 
each tube of macrophages and after 30 seconds 1 ml of PBS was 
added and the macrophages washed 3 times before being 








The image above was obtained at the cell imaging suite of the 
University of Liverpool using a Zeiss confocal microscope.  Ex-vivo 
alveolar macrophages and autologous neutrophils are in co-culture in 
complete media in specialised cell imaging wells at 37˚C in 5% CO2.  The 
image is a composite of two images – a standard bright field image is 
combined with a blue laser image.  The bright green small cells 
(fluorescing green in blue laser light) are apoptotic neutrophils that 
have had their cytoplasm stained green (see 4.4.3).  The larger cells are 
healthy alveolar macrophages.  Macrophage podosomes can be seen 
reaching out to neutrophils. 
 
  
Figure 4.3 Confocal fluorescence microscopy image of alveolar 
macrophages in co-culture with apoptotic neutrophils 
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4.4.6 Development of the flow cytometry acquisition protocol to 
determine efferocytosis 
A literature search discovered only one publication of a flow-
cytometric analysis of efferocytosis of neutrophils by 
macrophages.[148]  The following is a modification of that method 
published by Michlewska et al. to suit our application where 
alveolar macrophages are used.[148]  The light scatter 
characteristics of alveolar macrophages, in particular SCC, varied 
considerably between subjects and this was most pronounced 
comparing macrophages from smokers and non-smokers.  Hence it 
was necessary to adapt the above settings using a number of 
different volunteers to create a protocol with acquisition settings 
that would capture all inter-patient variations in macrophage 
light scatter within the plot boundaries (see figure 4.6).  
4.4.7 Analysis of efferocytosis 
See figure 4.7  A sample of green neutrophil apoptotic target was 
acquired first and the light scatter observed on a bivariate plot of 
forward scatter / side scatter (FSC/SCC) using a linear scale.  
Gain and voltage settings were modified to capture the neutrophil 
population in the left hand corner (first log order) of the plot.  
Next a tube of macrophages (unchallenged by neutrophils) was 
acquired and visualised on the same light scatter plot and 
settings adjusted to ensure the whole of the macrophage 
population could be observed.  A gate was drawn around the 
macrophages and this population observed on histogram of log 
FITC.  The FITC voltage was adjusted to place the macrophage 
population in the first log order of this plot.   Next the control 
experiment was acquired which included a mixed population of 
macrophages challenged by unstained neutrophils.  Any 
macrophages that had ingested unstained neutrophils should 
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have an unaltered level of FITC fluorescence.  By observing the 
statistics produced by the software a new gate was created that 
excludes all but the highest 0.1% by FITC expression of these 
control macrophages.  Finally the efferocytosis experiment was 
acquired which was a mixed population of alveolar macrophages 
along with green stained neutrophils.  Any of the gated 
macrophages that had a level of FITC fluorescence greater than 
the control macrophages must have ingested a green apoptotic 
neutrophil.  The read-out of the experiment was therefore the 
proportion of macrophages falling in the high FITC expression 
gate. 
4.4.8 Statistical Analysis 
The analysis was performed using R (R core team, 2013).  
Associations with efferocytosis were analysed by multiple 
regression.  For the purposes of this analysis it was assumed, a 
priori, that efferocytosis is a good thing i.e. a higher value is 
associated with improved outcome following community acquired 
pneumonia.  An initial univariate analysis using the lm (linear 
model) function (core R package) was undertaken to determine 
which observed parameters to select as explanatory variables in 
subsequent multivariate modelling.  For the univariate analysis, 
for each subject, the mean of efferocytosis experimental replicates 
was used. 
A maximal linear mixed effects model using the LME (linear 
mixed effects) function of the nlme package (Jose Pinheiro, 
Douglas Bates, Saikat DebRoy, Deepayan Sarkar and the R 
Development Core Team (2013). nlme: Linear and Nonlinear 
Mixed Effects Models. R package version 3.1-111.) was 
constructed using efferocytosis as the response variable, all 
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correlated variables from the univariate analysis as the fixed 
effects and subject id as a random effect.  The inclusion of the 
random effect “subject id” enabled the stochastic variation 
associated with the experimental technique to be separated from 
the stochastic variation between subjects, a process which was 
helped by including experimental replicates.   
A backwards, stepwise, model simplification was performed to 
derive the minimum set of explanatory variables required to give 
a statistically acceptable fit.  At each stage in the model 
simplification, parameters were removed if their association with 
efferocytosis was not statistically significant (p>0.05).  The 
contribution of individual parameters to the ‘fit’ of the model was 
assessed by likelihood (using ANOVA), equivalent to a likelihood 
ratio test between the model containing and the model without 
the parameter of interest.  Once this model simplification was 
complete, interactions between the remaining explanatory 
variables were explored using ANOVA to compare a null model 
without interactions with a model including interactions.  A 
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Figure 4.4 Flow cytometric 
measurement of neutrophil 
apoptosis 
Top row – neutrophils from 4 tubes are identified by gates labelled with letters.  Bottom row – displays neutrophils from the gates 
above and quadrants identify cells with different staining patterns.  FSC=forward scatter SCC=side scatter.   
[E] unstained (negative control) cells are placed in F--   
[G] cells in early stage of apoptosis (annexin-APC only control) are seen in H-+  
[I] late stage apoptotic cells (7AAD only control) are seen in J++   
[k]Total apoptosis (dual stained) = sum of % cells that fall into L-+ and L++   
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Figure 4.5  Effect of 
quenching on alveolar 
macrophages and 
neutophils 
Top left plots show the light scatter characteristics of two tubes alveolar macrophages from the same subject.  The pair of plots top 
right show the light scatter characteristics of two tubes of green stained neutrophils from the same subject.  The macrophages and 
neutrophils have been gated and those coloured red have been exposed to crystal violet and those coloured green have not.  The plots 
on the bottom row display the FITC signal from (left plot) the gated macrophages and (right plot) the gated neutrophils.  Exposure to 
crystal violet can be seen to reduce the FITC signal of the macrophages and neutrophils by approximately 1 log.       
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Figure 4.6  Comparative light-scatter properties of 
alveolar macrophages from smokers and non-
smokers 
Smokers tended to have significantly greater side scatter 
(SCC) than non-smokers.  Laser light from the cytometer 
is side scattered by internal cellular components and is a 
surrogate for internal complexity.  It is likely that 
particulates from smoking that have been taken up by 
phagocytosis lead to this increased SCC.      
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Figure 4.7 Flow cytometric 
measurement of 
efferocytosis 
Cells in gate [F] are quenched, 
green stained neutrophils.   
 
Gate [D] excludes all but 
0.11% of neutrophils but 
includes alveolar macrophages.   
 
Gate [E] excludes all but 0.1% 
of control macrophages.          
51.87% of macrophages fall in gate [E] in the experimental cells.  This increase in FITC signal (when compared to the control 
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4.5 Results 
4.5.1 Subjects undergoing bronchoscopy 
(See figure 4.8 flow chart).  112 of 169 subjects were seen at 
timepoint 4 (one month follow-up) and were assessed for their 
eligibility for bronchoscopy and bronchoalveolar lavage (BAL).  47 
of those 112 assessed were eligible, of whom 15 declined the 
procedure.  Of those who underwent bronchoscopy, most tolerated 
the procedure well and efferocytosis was analysed among alveolar 
macrophages derived from 22 subjects.  The characteristics of 
those 22 subjects are compared to the complete PASS cohort in 
table 4.1  Compared to those who did not have a bronchoscopy the 
subjects contributing to this work were younger (median age 51 v 
71 years p=<0.0001) and had a higher CRP (median CRP in 
bronchoscopy group 188 v 139 p=0.02).  
4.5.2 Efferocytosis 
BAL produced a range of cell yields and some subjects generated 
enough alveolar macrophages for several replicates of the 
efferocytosis experiment: see table 4.2 for the raw data.  Levels of 
apoptosis among neutrophils cultured for 20 hours varied between 
subjects.  In order to control for the proportion and degree of 
apoptosis in each subject’s neutrophils we quantified these 
parameters and included them as explanatory variables in the 
regression analysis.  In both the univariate analysis and mixed 
effects modelling there was no association between the proportion 
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Figure 4.8 Bronchoscopy subjects flow-chart 
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Median Age, (IQR) 51(42-58) 71(56-79) <0.0001# 
Male, n (%) 14(63.6) 74(50.3) 0.7* 
Smoking,  
n (%) 
Active 13(59.1) 50(36.0) 
0.7* Quit 4(18.2) 62(44.6) 





0 13(59.1) 43(29.3) 
0.8* 
1 5(22.7) 64(43.5) 
2 2(9.1) 16(10.9) 
3 2(9.1) 15(10.2) 
4 0 6(4.1) 
5 0 2(1.4) 
6 0 1(0.7) 
Prior statin use, n (%) 5(22.7) 52(35.6) 0.7* 
COPD, n (%) 6(27.3) 67(45.6) 0.7* 
CURB65, n (%) 
0 14(63.6) 26(17.7) 
0.7* 
1 2(9.1) 37(25.2) 
2 5(22.7) 45(30.6) 
3 1(4.5) 35(23.8) 
4 0(0) 4(2.7) 
5 0(0) 0(0) 
Presenting CRP, 
median (IQR) 
188(135-316) 139(60-229) 0.02$ 
BMI, median (IQR) 27(24-30) 24(22-31) 0.8$ 
Flu, n (%) 5(23.8) 13(15.1) 0.7* 
Pneumococcal 
bacteraemia n (%) 
3(13.6) 5(3.6) 0.7* 
#  Wilcoxon rank sum test 
* Chi squared test 
$ Welch’s t test 
Data was incomplete for the highlighted clinical variables, n for 
those groups is indicated below:- 
Smoking status, no bronchoscopy group, n=139 
CRP, no bronchoscopy group, n=144 
BMI, no bronchoscopy group, n=109 
Flu, bronchoscopy group, n=21; no bronchoscopy group, n=86 
Pneumococcal bacteraemia, no bronchoscopy group, n=137 
Prior statin use, no bronchoscopy group, n=146 
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42 39.8 4661 3.0 
42 41.5 4661 2.5 
1420 64.6 4690 18.9 
1420 58.6 5048 45.7 
1571 6.4 5048 44.0 
2123 17.5 5432 9.7 
2123 21.0 5432 7.9 
2506 26.9 6391 58.6 
2506 31.8 6391 58.3 
2738 6.5 6391 70.9 
2738 5.3 6391 61.8 
2738 6.1 6391 54.8 
2738 3.0 6391 53.2 
2841 41.8 7094 31.7 
2841 44.0 7201 36.2 
3091 4.3 7201 40.6 
3091 8.6 8902 7.8 
3091 7.5 8902 4.7 
3925 1.5 8902 7.6 
3967 58.1 8902 7.7 
3967 59.8 8914 11.6 
3967 69.2 8914 13.6 
4105 1.4 9961 6.8 
4105 3.0 9961 8.2 
4238 7.6   
4238 7.7   
4238 5.8   
 
  
Subjects are arranged by study id number in the shaded columns.  
Multiple efferocytosis values for a single id are experimental 
replicates.  Highlighted values indicate outliers as identified in figure 
3.16 and 3.17 
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4.5.3 Univariate analysis 
Univariate analysis of the mean of replicates for each subject 
revealed four variables that were significantly (P<0.05) correlated 
with efferocytosis: smoking status, prior statin use, BMI and 
gender (see table 4.3 and the figures 4.9 – 4.13).  Three subjects 
presented at recruitment with consolidation which was reported 
to include the right middle lobe.  Presence or absence of middle 
lobe consolidation was included as a variable in the univariate 
analysis of factors which may affect rates of efferocytosis and no 
statistically significant association was found (table 4.3). 
 
4.5.4 Multi-variate analysis using a linear mixed effects 
model 
Variables which were significantly associated with efferocytosis in 
univariate analysis were combined in a maximal linear mixed 
effects model.  Those variables that were not significantly 
correlated with efferocytosis when combined were sequentially 
removed from the model.  This backwards stepwise approach is 
explained further in table 4.4.  The final model, containing only 
variables with statistically significant effects (P<0.05), included 
the interaction of smoking status and prior statin use with 
adjustment for BMI.   
4.5.5 Exploring the residuals to assess the fit of the model 
From a plot of the residuals of the efferocytosis data against the 
fitted values from the model it was possible to detect a pattern 
with largest variance at large fitted value (figure 4.14).  The above 
analysis was therefore re-run with log transformed efferocytosis 
values (figure 4.15).  The residual plot from the log transformed 
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data  showed largest variance at small fitted values.  Several data 
points were identified as outliers and were removed (figures 4.16 
and 4.17).  In each case these represented anomalous 
experimental replicates from a set of replicates of an individual 
subject’s efferocytosis experiment.  The modelling was re-run with 
these replicates removed and the resulting residual plot was 
satisfactory – i.e. was consistent with a model which fitted the 
data (figure 4.18). 
4.5.6 Final model characteristics 
The final model that best explained this non-transformed data 
with outliers removed data was an interaction between smoking 
status and statin use adjusted for BMI.  The model accounted for 
72.0% of the variation in the data of which 83.1% was explained 
by inter-subject variation and 17.0% by intra-subject 
(experimental replicates) variation.  The log likelihood of the 
model was -119.4.  The parameter estimates for the interactions 
in this final model can be seen in table 4.5 and a graphical 
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Statin use 34.98 19.33 to 50.62 0.497 0.0001 
Smoker 10.13 2.7 to 17.6 
0.62 
0.01 
Ex-smoker 39.93 24.6 to 55.2 <0.0001 
Never smoker 26.17 12.1 to 40.3 0.0009 
Gender 19.7 2.3 to 37.12 0.18 0.03 
BMI 1.77 0.116 to 3.43 0.167 0.037 
Oral steroid use -21.56 -47.26 to 4.14 0.09 0.096 
Macrolide use -21.03 -46.8 to 4.77 0.08 0.105 
Admission CAP-
sym score 
-0.426 -1.1 to 0.25 0.03 0.203 
COPD -12.67 -33.10 to 7.76 0.03 0.21 
Presenting aPTT 
waveform 
-0.52 -1.39 to 0.35 0.03 0.227 
Late apoptosis -0.9 -2.49 to 0.69 0.019 0.25 
Early apoptosis -0.16 -0.55 to 0.23 -0.012 0.394 
Combined apoptosis -0.102 -0.44 to 0.24 -0.029 0.538 
Pneumococcal blood 
culture positive 
-0.42 -41 to 12.6 -0.03 0.57 
Presenting pro-
calcitonin 
0.44 -1.17 to 2.05 -0.03 0.574 
Inhaled steroid use -4.85 -29.3 to 19.6 -0.041 0.683 
Presenting CRP -0.01 -0.08 to 0.06 -0.04 0.689 
CURB65 1.15 -8.58 to 10.89 -0.047 0.81 
Age -0.03 -0.64 to 0.58 -0.05 0.9 
Influenza infection -1.15 -24.2 to 21.9 -0.05 0.93 
Middle lobe 
consolidation 
0.81 -26.8 to 28.4 -0.05 0.95 
Mean % efferocytosis was calculated from replicate wells for each 
subject.  Using linear modelling we performed a univariate analysis to 
determine which clinical covariates were associated with 
efferocytosis.  Variables in the lower, shaded part of the table showed 
no statistically significant association with efferocytosis.  Macrolide 












Figure 4.9 Relationship between BMI and efferocytosis 
Figure 4.10 Relationship between age and efferocytosis 
This page and next - representative plots of the univariate analysis of 
observed variables with efferocytosis.  Fig.4.9 A positive association 
between BMI and efferocytosis (p=0.036).  Blue line represents the 
fitted linear model with the shaded area showing the 95% confidence 
intervals.  Fig. 4.10 No significant association was found between age 
and efferocytosis (p=0.9).  Fig.4.11 Men had higher efferocytosis than 
women (p=0.03).  Fig. 4.12 Smoking status was associated with 
efferocytosis (p<0.01).  Fig.4.13 Statin use was associated with 
efferocytosis (p=0.0001).  
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Figure 4.11 Relationship between gender and efferocytosis 
Figure 4.12 Relationship between smoking and efferocytosis 
Figure 4.13 Relationship between statin use and efferocytosis 
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Model Parameters Log Likelihood of Model 
Comparison of Models 
1 
Statin + Smoking + Gender + BMI + 
macrolide + flu 
-120.9 
2 
Statin + Smoking + Gender + BMI + 
flu 
-121 Anova 1 v 2 P=0.75 (no difference – lose macrolide) 
3 Statin + Smoking  + BMI + flu -122 Anova 2 v 3 P=0.16 (no difference – lose gender) 
4 Statin + Smoking  + BMI -122.1 Anova 3 v 4 P=0.77 (no difference – lose flu) 
5 Statin + BMI -131.1 Anova 4 v 5  P=<0.0001 (favours 4 keep smoking) 
6 Statin + Smoking  -124.2 Anova 4 v 6 P=0.04 (favours 4 keep BMI) 
7 Smoking  + BMI -134.5 Anova 4 v 7 P=<0.0001 (favours 4 keep statin) 
8 Statin * Smoking + BMI -119.5 Anova 4 v 8 P=0.05 (favours 8 – keep interaction) 
This regression was based on data from 20 of the 22 subjects.  The two exclusions had missing values for some of the covariates of interest.   
 
Model 1 is the maximal model including all the statistically significant covariates from the univariate analysis.   
 
Model 2 has the term “macrolide” removed as it was least significant in model 1.  When models 1 and 2 were compared using analysis of variance 
(anova), there was no statistically significant difference (i.e. P= >0.05) indicating “macrolide” makes little contribution.   
 
The above process was repeated until the three variables smoking, statin and BMI remained; all three were shown to significantly increase the log 
likelihood of the model when included. 
 
Model 8 includes and interaction (symbol *) between smoking and statin and this produced a significant increase in the log likelihood by comparison 
with model 4 (which had the same variables but no interactions). 
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Final Model (model 8) Interactions Estimate Standard error Log likelihood of model 
Statin * Smoking + BMI 
Smoking active | no statin 
Smoking active | statin 
Smoking never | no statin 
Smoking never | statin 
Ex-smoker | no statin 

















A linear mixed effects model took each of the six combinations of smoking status and statin use and summarised the relationship by 
one of six parallel lines.  Each line had slope 0.6 and intercepts, as given in the “Estimate” column of the table, representing the 
estimated mean efferocytosis value for subjects in each interaction group.  The precision of these estimates is indicated by the standard 
errors.   
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This is generated from the same model using log transformed 
efferocytosis values and residuals and shows a reversed pattern 
with increasing variance – this time at lower fitted values.   
Figure 4.14 Residuals versus values fitted by the efferocytosis 
model 
Figure 4.15 Residuals versus fitted values from modelling log 
transformed efferocytosis data 
The residuals of the efferocytosis data plotted against the fitted 
values from the final LME model.  The “horn-shaped” distribution 
(with the horn bell to the right) suggests this model is not a good fit 
for the data.  This may be caused by the non-normal distribution of 
the efferocytosis data or by a number of outliers that are influencing 
the fit of the model. 
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Figure 4.16 is identical to plot 4.14 but this time two data-points 
have been identified as having a residual value outside of the 95% CI 
for all residuals.  These points have been labelled with their row-
names in the data-frame. 
Figure 4.17 point 37 and 22 have been removed and repeated 
analysis reveals point 38 is an outlier in this new distribution. 
Figure 4.18 with point 38 removed the analysis is re-run and no 
outlying residual values are found.  This distribution of residuals now 
looks more random, indicative of a better model fit. 
Figure 4.16 Two experimental replicates are identified as 
outliers 
Figure 4.18 An acceptable residual plot following removal 
of outliers 
Figure 4.17 A further outlying experimental replicate 
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The result of the linear regression was a 
model that included the interaction of 
smoking and statin with adjustment for BMI. 
 
The  efferocytosis values fitted by the model 
are on the Y axis with BMI on the x axis.  
Points are “jittered” to avoid overlap 
 
 
The interactions of each level of smoking and 
statin are represented by 6 straight lines.  
These lines are displayed in colour pairs 
based on smoking status. 
The y intercepts of each line are derived from 
the model as is the BMI dependent slope of 
0.6. 
 
From these lines it can be seen that without 
statins the differences between smoking 
status are large but with statins the 
differences are smaller.  The magnitude of 
the statin effect is greatest in smokers. 
Figure 4.19 Graphical representation of the final linear mixed effects model 
of efferocytosis 
4.6 Discussion 
4.6.1 Summary of results 
The results show that in this cohort of patients recovering from 
CAP, variation in efferocytosis was best explained by an 
interaction between smoking status and prior statin use with the 
model being adjusted for BMI which had a positive association 
with efferocytosis.  Efferocytosis was negatively associated with 
smoking and positively associated with prior statin use and the 
effect of statin was maximal in those who smoked although this 
finding was not statistically significant.   
4.6.2 What were the strengths of this work? 
4.6.2.1 Study design and cohort characteristics 
As described in chapter 3, the subjects enrolled in this study were 
carefully characterised.  It is therefore possible to extrapolate 
these results to other study cohorts with similar characteristics 
and, with certain caveats (see below), to the generality of adult 
patients with CAP.   
4.6.2.2 Neutrophils 
The use of neutrophils as the apoptotic target in the efferocytosis 
assay is more pathophysiologically appropriate, in the context of 
CAP, than the immortalised T cell lines that are commonly used.  
Moreover, because we used autologous neutrophils we were able 
to control for the possibility that unknown ‘self’ receptors may 
play a role in the recognition of apoptotic cells by macrophages.  
There are various ways to derive apoptotic neutrophils and the 
most commonly used methods are induction by exposure to UV 
light or reagents such as corticosteroids.[149]  The advantage of 
these techniques is that a consistently high proportion of a 
population of exposed neutrophils can be rendered apoptotic in a 
short period of time.  However, both of these methods are artificial 
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and don’t necessarily replicate the state of neutrophils in a lung 
recovering from an acute inflammatory insult.  In vivo, due to 
their terminally differentiated nature, all neutrophils will 
naturally progress towards apoptosis but the rate at which they 
apoptose depends on many factors including how recently they 
have arrived in the lung, the local cytokine profile and whether or 
not they have encountered a pathogen.[99]  This natural 
progression to apoptosis can be approximated ex-vivo by 
prolonged culture in media containing human serum, as was done 
here.  Whilst this method of apoptotic induction is likely to be 
closer to the in vivo situation, patient factors determine that a 
varied proportion of apoptotic cells are produced.  In order to 
control for the proportion and degree of apoptosis in each subject’s 
neutrophils we quantified these apoptotic parameters in the cells 
offered for efferocytosis.  Despite there being a wide range of 
apoptosis between subjects’ neutophils, in  the univariate analysis 
there was no association between the proportion of apoptotic 
neutrophils and rates of efferocytosis.  This finding may be a 
function of the 5:1 ratio of neutrophils to macrophages – even if a 
smaller proportion of neutrophils were apoptotic, each 
macrophage was never far from a potential target.   
4.6.2.3 Replicates 
From the BAL to the cytometer the alveolar macrophages were 
pipetted and washed 10 times and transferred between 5 pieces of 
plastic ware with each of these steps introducing the potential for 
laboratory variation between assays. However, in 18/22 subjects 
we had enough cells to run at least one replicate well of the 
efferocytosis experiment.  This enabled an accurate assessment of 
the contribution of experimental variation to the final 
efferocytosis result by specifying ‘subject id’ (a surrogate here for 
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replicate) as a random effect in the mixed effect model.  This has 
two benefits: - first we can confidently conclude that the effect of 
laboratory error on the variability of the efferocytosis data was 
minor (17.0% of data variation) in comparison to the inter-subject 
variation (83.1% of variation).  Secondly, a detailed knowledge of 
the extent of assay variation gives us the ability to impute more 
accurate estimates of effect size and standard deviation for 
sample size calculations in future studies involving measures of 
efferocytosis.   
4.6.2.4 Simplicity of the cytometry 
Our flow-cytometric method of estimating efferocytosis was based 
on gating macrophages by their light scatter characteristics from 
a plot of all cells harvested from the efferocytosis well.  This 
method has the advantage of requiring fewer preparatory steps 
than gating strategies based on staining surface markers and 
enabled us to study fresh, unfixed, unstained macrophages.  As 
well as adding steps to an already involved SOP, immunologically 
labelling cell surface markers can activate cell processes that may 
affect efferocytosis and by avoiding this we can remove a source of 
misinterpretation.     
4.6.3 What were the limitations of this work? 
4.6.3.1 Study design and cohort characteristics 
The design of the Pneumonia Aetiology and Severity Study 
(PASS) imposed certain limitations on the degree to which the 
results of these experiments can be extrapolated.  PASS screened 
thousands of acute admissions across two hospitals to recruit 169 
patients with pneumonia (see chapter 2 more a more in depth 
discussion of PASS).  Primarily because of ineligibility due to co-
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morbidity, only 22 patients contributed cells to the efferocytosis 
study. Of these only 5 were never smokers and of the smokers all 
but one was not taking a statin.  Therefore analysis of sub-groups 
had no statistical power.  It would be interesting to see which 
factors - age, BMI, statin and macrolide use for example - 
influence efferocytosis in a larger group of non-smokers and 
whether the trends seen here with statin use are replicated in 
larger cohorts.  
The majority of patients with CAP in the UK and similar 
developed nations are treated in primary care.  Since PASS 
sampled a population admitted to hospital we do not know which 
factors  most influence efferocytosis in CAP patients treated in 
the community.  In our analysis smoking had a dominant effect on 
efferocytosis, even when adjusted for factors such as and COPD, 
steroid use and initial CAP severity, factors which could be 
expected to be more influential in a hospital population than in 
primary care.  Given this, it may be that smoking has a more 
dominant effect in a community population with fewer and less 
severe comorbidities and milder CAP.  PASS also excluded the 
most severe CAP cases that were unable to complete the CAP-sym 
questionnaire due to being moribund or ventilated on critical care.  
It may be that effects of the intubation, ventilation and severe 
sepsis dominate in that group and that smoking and statins are 
relatively less influential.   
All subjects who contributed to the efferocytosis data were 
caucasian apart from one – a distribution that reflects the 
population served by our hospitals.  It is therefore not possible to 
extrapolate these results to the rest of the world or indeed many 
areas of the UK where racial factors may be influential. 
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4.6.3.2 Timing and longitudinal effects 
We chose one month following admission from hospital for the 
timing of our efferocytosis experiment since this was felt to best 
balance, on the one hand, the desire to capture the recovery phase 
of CAP, and on the other the risks associated with bronchoscopy 
in unstable patients. It was clear to the author that earlier, 
awake, research bronchoscopy and BAL would be unsafe and 
poorly tolerated in many patients recovering from CAP.  
Restrictive spirometry and cough were a very common finding at 
discharge and would have led to poor cell yields even in those who 
could safely complete the procedure.   
Three of the subjects were recovering from CAP which had been 
radiologically reported as involving the right middle lobe.  Since 
we consistently lavaged the middle lobe it is possible that the 
recent local inflammation of that lobe may have affected rates of 
efferocytosis in those three patients when compared to those 
whose inflammation was radiologically elsewhere.  Any difference 
associated with middle lobe consolidation was small as no 
statistically significant difference was detected in the univariate 
analysis.  Two possible interpretations of this are that despite the 
radiological appearances of lobar disease the CAP was infact 
widespread leading to relative similarity between middle lobe and 
non-middle lobe pneumonias with repsect to efferocytosis.  An 
alternative explanation is that any differences relating to lobe of 
CAP had resolved and we were in fact measuring efferocytosis in 
stable state.  Furhter studies of a different design would be 
required to tease these possibilities apart. 
To confidently conclude that we were assessing efferocytosis 
under the influence of recovery – rather that in stable state, it 
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would be necessary to perform repeat bronchoscopies on each 
subject.  This was an ambition for this study but only 2 subjects 
successfully contributed paired efferocytosis data and an analysis 
of these was not attempted.  What we have learnt is that a much 
larger cohort would be needed to capture enough subjects willing 
and able to accept repeat bronchoscopy. 
4.6.4 Comparison with other published work 
4.6.4.1 Mechanistic  studies of cigarette smoke on 
efferocytosis   
A number of studies have investigated the mechanisms by which 
cigarette smoke leads to impairment in efferocytosis.  Hodge et al. 
demonstrated that smoking has a detrimental effect on the 
efferocytosis of apoptotic alveolar epithelial cells (immortalised 
cell line) by alveolar macrophages. [150]  The effect was greatest 
in smokers with established COPD, but was significant even in 
smokers who were otherwise healthy.  The effect of smoking was 
at least partly reversible.  Efferocytosis improved when those with 
COPD stopped smoking reaching higher levels than ‘healthy’ 
active smokers but did not return to the levels of never smoking 
controls.  Kirkham et al showed that monocyte derived 
macrophages had a greater propensity to adhere to surfaces 
coated in extracellular matrix proteins that had been exposed to 
cigarette smoke extract (CSE). [151]  Reactive carbonyl groups in 
CSE led to modification of these proteins and macrophages that 
were adherent to them showed reduced efferocytosis of apoptotic 
autologous neutrophils.  More recently Minematsu et al. have 
shown that exposure to CSE leads to impairment of RAC1 and 
consequently impairment of the cytoskeletal rearrangements 
required for phagocytosis – including efferocytosis. [152]  Noda et 
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al studied the efferocytosis of apoptotic human neutrophils by 
mouse alveolar macrophages.   They found that pre-treatment of 
macrophages with cigarette smoke extract (CSE) impaired the 
function of the enzyme histone deacetylase (HDAC) a consequence 
of which was inhibition of RAC and impairment of 
efferocytosis.[153]  More recently Petrusca et al have shown that 
cigarette smoke inhibits the enzyme ACDase which catalyses the 
conversion of ceramide to sphingosine.  This results in an increase 
in sphingosine which in turn has an inhibitory effect on HDAC6 
and  reduced efferocytosis. [154]  In summary, cigarette smoke 
affects several molecular pathways that lead to the activation and 
membrane localisation of a key enzyme RAC – the function of 
which is to facilitate the cytoskeletal rearrangements needed for 
efferocytosis.  RAC is a member of the family Rho GTPases and 
the finding that cigarette smoke has an effect on these is 
intriguing in the light of the results of this study since, as will be 
seen below, one of the ‘off-line’ effects of statins is their effect on 
the balance of Rho-GTPases.[155] 
4.6.4.2 Statin effects on efferocytosis 
Statins are reversible inhibitors of the enzyme HMG-CoA 
reductase which is involved in cholesterol biosynthesis in the 
liver.  They are extensively prescribed to reduce LDL-cholesterol 
(LDL) with the aim of cardiovascular disease risk modification.  
However, statins have many “off-line” effects, i.e. those beyond 
their desired primary pharmacologically intended effect.[156]  
Some of these effects are thought to be responsible for highly 
beneficial effects beyond their lipid lowering potential.  The 
JUPITER study demonstrated that, in 17802 subjects with 
normal LDL but raised CRP, rosuvastatin led to a significant 
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reduction in cardiovascular events, suggesting an anti-
inflammatory role.[157]    
One statin effect is the inhibition of isoprenylation which is a key 
mechanism in the post translational modification of many 
proteins including the Rho GTPase family.   Exposure to statins 
inhibits the isoprenylation of RAC and RhoA leading their 
inactive forms to sequester in the cytosol.[156]  RAC facilitates 
efferocytosis and RhoA is inhibitory. [158]  This has led several 
investigators to study the effects of statins on efferocytosis.  
Morimoto et al found that lovastatin inhibited the membrane 
localisation of RhoA and RAC1.  The effect was greater on RhoA 
and the balance of these two anatagonistic enzymes was such that 
efferocytosis of apoptotic neutrophils was potentiated. [102] 
 
Taken together the studies above suggest that smoking reduces 
efferocytosis by the impairment of RAC1 whereas statins alter the 
membrane balance of RhoA and RAC1 in such a way as to 
increase efferocytosis.  This provides a possible mechanistic 
explanation for the findings of our study – that smoking impairs 
efferocytosis but statins can moderate the effect.   
4.6.4.3 BMI and lung disease and efferocytosis 
Several studies have demonstrated strong associations between 
BMI and risk of CAP.  Phung et al reviewed the relationship 
between BMI and risk of developing CAP and found that those 
who were underweight had an 80% increase in their risk of 
developing CAP where as those who were overweight had an 11% 
reduction in risk.  The risk increased again, though not 
statistically significantly, in those categorised as obese.[159]  
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Our results suggested a statistically significant association 
between BMI and efferocytosis such that as BMI increased so did 
efferocytosis and this association has not been shown previously.   
If increased efferocytosis is regarded as beneficial then one would 
expect increased BMI to be associated with better outcome in 
CAP.  The literature supports this with several studies 
consistently demonstrating reduced mortality in those with high 
BMIs.    Kalon et al compared mortality between those who were 
under weight, normal weight, overweight or obese.  They 
demonstrated a statistically significant reduction in mortality, in 
the obese patients (BMI>30) compared to those with normal 
weight and this was not replicated in those who were overweight 
or underweight.[160]   
It may be that differential rates of efferocytosis are in part 
responsible for the association between BMI, risk and outcome in 
CAP.  Studies have suggested a role for the adipokine adiponectin 
in modulating inflammatory responses in acute and chronic 
inflammatory conditions including those of the lung.[161]  Some 
of these studies demonstrate direct effects of adiponectin on 
innate immune cells and a possible mechanistic link between 
adiponectin levels and efferocytosis may be worth exploring.  
However, in other inflammatory lung diseases the association 
between efferocytosis and BMI is negative and it is clear the 
interactions are complex.[162]   
4.6.5 Implications 
4.6.5.1 Future assay development 
It is now clear that alveolar macrophages have distinct 
immunological properties that distinguish them from 
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macrophages resident at other anatomical sites, and that their 
phenotype it plastic.  We did not attempt a phenotypic 
examination of our cells but it would be fascinating to explore the 
initial phenotype recovered from the subjects and to relate this to 
the potential for efferocytosis and to patient related factors – in 
particular the effect of prior statins and steroid use on phenotype.   
In the literature and by personal communication with experts we 
were unable to find a single reagent or simple panel of reagents 
that could reliably separate human alveolar macrophages from 
autologous apoptotic neutrophils.  CD16b is said to be a specific 
marker of neutrophil granulocytes but is lost during apoptosis.  A 
combination of CD14 and 16 have been used to distinguish the 
two cell types but some cells in both populations express both.  It 
was beyond the scope of this study to enter into a systematic 
validation of new surface marker combinations and our solution 
was to use the distinct size and granularity differences between 
the populations to identify a gate that excluded the vast majority 
of neutrophils while capturing macrophages.  Light scatter has 
been used in this way in previous studies [148], however this 
strategy excludes a proportion of macrophages whose light scatter 
over-laps with that of the neutrophils and we were therefore not 
able to assess efferocytosis in this population.  A future project 
would be to identify a panel of reagents that would enable the two 
cell types to be sorted enabling the efferocytotic potential of the 
whole macrophage population to be assessed. 
4.6.5.2 Clinical implications 
On the basis of this data, subjects with low BMI have lower rates 
of efferocytosis and could therefore be expected to recover more 
slowly and may benefit from enhanced follow-up and, in the 
125 
 
    125 
 
future, from pro-recovery therapy in the form of dietetic advice 
and supplementation, pro-resolution medication and or physical 
rehabilitation.  This association has not been proven by this study 
but the data would suggest it should be studied in future 
observational studies 
The detrimental effects of smoking are well known and 
epidemiological studies have demonstrated that up to 50% of 
pneumococcal pneumonia cases in smokers can be attributed to 
smoking [22].  Clearly prevention by promoting smoking cessation 
is the best strategy but in order to develop interventions to 
improve recovery from CAP the mechanisms involved must be 
elucidated. This is reinforced by evidence which suggest that 
although some BAL parameters improve within the first month 
following smoking cessation, the alveolar macrophage cytometric 
abnormalities described in figure 4.6 remain for at least 15 
months.[163]  This implies that even if patients were to give up 
smoking at the time of developing pneumonia and remain 
abstinent throughout their recovery their alveolar macrophage 
function may remain abnormal. The demonstration of a link 
between smoking, statins and efferocytosis provides a potential 
target for trials of treatment.  In chapter 5 the effect of 
efferocytosis on outcomes following CAP will be explored.   
The effect of statins in the context of patients with CAP is 
controversial. The proposed benefits can be split into reduced risk 
of developing pneumonia [164,165] and improved outcome 
subsequent to the onset of pneumonia [166,167].  From a 
therapeutic perspective it is not clear if any potential benefit is 
seen acutely [168] or whether the effects are mediated during the 
convalescent phase [169].  Moreover, there is significant debate in 
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the literature as to what extent all these potential benefits are 
due to confounding as a result of the healthy user effect [170,171].   
What is clear is that statins do have a range of measurable 
immune-modulatory effects.  Murine pneumonia models have 
shown that, when fed to mice, statins have a wide range of effects 
such as reduced consolidation due to reduced neutrophil 
migration – but the overall impact on mortality is small [172].  All 
authors are consistent in suggesting that the only way to solve the 
question of whether statin effects are beneficial in pneumonia is 
to conduct randomised control trials.  It will be vital that these 
trials are designed to take into account the available mechanistic 
data.  Subjects will vary in their response to statins and trials 
should be designed to test for effects in those most likely to derive 
benefit and from the evidence of this study that would be 
smokers. 
5 WHICH PATIENT FACTORS ARE ASSOCIATED WITH 
SPUTUM MICROBIOTA IN CAP? 
5.1 Introduction 
The concept of a bacterial microbiome and contemporary work on 
describing this in the lower airway was discussed in chapter 1.  
An analysis of the bacterial microbiota of sputum from patients 
with community acquired pneumonia (CAP) has only been 
published once previously in a cohort of 45 patients recruited in 
China.[173]  That work focussed on defining bacterial community 
differences between health, CAP and Hospital Acquired 
Pneumonia (HAP).  Those distinctions are important but in 
addition it would be useful to determine if the range and relative 
abundance of various bacteria differs in association with other 
clinical features.  Understanding these differences may give an 
insight into the biology of pneumonia but may also have clinical 
implications for the future.  The ability to refine future empirical 
antibiotic therapy based on how clinical factors influence the 
bacterial patterns in CAP may lead to improved outcomes.  We 
therefore conducted an analysis of the bacterial microbiota of 
sputum collected from patient in the Pneumonia Aetiology and 
Severity Study (PASS) and related the microbiota to clinical 
variables. 
5.2 Hypotheses 
a) The bacterial community composition of sputum from 
patients with CAP is influenced by pre-existing patient 
characteristics. 
b) The abundance of individual bacterial taxa in sputum from 
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5.3 Methods 
5.3.1 Subjects and samples 
The study team collected sputum samples from subjects who were 
able to self-expectorate at the time of enrolment into the 
Pneumonia Aetiology and Severity Study (PASS).  Sputum was 
collected into security sealed, gamma irradiated pots and within 
one hour of collection these were frozen at -80°C without the 
addition of any additives or processing.  These samples were 
independent of those taken at the discretion of the clinical teams 
for clinical microbiological investigation. 
5.3.2 DNA extraction 
Sputum samples were defrosted in batches of 24 or 48 and kept on 
wet water ice.  DNA extraction was performed using the 
proprietary ‘FastDNA™ SPIN Kit for Soil’ from MPbio.  The kits 
were used in accordance with the manufacturer’s instructions and 
using a standard operating procedure optimised by the National 
Heart Lung Institute (NHLI).  In brief: - 300µL of mucopurulent 
sputum was added to lysing matrix tubes which were pre-filled 
with buffers to protect and solubilise DNA following cell lysis.  
Cell lysis was achieved using an MPbio FastPrep®-24 bench-top 
homogeniser (figure 5.1).  The resulting lysate underwent 
prolonged high-speed centrifugation to pellet the lysing beads and 
cell debris.  The supernatant was mixed with protein precipitation 
solution and pelleted. The DNA containing supernatant was 
removed from the protein pellet, added to a suspension of DNA 
binding matrix, and left to adhere.  The binding matrix was 
placed in a tube containing a fine filter and centrifuged.  The 
liquid component passed through the filter leaving the DNA laden 
matrix above the filter.  Finally the DNA was eluted from the 
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binding matrix by re-suspending the matrix in 100µL DNAase 
free water and centrifuging.  The matrix remained above the filter 
and the 100µL of concentrated DNA solution was removed from 






















Figure 5.1 Lysing sputum to obtain DNA 
A) An aliquot of each subject’s sputum is placed in a pre-labelled 
lysing matix tube along with stabilisation buffers.   
B) Optimised mix of ceramic and silica beads of various sizes 
mechanically degrade cell walls when sample is agitated.   
C) 24 samples are clamped in place in the carousel of a ‘bead beater’.  
Samples are homogenised by rapid, multi-directional movements 
which lead to bead impaction and cell lysis. 
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5.3.3 16S rRNA PCR 
To identify which bacterial taxa were present in the sputum 
samples we amplified the V3-V5 regions of the 16S rRNA gene 
(see section 1.6.3 for background).  PCR preparations were made 
in a dedicated PCR hood in a dedicated room in which no DNA 
template was stored.  We used a 25µl PCR based on a standard 
operating procedure (SOP) that had been optimised by the 
department of Genomic Medicine at the NHLI.  The SOP included 
a proprietary DNA polymerase master-mix from New England 
BioLabs Inc.  The following reagents were mixed to create a stock 
solution and then 23µl was added, to each well of a 96 well PCR 
reaction plate:- 
 Q5® master High Fidelity Master Mix containing: 
o DNA polymerase, 
o a source of Mg++,  
o a proprietary buffer 
o deoxynucleotides 
 High purity molecular grade water 
 16S rRNA V3-5 forward primer 
5’CCGTCAATTYMTTTRAGT3’ 
 
Next 1µl of “bar-coded” reverse primer 
5’CCTACGGGAGGCAGCAG3’ was added to each well – the same 
primer with a different bar code for each well.[174]  The use of a 
bar-coded primers meant the 16S rRNA amplicons generated by 
the PCR reaction would include in their sequence a short 
nucleotide string (analogous to a bar code) which was unique to 
that sample. This bar-code would eventually allow amplicons 
derived from individual samples to be identified (by their bar 
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code) from a mixture of many samples.  Lastly, 1µl of template 
DNA (DNA derived from each sputum sample to act as a template 
for replication during the PCR reaction) was added to 94 of the 96 
wells.  The 95th well had no template and acted as a negative 
control and the 96th well had 1µl of template DNA derived from a 
pure culture of Vibrio natriegens, a halophile (salt loving) bacteria 
first isolated from salt marshes and not known or suspected of 
being present in the lower airway.  The PCR plate was then 
sealed and briefly centrifuged before being placed on the thermal 
cycler.  Reaction steps for the 16S rRNA PCRs were:- 
95oC for 2 minutes then 35 cycles of :- 
95oC for 20 seconds 
50oC for 30 seconds 
72oC for 5 minutes 
For each sputum derived DNA sample, the above was repeated 4 
times i.e. for each sample we conducted four separate but 
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5.3.4 Quality control of PCRs 
When each PCR plate had completed its thermal cycling we took 
aliquots from a sub-set of the samples (one row) and performed an 
agarose gel electrophoresis (figure 5.2). This quality control step 
checked for the presence of a DNA band of an approximate weight 
equivalent to that of the 16S rRNA gene in the positive control i.e. 
the PCR had been successful.  It checked for an absence of a band 
in the negative control – i.e. the PCR reagents were not grossly 
contaminated with bacterial DNA.  And finally it checked that at 
least some of the samples had positive bands – i.e. the quantity of 
template DNA had generated an adequate amplicon level to take 
forward to sequencing. 
 
  
Figure 5.2 Agarose Gel Electrophoresis of a 16Sr RNA PCR 
DNA is stained with a fluorescent intercalating nucleic acid stain 
called ‘Gel Red’ the fluorescent intensity of which increases when 
bound to DNA.  Images are captured using a UV illuminator.     
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5.3.5 Pooling PCR products 
Once the four, replicate PCR plates were completed and had 
passed the ‘gel’ quality control steps, the contents of all four plates 
were carefully transferred to the corresponding well of a fresh 96 
well plate.  This process of pooling four separate but identical 
PCRs has several advantages.  It increases the amount of 
template DNA that is sampled, and by doing so increases the 
likelihood that bacterial species present at low concentration in 
the original sputum sample will be detected.  Pooling has also 
been thought to be beneficial as each PCR, though prepared 
identically, will in fact yield subtle, but important qualitative 
differences in the spectrum of amplicons produced and by 
repeating the PCR four times, the full spectrum of possible 
products is realised.  Recent evidence suggests that of the two 
arguments for pooling, increasing the absolute amount of 
template is probably the most important.[175]         
5.3.6 Quantification of PCR products 
The absolute quantity of double stranded DNA (dsDNA) 
amplicons in each well containing the products of four pooled 
PCRs was measured using a kit called Quant-iT™ (Invitrogen) 
according to the manufacturer’s protocol.  This assay uses a 
proprietary, fluorescent DNA stain called PicoGreen®.  This 
reagent has a strong selectivity for dsDNA and the degree of 
fluorescence in a sample is therefore directly proportional to the 
concentration of dsDNA.    
5.3.7 Pooling all samples for multiplex-sequencing 
Next we created a final “pool” containing amplicons derived from 
all the original sputum samples.  Each sample needed to 
contribute equimolar concentrations of amplicon.  The 
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concentration of dsDNA amplicons in each well of the plate 
containing pooled PCR products was known from the Quant-iT™ 
assay; therefore a calculation determined the aliquot volume of 
each well to be transferred to a single DNA free tube.   
5.3.8 Purification prior to sequencing 
Each of the completed PCR reaction wells above will have 
contained unused deoxyribonucleotides (dNTPs), primers, and 
primer-dimers (see figure 5.2).  These unwanted residual nucleic 
acids will have been transferred through to the final pool of 
samples.  To remove these from our final pool we used a kit called 
Agencourt® AMPure® XP.  This size-selection purification assay 
involves creating a suspension of magnetic beads within the 
pooled PCR solution.  The beads selectively bind dsDNA above 
100 base pairs in length, leaving the rest in solution.  By placing 
the reaction tube next to a strong magnet the beads are drawn 
into a pellet on the side of the tube allowing the contaminated 
solution to be carefully pipetted away.  The tube is removed from 
the magnet and the DNA loaded beads washed with 70% ethanol.  
The tube is replaced near the magnet and the beads re-pelleted 
allowing the ethanol and dissolved contaminants to be removed.  
Finally the DNA is eluted off the beads, the beads re-pelleted and 
the purified dsDNA amplicon containing solution removed.       
5.3.9 Quantification of the final amplicon pool 
The final step in preparing a multiplexed pool of amplicons to 
take forward to sequencing is to quantify the concentration of 
dsDNA in the pool.  This is done using the Quant-iT™ kit as in 
section 5.3.6 above. 
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5.3.10 FLX-454 sequencing of 16S-rRNA gene 
An aliquot was taken of the sample pool.  Adapter sequences were 
attached to each DNA fragment and the double stranded 
fragments split into single strands.  These single stranded DNA 
library fragments were mixed with oil, capture beads and a water-
based solution of PCR reagents.  Mixing and shaking took place 
and each hydrophilic bead became surrounded by a droplet of the 
PCR mixture.  Each of these droplets itself was suspended in an 
envelope of oil.  Each oil droplet therefore became an oil-isolated 
‘reaction vessel’ capable of carrying out a PCR of the bead-bound 
DNA library contained within.  Thermal cycling took place and at 
the end of this process the bead within each droplet of oil was 
loaded with millions of ‘clonal’ copies of its original DNA 
sequence.  
These beads were then sunk, one bead per well, into the wells of a 
PicoTitrePlate (PTP) by centrifuging the plate.  In the wells with 
the DNA library beads were smaller polymerase coated beads 
capable of facilitating the generation of complementary strands of 
DNA against the single stranded DNA templates.  
Nucleotides were washed across the plate in sequence multiple 
times.  As each nucleotide-mix fell into a PTP reaction well it was 
added to the template DNA at the complementary position(s).  
The insertion of a complementary nucleotide triggered a 
luciferase mediated reaction generating light.  Light was detected 
on a silicon sensor with the quantity of light being proportional to 
the number of nucleotides added; i.e. the addition of two adjacent 
TTs created more light than one T. 
The read out of the sequencer was thus a list of sequential light 
intensity measurements occurring in relation to the flow of 
137 
 
    137 
 
particular nucleotides across the plate and corresponding to a 
yes/no for the addition of that nucleotide - and if ‘yes’ how many 
iterations for that nucleotide were added.  From this ‘flow-gram’ 
the nucleotide sequence of the DNA attached to the bead within 
an individual well was computationally inferred.  Quality 
information relating to each nucleotide in the sequence was 
incorporated in the output so that sequences based on lower 
quality detection could be identified and discarded. 
5.3.11 Curating the raw sequence Data 
Pre-processing of the raw sequencing data was performed using 
the Quantitative Insights into Microbial Ecology (QIIME) pipeline 
for analysis.[176]  Standard flowgram format (.sff) files derived 
from the Roche-FLX sequencer were provided from the DNA 
Sequencing Facility of the University of Cambridge.  sff files were 
then used as the input for the QIIME analysis pipeline.  Within 
QIIME, the programme AmpliconNoise was used to de-noise and 
de-multiplex the samples and Perseus was used to remove 
chimeras.[177]  Operational taxonomic units (OTUs) were 
assigned by clustering sequences at a 97% identity threshold in 
the UCLUST program and the most abundant sequence within an 
OTU cluster was chosen as the representative sequence for that 
OTU.  The Silva SSU Ref ND database (version 111) was used for 
taxonomical assignment of each OTU by using an 80% bootstrap 
confidence around a representative sequence from each OTU.[178]  
PyNAST was used for alignment of representative sequences by 
accessing the Silva reference set.[179]  FastTree was used for 
phylogenetic tree reconstruction from a representative sequence 
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5.3.12 Contaminants 
It is now clear that many commercial DNA extraction kits have 
low levels of contamination by bacterial DNA.[181]  It is possible 
to draw the wrong conclusion regarding microbiota diversity if 
these contaminants are not identified and removed.[182]  Certain 
bacterial OTUs are consistently found in PCRs of kit reagents and 
in low biomass experimental samples.  We removed these from 
the list of OTUs in our samples prior to further processing.  The 
OTUs removed were from the following taxanomic groups:- 
All bacteria of the phylum:-  
Cyanobacteria 











All bacteria of the families:- 
Oxalobacteraceae 
Comamonadaceae 
5.3.13 Data analysis 
5.3.13.1 Alpha diversity 
To address hypothesis one, we considered how diverse each 
sputum sample was in terms of distinct OTUs.  This per sample 
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diversity is referred to as alpha diversity, which is an ecological 
term.  Alpha diversity was originally used to refer to the ecology 
of an individual ‘site’ (e.g. rock-pool) within a larger region (e.g. 
beach containing many rock-pools).[183]  Using this analogy, in 
this sample set each sputum sample was a site which had certain 
pre-existing characteristics e.g. subject age, smoking status and 
comorbidities.  The alpha diversity of each sputum sample was 
expressed in a number of ways.  The total number of distinct 
bacterial OTUs in each sputum sample was referred to as species 
“richness” such that a sample with 50 OTUs had greater richness 
than a sample with 10 OTUs.  The relative proportions of these 
OTUs in each sample were referred to as “evenness”.  A sample 
with 50 OTUs, where one of the OTUs accounted for 90% of all 
reads (16S rRNA sequences), was less “even” than a sample with 
10 OTUs, where each OTU accounted for 10% of the total number 
of reads.  Finally, Shannon’s Diversity Index was calculated for 
each sample.  This index takes into account both the richness and 
evenness of the sample when describing diversity.  Shannon’s 
index is a numerical quantification of the uncertainty in 
predicting the next component (originally letters, here OTU) to be 
identified from a composition (originally alphabetically coded 
message, here sputum sample), such that a higher number 
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The alpha diversity measures are formally defined below: 
Formulas, 
H = -SUM [(pi) * ln(pi)] 
E = Eveness=H/Hmax 
Where, 
H = Shannon’s diversity 
SUM = Summation 
pi = proportional abundance of OTU = number of reads of OTU 
i/total number of reads for all OTUs in that sample 
* = symbol for multiply 
In(pi) = natural log of pi 
S = number of species = Richness 
Hmax=maximum diversity possible = In(S) 
Values for each of the three measures of alpha diversity 
(“richness”, “evenness” and “Shannon”) were calculated for all 
sputum samples and mean alpha diversity values for samples, 
grouped by patient characteristic (e.g. smoking status), were 
compared.   
5.3.13.2 Rarefaction 
Since sequencing more reads from a sample inevitably increases 
the number of distinct OTUs that are identified, the richness 
(number of distinct OTUs) attributed to a sample is highly 
influenced by technical variation.  To get around this, the alpha 
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diversity measures described above were calculated on a rarefied 
data-set.  This means that, for each sputum sample, the software 
randomly sampled from the complete set of reads available for 
that sample and chose a specified sub-set of reads to represent 
that sample. The rarefaction level, that is the number of reads to 
be randomly chosen from each sample, was high enough to be 
representative but not so high that many samples fell below the 
rarefaction level and were excluded from the analysis.  In this 
way, the total number of reads for each sputum sample was 
adjusted to an even sequencing depth. 
5.3.13.3 Compositional analysis  
To address the second hypothesis we regarded the complete, un-
rarefied set of reads from all samples as a composition.  Data is 
compositional when the relative proportions of the components 
are of interest but the absolute value of each component (for 
example reads) is non-informative.[184,185]  This is the case with 
16S rRNA data where the absolute number of reads per OTU, per 
sample and for the pool as a whole is governed primarily by the 
sequencing platform (as discussed in 5.5.3.3). When considering 
each component of the composition as a proportion of the whole it 
is helpful to consider the components as summing to 1 then, if the 
count for one gene/bacteria goes up, then it must force the count of 
another one down - proportionally.  Data of a compositional 
nature require an initial transformation – since the absolute 
difference between values is not of interest.  The transformation 
should be one which renders the data scale-invariant, a property 
which would allow comparisons to be made across different 
sequencing platforms that generate total read numbers which are 
orders of magnitude different.[186] 
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Aitchinson proposed a number of different transformations, 
including the population centred log-ratio (clr). To determine the 
centred log ratio (clr) the count for each component is divided by 
the geometric mean of the counts for all components and then the 
logarithm of result is taken.  Equivalently, if we observed counts 
n1, n2, …, nm, for features 1, 2, …, m, with a total read count of N 
= n1 + n2 + … + nm, then we can scale to proportional abundances 
by dividing each individual read count by N. That is we calculate 
pi = ni / N for i = 1, 2, …, N, such that p1 + p2 + … + pm = 1. With 
this, the CLR transformed data are given by  
ci = log[pi / g(p1, p2, ..., pm)], 
where g(.) represents the geometric mean: (p1.p2…pm)1/m.   
Once transformed by the clr the data have another useful 
property in that they can be subset without disturbing the 
relative difference between components.  For example, if we 
wanted to explore OTUs at the taxonomic level phylum and 
restricted our analysis to just those OTUs belonging to the 
phylum firmicutes, we would want the relative proportions of 
OTUs within that subset analysis to be the same as they would be 
if we determined their proportions in the complete dataset; the clr 
facilitates these comparisons. 
A characteristic of 16S rRNA sequence data is that it contains 
many zeros.  For example, in many of our sputum samples OTUs 
that have been detected in at least one sample have read counts of 
zero in most other samples.  Zeros are a problem when using the 
centred log ratio owing to the fact that the logarithm of zero is 
undefined. We adopt a two-stage procedure for handling zero 
counts as proposed by Fernandes et al.[186] The first step is 
143 
 
    143 
 
remove any components from the data if the counts are zero for all 
samples, based on the reasoning that they are uninformative for 
the purposes of the analysis. The second step is to assume that 
the observed read counts for a given sample are subject to 
sampling variation. We do so by assuming that the counts n1, n2, 
…, nm are realisations from a multinomial distribution—a 
generalisation of the ubiquitous binomial distribution for 
dichotomous data—with event probabilities p1, p2,…, pm.  also 
note that the classical maximum likelihood estimates of pi = ni / N 
(as defined above earlier) are inaccurate in the case of very small 
(or zero) read counts.[187] To overcome this, Fernandes et al. 
(2013, 2014) consider the event probabilities as unknown random 
variables and model them in a Bayesian framework. A non-
informative conjugate Dirichlet(½,½, …, ½) prior distribution is 
used. The posterior distribution for p1, p2, …, pm conditional on 
the data is then Dirichlet(n1+½, n2+½, …, nm+½). From the 
posterior distribution, several (128 in our case) Monte Carlo 
samples of the vector (p1, p2, …, pm) are drawn, which are 
interpreted as proportional abundances for the components.  
Monte Carlo sampling is a statistical technique for random 
sampling from probability distributions.[188]  For each of the 
Monte Carlo draws, the clr transformation is applied (as described 
above), leading to so-called ‘relative abundance values’.  With the 
transformed data, standard statistical tests can be applied, such 
as Welch’s t-test or the Wilcoxon-Mann-Whitney U-test, to derive 
P-values. The P-values are then averaged over the Monte Carlo 
draws, which we report as the test P-value.  In addition to P-
values q-values are also returned which represent adjustments for 
multiple testing and used the Benjamini-Hochberg method.  The 
analysis was performed using the R package ALDeX2.[189]    
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The 169 PASS subjects provided 86 acute sputum samples of 
which 9 were deemed inadequate (had no obvious muco-
purulence) and 77 went through to sequencing.  Characteristics of 
the subgroup with sequenced sputum can be compared to the 
remainder of the PASS cohort in table 5.2.   Age, gender and 
comorbidities were similar between the two groups.  However, 
nearly twice as many (50%) of those with sequenced sputum were 
active smokers when compared to those without sequenced 
sputum (26.9%).  Sputum samples yielded between 130 and 4065 
copies (reads) of the v3-v5 region of the 16S rRNA gene.  A 
rarefaction level of 549 reads was chosen and this meant 
excluding one sample (with 130 reads) from the analysis of alpha 
diversity.  Following rarefaction to 549 reads and removal of 
singletons (reads that appeared only once in only one sample), 774 
OTUs were identified across all sputum samples.  The median 
per-sample was 43 (IQR 23-62). 
5.4.2 The most abundant OTUs 
Exploratory analysis revealed that the dominant bacterial OTU in 
this study of community acquired pneumonia was 
Haemophilus_617.  This was determined by analysing the read 
counts for all OTUs in all 76 samples together – analogous to 
pooling all 76 sputum samples into one pot, then mixing and 
sequencing the ‘pneumonia super-sample’.  The second most 
abundant OTU was Veilonella_1328.  Bacteria of the genus 
Veilonella are Gram negative anaerobic cocci. They exist as 
commensals of the gut and oral mucosa.  The most abundant 
streptococcal OTU was less than half as abundant as 
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Haemophilus_617.  The top 20 OTUs in are displayed in Figure 
5.3 and counts for each of the top 20 most abundant OTUs can be 
seen for each subjects sputum sample in appendix 3. 
5.4.3 Important species with low abundance 
We specifically explored the abundance of certain OTUs due to 
their prominence in the pneumonia literature.  Mycoplasma 
pneumoniae occurs in epidemic cycles during which it is 
responsible for large numbers of relatively mild cases of CAP.  
Pneumonia due to Legionella pneumophila is associated with 
contact with infected water and can cause a severe pneumonia.  
Staphylococcus aureus is associated with prior influenza infection, 
underlying lung disease and pneumonia among patients on 
Intensive Care units.  Mycoplasma pneumoniae and 
Staphylococcus aureus were present at low levels of abundance 
and Legionella pneumophila was not detected in any samples.  
Legionella pneumophila was detected in one patient by urine 
antigen testing (see chapter 3) but this patient did not provide 
sputum for sequencing.  Table 5.1 (next page) compares the 
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Most abundant OTU 















Haemophilus 41 Haemophilus_617 8429 218 
Streptococcus 73 Streptococcus_4318 3644 94 
Mycoplasma 5 Mycoplasma_3100 174 4.5 
Staphylococcus 5 Staphylococcus_2814 143 3.1 
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5.4.4 The relative abundance of individual OTUs per-sample 
Next we explored the relative abundance of OTUs in individual 
samples.  To do this, read counts for each individual OTU in a 
sample were converted to a percentage of the total read count for 
that sample.  To reduce the dimensionality of the data to a level 
that could be explored graphically, for each sample, we grouped 
together, into a bin called ‘other’ all OTUs that made up 12% or 
less of the total for that sample.  The relative abundances within 
and across samples could then be displayed in a stacked bar-chart 
(figure 5.4).  This bar-chart shows some samples were more 
diverse than others i.e. they were composed of many OTUs but 
each individual OTU accounted for a small proportion of the 
sample.  Other samples were less diverse and were dominated by 
a single highly abundant OTU.  
5.4.5 The relative abundance of selected OTUs in distinct clinical 
groups 
Next we explored how the abundance of several distinct OTUs 
varied between different clinical groups.  The choice of OTUs to 
display was based on the data displayed in figure 5.4 and prior 
assumptions about the importance of certain bacteria; for example 
the species of the genera Streptococcus, Haemophilus and 
Pseudomonas have previously been described as key pathogens in 
lower respiratory tract infections and CAP.  The three most 
abundant streptococcal OTUs were explored further as all 
previous studies of CAP have highlighted that Streptococcus 
pneumoniae is a key aetiological agent in CAP.  The most 
abundant OTU from the genera Moraxella, Haemophilus, 
Psudomonas and Klebsiella were all chosen for further 
exploration as each was seen (in figure 5.4) to be dominant in at 
least one sputum sample and previous studies have identified 
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species from these genera as significant respiratory pathogens.  
Differences in relative abundance of these OTUs were most 
apparent when subjects were divided into those who had or did 
not have prior pulmonary disease.  Results are displayed in 
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Table 5.2 Clinical characteristics of PASS subjects with and 













Median Age, (IQR) 68.5 (49 – 76) 71 (55-79) 
0.1
* 





Active 38 (50) 25 (26.9) 
0.7
# 
Quit 28 (36.8)   40 (43.0) 






0 23 (30.3) 32 (34.4) 
0.8
# 
1 32 (42.1) 38 (40.9) 
2 8 (10.5) 10 (10.8) 
3 10 (13.2) 7 (7.5) 
4 2 (2.6) 4 (4.3) 
5 1 (1.3) 1 (1.1) 
6 0 1 (1.1) 
Prior statin use, n 
(%) 




disease, n (%) 





0 22 (28.9) 18 (19.4) 
0.8
# 
1 13 (17.1) 26 (28.0) 
2 22 (28.9) 28 (30.1) 
3 18 (23.7) 18 (19.4) 
4 1 (5.3) 3 (3.2) 
5 0 0 
Presenting CRP 
median (IQR) 
150 (81 – 235.5) 144 (43-249.5) 
0.3
≠ 
BMI median (IQR) 25.5 (22.2-29.7) 25.9 (23.0-30.9) 
0.5
≠ 






5 (6.8)  3 (3.7) 
0.7
# 
*Wilcoxon rank-sum test 
#Chi Squared test 
≠Welch’s t test 
Data was incomplete for the highlighted clinical variables, n for those 
groups is indicated below:- 
Smoking status, no bronchoscopy group, n=139 
CRP, sputum group n=75 no sputum group, n=91 
BMI, sputum group, n=62 no sputum group n=60 
Flu, sputum group, n=53; no sputum group, n=54 
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In this figure, all reads from all 76 
sputum samples are pooled.     
 
The bar lengths represent the number 
of reads attributed to each OTU 
(bacterial species) in the pool.   
 
This demonstrates that, in this cohort 
of patients with CAP, 
Haemophilus_617 was dominant and 
was more than twice as abundant as 
any Streptococcal species (OTU). 













Figure 5.3 Top 20 OTUs 
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Each stacked bar represents 
one of 76 sputum samples.   
 
The coloured bar segments 
represent distinct bacterial 
OTUs and their proportional 
abundance in that sample.   
OTUs that represent less 
than 12% of a sample were 
binned into a group called 
“other”.   
 
Some samples are seen to be 
diverse with a large 
proportion of OTUs assigned 
to “other” whereas other 
samples are almost entirely 
dominated by a single OTU.  
Figure 5.4 Proportional 








Figure 5.5 Abundance of Veillonella_1328 in sputum of subjects with and without pulmonary disease 
Each bar represents a sputum sample.  Bar heights represent the % of reads in a sample attributed to Veillonella_1328.  
Veillonella_1328 was one of the most commonly detected OTUs but was rarely a dominant OTU and only once did it represent more 









Figure 5.6 Abundance of Haemophilus_617 in sputum of subjects with and without pulmonary disease. 
 The bars represent the proportion (%) of reads in that sample that were attributed to Haemophilus_617.  Bars coloured red are from 
subjects whose sputum grew Haemophilus influenzae.  In 14/46 (30%) of those with prior pulmonary disease Haemophilus_617 was the 
dominant OTU with >50% of reads compared with 3/30 (10%) of those who did not have pulmonary disease before they developed CAP.    
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Figure 5.7 Abundance of Streptococcus_4318 in sputum of subjects with and without pulmonary disease 
The bars represent the proportion (%) of reads in that subjects sample that were attributed to Streptococcus_4318.  Bars coloured red 
are from subjects who grew Streptococcus pneumoniae in their blood cultures (one subject did not have a blood culture).  
Streptococcus_4318 was rarely dominant with an abundance >50%, in only one sample.  
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Figure 5.8 Abundance of Klebsiella_1954 in sputum of subjects with and without pulmonary disease  
The bars represent the proportion (%) of reads in that sample that were attributable to the OTU Klebsiella_1954.  This OTU was 
identified infrequently but on one occasion was highly dominant with nearly 75% of all sequences being from the OTU Klebsiella_1954.     
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Figure 5.9 Abundance of Pseudomonas_3976 in sputum of subjects with and without pulmonary disease 
The bars represent the proportion (%) of reads in that sample that were attributable to the OTU Pseudomonas_3976.  This OTU was 
identified rarely from subjects without prior pulmonary disease.   On one occasion Pseudomonas_3976 was highly dominant with 
nearly 90% of all sequences being from this OTU.  Red bars represent samples from subjects whose sputum grew Pseudomonas 
aeruginosa in the NHS microbiology lab.      
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Figure 5.10 Abundance of Moraxella_2510 in sputum of subjects with and without pulmonary disease 
The bars represent the proportion (%) of reads in that sample that were attributable to the OTU Moraxella_2510.  Moraxella was rarely 
identified in this set of samples suggesting it is not a commensal organism in either the upper or lower respiratory tract. In one sample it 
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5.4.6 Alpha diversity 
To explore the diversity of bacterial OTUs in each sample we 
calculated the species ‘Richness’ (number of different OTUs), 
‘Evenness’ (how evenly distributed the OTUs were) and 
‘Shannon’s’ diversity index.  Several clinical characteristics were 
independently associated with each measure of alpha-diversity 
(see tables 5.3 – 5.5).  Backwards stepwise multiple linear 
regression (table 5.6) demonstrated that the richness of species in 
the sputum of subjects with CAP was associated with age and 
prior statin use (figure 5.11 and 5.12).  Multiple-linear regression 
revealed that underlying pulmonary disease was independently 
associated with the evenness (p=0.001) and Shannon’s diversity 
index (p=0.002) of bacterial species in a subject’s sputum after 
adjustment for other clinical factors (Figures 5.13 and 5.14 and 
tables 5.7 and 5.8).  
5.4.7 Distribution of individual bacterial OTUs 
The exploratory analysis of figures 5.4-5.10 revealed several 
individual bacterial operational taxonomic units (OTUs) that 
appeared to be associated with prior pulmonary disease.  
However, when the un-rarefied dataset was subjected to 
compositional analysis using the ALDeX2 packages, none of the 
OTUs were significantly associated with any of the clinical 
parameters tested after correction for multiple testing 











Each circle represents a sputum sample.  The y axis indicates the 
number of bacterial OTUs in that sample.  The line demonstrates a 
linear model of the relationship between richness and subject age 
(p=0.0003) and the shaded area shows the 95% confidence interval 
around the position of that line. 
Figure 5.11 The relationship between age and species richness 
The relationship between the ‘Richness’ (number of OTUs) in the 
samples and statin usage (p=0.01).  The box limits are defined by the 
inter-quartile range of values for that group and the horizontal line is 
the median value.  Whiskers extend to 1.5x the inter-quartile range. 
Figure 5.12 Relationship between richness and prior statin use 
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Figure 5.13 Relationship between evenness and prior 
pulmonary disease 
Those with no pulmonary disease had more even distribution of 
species abundance (p=0.001).  Whiskers extend to 1.5x the inter-
quartile range and points outside of the whiskers indicate sputum 
samples whose evenness value is outside of 1.5 x the inter-quartile 
range.  
 
Figure 5.14 Relationship between prior pulmonary disease and 
bacterial species diversity in pneumonic sputum.  
Those with no prior pulmonary disease a higher species diversity 
(p=0.002).   
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Table 5.3 Univarite analysis of richness and clinical variables 
  
































































No prior pulmonary disease 
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Table 5.4 Univariate analysis of evenness and clinical variables 
  










































































No prior pulmonary disease 
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Table 5.5 Univariate anlysis of Shannon’s diversity and clinical 
variables 
 














No pulmonary disease 
































































No antibiotics pre-admission 
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Model Parameters Log Likelihood of Model 
Comparison of Models by Likelihood Ratio 
1 
Statin + flu + age + prior 
pulmonary disease 
-226.0 
2 Statin+flu+age -226.9 ANOVA 1 v 2 
p=0.2 no significant difference so drop prior pulmonary 
disease 
3 Statin+age -228.6 ANOVA 2 v 3 p=0.08 no significant difference so drop flu 
4 Age -231.2 ANOVA 3 v 4 p=0.03 significant difference so keep statin 
5 Statin*age -228.5 ANOVA 3 v 5 p=0.7 no significant interaction 
Model 1 is the maximal model including all variables that were significantly associated with richness in the univariate analysis.  
Model 2 has the least significant variable (prior pulmonary disease) from model 1 removed.  An analysis of variance (anova) of model 
1 and 2 demonstrates that there is no statistically significant difference between the two models indicating prior pulmonary disease 
contributes little.  Repeating the process anova demonstrates that statin but not age should be included as a main effect in the model.  
Model 5 includes an interaction term (*) and ANOVA demonstrates there is no statistically significant interaction between statin and 
age.  In summary age and statins are the most important factors in determining species Richness in these samples. 
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Table 5.7 Multiple linear regression of bacterial species evenness in pneumonic sputum and clinical variables 
Model Parameters Log Likelihood of Model 
Comparison of Models 
1 Age + gender + prior pulmonary disease 16.7 
2 Gender + prior pulmonary disease 15.9 Anova 1 v 2 p=0.2 no significant difference lose age 








Model 1 is the maximal model including all variables that were significantly associated with evenness in the univariate analysis.  
Model 2 has the least significant variable (age) from model 1 removed.  An analysis of variance (anova) of model 1 and 2 demonstrates 
that there is no statistically significant difference between the two models indicating age contributes little.  Repeating the process 
anova demonstrates that gender contributes little and that only prior pulmonary disease has a statistically significant association with 
evenness after adjustment for the other variables. 
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Model Parameters Log Likelihood of Model 
Comparison of Models 
1 Age + gender + prior pulmonary disease -63.5 
2 Age + prior pulmonary disease -64.9 Anova 1 v 2 p=0.1 not significant lose gender 
3 Prior pulmonary disease -66.8 Anova 2 v 3 p=0.06 not significant lose age  
Model 1 is the maximal model including all variables that were significantly associated with evenness in the univariate analysis.  Model 
2 has the least significant variable (gender) from model 1 removed.  An analysis of variance (anova) of model 1 and 2 demonstrates that 
there is no statistically significant difference between the two models indicating gender contributes little.  Repeating the process anova 
demonstrates that gender contributes little and that only prior pulmonary disease has a statistically significant association with 
Shannon’s diversity after adjustment for the other variables. 
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Variable Test OTU identified p<0.05 p q Genus identified @ p<0.05 p q Interpretation 




































Modified Charlson co-morbidity 
index 
glm None identified NA NA None Identified NA NA NA 
Flu ttest None identified NA NA None identified NA NA NA 
Anti-biotics pre-admission ttest None identified NA NA None Identified NA NA NA 
Gender ttest None identified NA NA None Identified NA NA NA 
Pulmonary co-morbidity ttest None identified NA NA None identified NA NA NA 
Statin ttest None Identified NA NA None Identified NA NA NA 
Relationship between either individual bacterial OTUs (species) or bacterial genus and clinical parameters.  glm = generalised linear 
model.  KW = Kruskal Wallis.  BH =  Benjamini-Hochberg method for correcting for multiple comparisons.   
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5.5 Discussion 
5.5.1 Summary of results 
This study of the bacteria present in the sputum of patients with 
CAP found statistically significant associations between patient 
characteristics and measures of ecological diversity.  After 
adjustment for other clinical factors, the number of bacterial 
species in a sample (richness) was inversely related to a patient’s 
age and was decreased if they were taking statins.  The 
proportional representation of OTUs was less ‘even’ in patients 
with prior pulmonary disease.  Combining the concepts of 
richness and evenness, and after adjustment for other clinical 
associations, the overall ecological diversity of bacterial species, as 
measured by Shannon’s diversity index, was decreased in the 
presence of prior pulmonary disease.  In this set of samples, the 
OTU Haemophilus_617 had the highest number sequences 
detected (reads) and was also the OTU which was most frequently 
dominant in individual samples.  Statistically significant 
associations with patient characteristics were not seen with 
individual bacterial species or at the higher taxonomic level of 
bacterial genera.   
5.5.2 What were the strengths of this work? 
Sputum remains the primary sample of interest when 
determining the microbiological aetiology of community acquired 
pneumonia (CAP) and this is the largest study to date of the 
sputum bacterial microbiota of CAP.  The subjects were well 
characterised and were representative of CAP treated in our 
region and in similar regions throughout the world (see section 
3.2).  Sputum samples were collected within 24 hours of 
admission to minimise the impact of antibiotic on the bacterial 
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DNA in sputum.  The size of the sample set and the extent of the 
clinical data available enabled us to adjust our models for 
confounding variables and to identify statistically significant 
factors that determine bacterial diversity in pneumonic sputum.  
The use of the new ALDEx2 package in the analysis of this data 
enabled us to apply a statistically robust approach to the 
compositional analysis of species and genus level associations and 
enabled us to account for technical variation introduced by the 
sequencing platform.   
Both of the a-priori hypotheses were adequately addressed. 
i. The range of bacteria in a sputum sample from a patient 
with CAP is influenced by subject specific characteristics.  
The most influential factor is the presence of prior 
pulmonary disease. 
ii. Several bacterial OTUs were identified more frequently 
and at higher abundance in subjects with particular 
characteristics. However, we were not able to predict from a 
subject’s baseline characteristics which individual OTU 
was likely to dominate their sputum sample.      
5.5.3 What were the limitations of this work? 
5.5.3.1 Incomplete data 
169 subjects were recruited to PASS but only 76 sputum samples 
were sequenced, representing 45% of the cohort.  It is well 
recognised that only a minority of patients with CAP, as we 
currently define it, produce sputum and that sputum production 
is less likely in the elderly.[190]  Ewig et al. conducted a study to 
directly assess the utility of sputum as an aetiological diagnostic 
specimen for CAP.[191]  They found that only 22% of patients 
were able to self-expectorate on admission, rising to 34% within 
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24 hours of admission.  The eligibility criteria for the Ewig et al 
study were very similar to those for PASS. 
In PASS, the subjects with sequenced sputum appeared different 
to those without in some key respects, although none of these 
observed differences achieved statistical significance.  A higher 
proportion (50% v 26.9%) of the sequenced group were active 
smokers. The sequenced group were more likely to have pre-
existing pulmonary disease (60.5% v 47.3%) and were more likely 
to have a pneumococcal bacteraemia (6.8% v 3.7%).  The 
implications of these differences, given the major findings of this 
work, are that we now know more about the microbiota of CAP in 
those with chronic lung disease but still have a limited 
understanding of the lung bacterial microbiota in patients with 
CAP who are non-smokers without prior lung disease.   
5.5.3.2 Lack of species level identification of key pathogens 
The bacterial genera Streptococcus and Haemophilus cannot be 
further sub-divided by 16S rRNA sequencing.  Thus Streptococcus 
mitis and Streptococcus pneumoniae cannot be distinguished nor 
can Haemophilus influenzae be separated from Haemophilus 
haemolyticus.  As a consequence two key pathogens in the context 
of lower respiratory tract infection and CAP are not clearly 
characterised in this study. Extended sequence analysis and 
comparison with a species-specific quantitative PCR of the sample 
would enable us to make the distinctions above but were beyond 
the scope of this study.  However, some inferences can be made as 
to the likely species of some OTUs in this data by comparing with 
NHS clinical laboratory cultures of the samples.  For example, 
several of the samples in which Haemophilus_617 was dominant 
were also reported as growing Haemophilus influenzae in culture.  
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Moreover, the distribution pattern of Haemophilus_617 – being 
more abundant in those with prior pulmonary disease and being 
the dominant OTU overall in a cohort with very high rates of 
smoking, is in line with previous associations between 
Haemophilus influenzae, smoking and pulmonary disease.[192]  It 
is therefore likely that the operational taxonomic unit 
Haemophilus _617 is Haemophilus influenzae. 
Inferences about which OTU represents Streptococcus 
pneumoniae are more difficult.  Streptococcus_4318 had the 
greatest number of reads of all the streptococcal OTUs and had 
the highest levels of abundance per-sample of all Streptococci.  
However, in contrast to other recognised respiratory pathogens it 
was rarely dominant and only once represented more than 50% of 
the total sequences in a sample.  The distribution pattern of 
Streptococci were similar between subjects grouped by clinical 
characteristics and when the pneumococcus was grown from the 
blood there was no association with high streptococcal abundance 
in sputum.  Streptococcus pneumoniae was not grown from any of 
the sputum samples sent to the hospital lab.   
These findings should be validated with larger studies as they 
may be an artefact of our study design.  For example subjects in 
this study had received variable amounts of antibiotic prior to 
submitting their sputum – some had received nearly 24 hours of 
intravenous antibiotic – and it may be that this suppressed the 
pneumococcal signal to a greater degree than for other OTUs.  
Against this is the finding that 5 subjects grew pneumococcus in 
their blood but had negative sputum cultures.  If antibiotic were 
the cause of negative sputum cultures it would be expected that 
the blood cultures would also be culture negative.   An alternative 
explanation is that this is a true finding, in which case it gives a 
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clue as to the pathophysiology of pneumococcal disease.  The 
assumption that the dominant species in a sample from a sick 
patient is the causative pathogen may not always be true; it is 
possible that pneumococci do not need to achieve airway 
dominance in order to cause disease. 
5.5.3.3 Sequencing platform 
In 2011, when this study was funded, the state of the art 16S 
rRNA gene sequencing platform for microbiota studies was 
Roche’s FLX version of their 454 technology.  Subsequently this 
platform has largely been superseded by the latest developments 
in Illumina sequencing.[193]  The differences between the two 
platforms are essentially that 454 is able to sequence longer 
sections of the 16S rRNA gene (read-lengths now up to 1000 base 
pairs vs. Illumina which now has a maximum of 300) whereas the 
Illumina platforms generate many times more reads per run 
(several billion reads per Illumina run vs maximum 700,000 with 
FLX-454).  More reads are equivalent to greater magnification for 
a microscope – it enables us to detect more of what is present in a 
sample, including rare bacteria whose signal would have been lost 
within a complex sample from which we had fewer reads.  Also, 
Illumina is now significantly cheaper than 454 sequencing.  
However, the longer read lengths of 454 technology still confer 
some advantages in terms of accurate identification of individual 
species within certain genera, and it is unlikely that the major 
conclusions of this chapter would be different if the samples had 
been Illumina sequenced.[194]  Moreover the bulk of the 
published work on sputum microbiota and respiratory microbiota 
in general has used 454 sequencing making comparisons with the 
work presented here valid.   
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5.5.4 Comparison with other published work 
5.5.4.1 Pneumonic sputum 
There is only one previous study of the bacterial microbiota of 
sputum from unventilated patients with CAP.  Chen et al. 
collected sputum from 45 immuno-competent patients who had 
been hospitalised for radiologically confirmed CAP.[173]  None of 
the patients had received antibiotic in the community although it 
is not clear if they had received any hospital antibiotic prior to the 
submission of their study sample.  In contrast to our study, this 
group performed a prolonged sputum lysis step (18 hours 
incubation with sodium hydroxide) prior to chemical (as opposed 
to our mechanical) cell lysis and DNA extraction.  They used a 
different 16S rRNA PCR protocol which involved an initial PCR 
using 50ng of template then then a second PCR using the PCR 
products from the first as substrate.  Their sequencing used the 
same Roche 454-FLX platform as ours.   
Chen et al. found that the bacterial genus Streptococcus had the 
highest average abundance per sample at 20.6% with the genus 
Haemophilus being ranked 11th with an average abundance of 
1.65% per sample.  In our data the genus Streptococcus was 
ranked second with and average abundance of 23.3% and the 
genus Haemophilus was top with an average of 23.7% per sample.  
However, the clinical implication of abundance at the taxonomic 
level of genus in the context of CAP is very limited since the 
Genus Streptococcus is composed of a large number of distinct 
species (68 OTUs in our data) and many of those detected in the 
sputum will not be causally linked to patient’s pneumonia.   
Our work went beyond the genus level and showed that, per 
sample, there were wide variations in abundance at the species 
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(OTU) level and distinct patterns began to emerge.  The most 
abundant Streptococcal OTU was very frequently isolated but 
rarely achieved high levels of dominance.  The most abundant 
Haemophilus OTU was less frequently isolated, but in some 
samples accounted for nearly all the bacteria isolated and this 
was most commonly the case in samples from patients with 
chronic lung disease.  Rates of lung disease are not specified in 
the Chen paper but 10% of subjects whose sputum was sequenced 
were active smokers as compared to 50% of ours.  This is further 
evidence that smoking and the consequent development of 
pulmonary disease may well account for the high abundance of 
Haemophilus in our study.       
5.5.4.2 Sputum from subjects with chronic lung disease 
Pneumonia is inflammation caused by infection in the lung and a 
criticism of sputum as a specimen for the description of lower 
respiratory tract infection is that, given the identification of a 
large number of bacterial species in a sputum sample how would 
we distinguish between those that originated in the ‘diseased’ 
lung from those that were from the ‘healthy’ mouth?   Recent 
work comparing bacterial microbiota in a range of samples from 
patients with cystic fibrosis in stable state has shown that using 
16S rRNA sequencing, oral wash and sputum samples were 
virtually identical in some individuals.[195]  In other patients the 
sputum microbiota diverged from the oral washes – suggesting a 
unique lung microbiota.  Where the oral wash and sputum 
differed there was an association with poor prognostic features 
such as increased markers of airway inflammation.  The 
conclusion was that, despite coming from the lung, ‘healthy’ 
sputum had similar bacteria to the mouth, and where differences 
existed between mouth and lung microbiota these could be easily 
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detected i.e. the mouth signal did not ‘swamp’ the lung signal.  
The implication of that study for our work is that in the case of 
CAP, although some of the sequences detected in sputum will 
have come from the mouth, the lung signal will not have been 
lost.  Indeed many of our subjects had sputum which contained a 
very dominant OTU and in all cases these OTUs were well known 
respiratory pathogens.  Venkataraman and colleagues have 
recently applied ecological theory to model the lung microbiota 
from healthy and disease lungs and their results suggest that, as 
proposed above, in health the low-biomass lung microbiota is 
highly influenced by dispersal from the mouth microbiota.[196]  
In disease states they found the microbiota could not be explained 
by a ‘neutral model’ and their data suggested that selective 
pressures were acting on the microbiota enabling certain species 
to thrive at the expense of others.  This fits with our findings that 
those with pulmonary disease had lower species diversity. 
Previous studies have demonstrated that conventional culture 
techniques for the identification of Haemohilus influenzae have 
high false negative rates.  Wood-Baker et al. found that culture 
identified Haemophilus influenzae in 5/36 (14%) sputum samples 
from patients with stable COPD where as a targeted PCR found 
14/36 (39%) were positive.[197]  Garcha et al. showed that during 
exacerbations of COPD bacterial biomass of sputum, as measured 
by quantitative PCR (qPCR) increases by as much as 20 fold.[198]  
Using species specific qPCR they showed that the most common 
isolate at exacerbation and in stable state was H. influenzae.  This 
is relevant to our work since many of the subjects in our study 
had COPD and there is significant overlap between the clinical 
syndromes of ‘infective exacerbation of COPD’ and ‘community 
acquired pneumonia in a patient with COPD’.    
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5.5.4.3 Bronchoalveolar lavage of HIV infected patients 
with CAP 
One study has investigated the bacterial microbiota of 
bronchoalveolar lavage (BAL) samples taken from HIV+ve 
patients being treated for CAP.[199]  60 BAL samples from 
Ugandan patients initially thought to have CAP were compared 
with 15 BAL samples from patients in San Francisco who were 
thought to have CAP.  None of these samples were taken during 
the acute phase of CAP and all patients were well into their 
antimicrobial treatment regime.  Moreover, when final diagnoses 
were assigned to each patient – 2 months after discharge – only 
7/60 Ugandan patients were felt to have “probable bacterial 
pneumonia” with 35/60 having been diagnosed with TB, 2/60 with 
PCP, 4/60 with pulmonary Karposi’s sarcoma and 20/60 in whom 
there was not enough data to evaluate the probability of CAP.  Of 
the San Francisco patients 7/15 had “probable bacterial 
pneumonia”, 7/15 had PCP, 1/15 had fungal pneumonia, 1/15 had 
CMV and 1/15 had pulmonary Karposi’s.  The total list of 
diagnoses for the San Francisco cohort came to 17/15 implying 
that several subjects had multiple primary diagnoses – although 
which had more than one is not specified.  Bacterial microbiota 
from all 60 Ugandan subjects was compared with all 15 subjects 
from San Francisco.  Due to the heterogeneity of diagnoses (with 
only the minority having CAP) and the duration of pre-sampling 
antibiotic it is very difficult to draw meaningful conclusions as to 
the bacteria that were present during acute CAP.    
5.5.5 Clinical implications of this work 
The clinical questions this study tackles are, what are the 
aetiological agents of CAP – and are they the same for everyone?  
If we could comprehensively answer these questions then we 
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could stratify our empirical prescribing guidelines by 
incorporating patient characteristics thus making them more 
personalised.  Microbiota studies that directly tackle such clinical 
questions have the potential to significantly improve clinical 
practice but care must be taken not to over-reach when drawing 
conclusions and in particular to avoid assuming causality where 
none has been established.[200]  We found a much larger range of 
bacteria in sputum from patients with CAP than has been 
described in culture based studies.  The ecological analysis of this 
data found that those with pre-existing lung disease had lower 
species diversity in their sputum.  Low species diversity can occur 
when a sample contains a single dominant species.  When we 
explored the relationship between individual species and prior 
pulmonary disease we showed that a single species from Gram 
negative genera such as Moraxella, Klebsiella, Pseudomonas and 
particularly Haemophilus was more likely to dominate.   
Our current empirical antibiotic regime is based on the 
assumption that Streptococcus pneumoniae is the most common 
cause of pneumonia in all groups.   The backbone of treatment is 
therefore a β-lactam with sicker patients also receiving a 
macrolide to broaden the spectrum of cover.  However, resistance 
to β-lactams is increasingly common among Haemophilus 
influenzae which also possesses an efflux pump which makes it 
inherently resistant to macrolides.[201]  Our work supports 
recent calls for more intensive study of Haemophilus influenzae as 
an under recognised pathogen.[202]  If future studies confirm that 
in patients with prior lung disease Hemophilus influenzae is a 
common cause of CAP then a randomised control trial of 
doxycycline vs. amoxicillin as first line treatment for CAP in the 
context of prior lung disease would inform changes to guidelines.   
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6 LONGITUDINAL ANALYSIS OF RECOVERY USING 
THE CAP-SYM QUESTIONAIRE 
6.1 Introduction 
The CAP-sym (community acquired pneumonia-symptom) 
questionnaire provides a quantitative measure of symptoms and 
was devised as a patient based tool for measuring outcome 
following community acquired pneumonia (see section 1.4.3).[58]  
By recording the CAP-sym questionnaire at a number of time-
points following an index case of pneumonia, recovery can be 
compared between individuals.[60]   
Statistical modelling uses mathematics to produce a function 
(model) that can explain how a series of observed responses have 
been generated.[203,204]  A successful statistical model generates 
an approximation to the behaviour of data derived from a study 
using as few input variables as possible    The input variables 
which produce the best fitting model give clues as to the 
mechanisms underlying the phenomenon being studied.  An 
example of this is a model describing the pattern of forced 
expiratory volume in 1 second (FEV1) measurements obtained 
from Danish children with cystic fibrosis (CF).[205]  In that study 
70448 FEV1 measurements on 448 CF patients were modelled 
with clinical data.  The derived model described the degree to 
which an initial FEV1 measurement predicted future variability 
in FEV1 and demonstrated that decline in FEV1 was related to 
pancreatic status, Pseudomonas aeruginosa infection and year of 
birth.   
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Using a similar approach, we recorded the CAP-SYM score at 
multiple time points for each subject recruited to the Pneumonia 
Aetiology and Severity Study (PASS) and created a model to test 
the following hypothesis:- 
6.2 Hypothesis 
Using a statistical model of CAP-sym scores,  recovery following 
community acquired pneumonia can be predicted from baseline 
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6.3 Methods 
6.3.1 Recording and calculating CAP-sym scores 
CAP-sym is an 18 question questionnaire (see figure 6.1).  During 
its validation, CAP-sym was completed by trained interviewers 
who asked the questions and recorded the answers.   Each 
question is phrased in a similar way, “in the last 24 hours how 
much have you been bothered by (e.g.) shortness of breath?”  The 
subject can choose one of six possible answers and each answer 
carries a numerical score:  
I do not have the symptom (scores 0),  
not bothered at all (scores 1)  
a little bothered (scores 2)  
moderately bothered (scores 3)  
bothered quite a bit (scores 4)  
extremely bothered (scores 5).   
If the scores for each of the 18 component answers are summed 
they come to a maximum score of 90 which represents the worst a 
patient could possibly feel with respect to these symptoms.  The 
total score for the questionnaire therefore represents the burden 
of pneumonia-related symptoms felt by that patient in the 24 
hours preceding the completion of the questionnaire.   
In the Pneumonia Aetiology and Severity Study (PASS) the CAP-
sym questionnaire was conducted by a trained study team 
member.  For a detailed description of PASS protocol see chapter 
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2.  Briefly, medical admissions were screened for possible 
community-acquired pneumonia (CAP).  Patients were eligible if 
they volunteered consent to join the study within 24 hours of their 
first dose of in-hospital antibiotic and did not meet any exclusion 
criteria.  Subjects were followed for up to one year.  At the time of 
enrolment subjects conducted the CAP-sym questionnaire twice.  
The first iteration of the questionnaire represented their 
symptoms in the previous 24 hours i.e. the day of admission to 
hospital with CAP.  The second was completed thinking back 30 
days prior to admission and represented how they felt before the 
pneumonia began.  CAP-sym was repeated at the next in-hospital 
study visit, two days following recruitment, then again on the day 
of discharge.  Due to the practical limitations of the study if the 
patient was discharged prior to day 2 or if day 2 or discharge fell 
at the weekend then a study visit was not completed and the 
CAP-sym was not recorded.  CAP-sym was conducted at each of 
the study out-patient follow-up visits which were at one month, 
six months and one year following recruitment. 
6.3.2 Statistical Analysis 
The score for each of the 18 questions in the CAP-sym 
questionnaire was summed and the total (the CAP-sym score) 
recorded against the time-point for that subject.  We compared 
our mean values of CAP-sym to those of the multi-centre study 
used to validate the CAP-sym score to confirm that our values 
were of similar magnitude and that the trend was comparable.  
Next, an exploratory analysis involved graphical representation of 
all subjects’ CAP-sym trajectories followed by representations of 
individual trajectories to draw out trends.  Transformations such 
as plotting ranked median CAP-sym residuals were also 
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explored.[204]  To begin to explore the relationship between 
clinical variables and median recovery for the group we initially 
defined recovery as the % difference in CAP-sym score between 
presentation and at the one month follow-up visit.  However, this 
is a naive measure of recovery and does not take into account the 
patients pre-morbid baseline symptom level nor does it correct for 
repeated measures on the same individual over time.  
Therefore we next attempted to use linear modelling to describe 
the data.  A linear model is one where each term in the prediction 
equation is either a constant or the product of a parameter and a 
predictor variable, hence  
Y= α + β1X1 + β2X2 + … + βkXk + Z 
where α is a constant, β1,…, βk are parameters,  X1,…, Xk are the  
predictor variables and Z is an independent error term.   The 
nature of our data was found to be such that, after initial 
explorations, linear modelling was deemed inadequate to describe 
the patterns of recovery.  As a consequence, non-linear modelling 
was applied.  Non-linear models take many forms but are defined 
as non-linear by not conforming to the linear form described 
above. An initial non-linear model was created without the pre-
morbid (t-30) CAP-sym scores.  This model was used to better 
understand the symptom trajectory from admission to recovery. 
The fit of this basic non-linear model was assessed.   
Once an adequate model framework was achieved the model was 
re-parameterised to include the pre-admission (t-30) CAP-sym 
score.  With this more elaborate model we were able to assess how 
covariates affected the degree of recovery from peak symptoms to 
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the mean baseline (pre-morbid) symptom level for the group.  The 
covariates tested were those that had been shown to be significant 
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Figure 6.1 The CAP-sym questionnaire 
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6.4 Results 
6.4.1 Initial exploratory analysis 
6.4.1.1 Trajectory of recovery for the PASS cohort 
Mean CAP-sym scores for the PASS cohort at each time-point are 
shown in table 6.1.  The scores at presentation were similar to 
those obtained in the multicentre study in which the CAP-sym 
questionnaire was validated.[206]  Compared to the validation 
study recovery scores were slightly higher at comparative time-
points.  The distribution of scores is revealed in figure 6.2 as is the 
median recovery trajectory for the group.   
6.4.1.2 Associations between smoking status and PASS 
CAP-sym scores over time 
We next plotted the summary CAP-sym scores for the PASS 
cohort over time but divided the subjects up by key variables to 
determine if, going forward, there were likely to be associations 
that could be explored by statistical models.  Due to the 
prominence of smoking status in the cohort and in the analyses of 
chapters 4 and 5, CAP-sym scores for PASS subjects were grouped 
by smoking status and we observed how they varied over time 
(see figure 6.3).  The pattern that emerged was of higher 
symptoms scores for smokers than ex-smokers who in turn had 
higher scores than never smokers.  This pattern was repeated at 
every timepoint.   
6.4.1.3 The relationship between efferocytosis and 
Haemophilus_617 abundance on symptom recovery 
at one month 
We next asked how the two key experimental variables explored 
in chapters 4 and 5 influenced recovery. There were limited data 
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available for both efferocytosis (22 subjects) and Haemophilus 
dominance (76 sequenced sputum samples) and we therefore 
began with the simple measure of % recovery of presenting 
symptoms at one month.  Figure 6.4 illustrates the non-
statistically significant trend towards increased recovery with 
increasing efferocytosis.  Figure 6.5 demonstrates that subjects 
with a sputum dominated by the OTU Haemophilus_617 had a 
statistically significantly worse recovery at one month than those 
in whom Haemophilus_617 was present, but not dominant.   
6.4.1.4 Exploration of individual recovery traces 
The trajectory of each PASS subject’s symptoms is displayed in 
figure 6.6.  Most subjects had a sharp rise in symptoms from 30 
days prior to admission to presentation with CAP.  In most cases, 
symptom scores then fell rapidly over the next few days and were 
close to, but above base-line by discharge.  By one month most 
subjects had resolved most of their symptoms and if that was the 
case the symptom score remained generally around baseline 
throughout follow-up to one year.  However, some patients did not 
follow this trend.  Figure 6.7 plots the residuals of the CAP-sym 
scores over time and picks out 10 randomly chosen subject traces.  
The residual was calculated by subtracting the mean CAP-sym 
value for all subjects at a given time point from an individual’s 
CAP-sym score at that time-point and dividing the answer by the 
standard deviation of all scores at that time point.  This 
transformation standardises the scores and enables the degree to 
which patients’ trajectories differ from one another at each time-
point to be made more obvious.  Some individuals actually 
described feeling better on admission than 30 days prior to 
admission, suggesting that the admission was part of a longer 
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running illness.  Others felt worse on day 2 than on day 0 
suggesting they had presented early in the illness and that 
symptoms were still evolving.  Some patients went home with a 
higher symptom burden than others and some actually felt worse 
at follow-up than on discharge.  
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Pre-morbid -30 13.6(14.5) NA NA 
Enrolment 0 32.8(14.6) 33.9 (13.6) 34.3 (13.2) 
Mid-treatment 2 23.8(15.1) 20.6 (11.0) 20.9 (11.8) 
Discharge Variable 15.3(10.6) 12.0 (10.3) 13.5 (11.5) 
Early  
follow-up 
28-35 13.6(11.8) 9.6 (10.8) 10.1 (10.9) 
Medium term 
follow-up 
160-200 12.6(11.8) NA NA 
Late follow-up 345-385 13.3(12.7) NA NA 
Figure 6.2 Median CAP-sym scores for the PASS cohort 
A skewed distribution of CAP-sym scores was seen at all time-points.  
Median values were joined to describe a summary recovery trajectory 
for PASS.  The mean time in days of each time-point was indicated on 
the x axis however the scale was compressed for ease of plotting.   All 
CAP-sym values (y axis) were jittered around the time-point to 
prevent over-plotting of points.   
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Figure 6.3 The influence of smoking status 
on the trajectory of symptom recovery for 
PASS cohort 
At every timepoint active smokers have a higher median level of symptoms than ex-smokers who have a higher burden of symptoms 








Figure 6.4 Exploration of the relationship 
between symptom recovery and 
efferocytosis 
Recovery was calculated as the percentage improvement in CAP-sym score at one month compared to the CAP-sym score at 
presentation.  This recovery measure is then plotted against the efferocytosis result for 22 subjects (see chapter 4).  The result is a non-
statistically significant trend towards increasing recovery with increasing efferocytosis as displayed by the blue line (shaded area = 
95% CI around the position of the line). 
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Figure 6.5 Exploration of the relationship 
between the OTU Haemophilus_617 and 
symptomatic recovery from CAP. 
Recovery was calculated as the percentage improvement in CAP-sym score at one month compared to the CAP-sym score at 
presentation.  PASS subjects are divided into those in whom Haemophilus_617 represented >50% of all reads in their sputum 
(dominant), <50% of all reads in their sputum (non-dominant) or was not detected in their sputum by 16S rRNA sequencing (absent).  
Those without Haemophilus_617 in their sputum and those in whom Haemophilus_617 was non-dominant both had significantly (p= 
0.005 ) greater symptom recovery than those in whom Haemophilus_617 was dominant.   There was no difference in recovery between 
the non-dominance group and the absent group.  
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Figure 6.6 Individual subject’s CAP-sym traces for the PASS cohort 
Most subjects’ symptoms followed a pattern of rapid initial recovery following admission then sustained low level symptoms.  However 
a significant minority had an alternative pattern with some being highly symptomatic out to one year. 
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Figure 6.7 Variation in recovery revealed by residuals of CAP-
sym scores 
In figure 6.3 CAP-sym scores were transformed to residuals by the 
following formula:-           




y was a CAP-sym score 
i was a particular subject  
j referred to a given time-point 
𝑦j was the mean of all subjects’ CAP-sym scores at time j 
sj was the standard deviation of all CAP-sym scores at time j 
 
The means of each subject’s residuals were then calculated and 
ranked. The traces above represent a selection of traces from the 
lowest mean residual to the highest.  Within these, substantial 
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6.4.2 Base Non-linear Model 
The following are the algebraic arguments for the initial non-
linear model we used to describe the CAP-sym recovery data from 
the Pneumonia Aetiology and Severity Study (PASS).  Let Yij 
denote the jth CAP-sym value for subject i and tij the 
corresponding time in days since admission. Model was:-  
Yij = α + β exp(-tij/γ) + Ui + Zij                (1) 
where α is the mean CAP-sym score at maximum recovery and 
α+β is the mean  CAP-sym score at maximum symptoms. The 
parameter γ controls the average rate of recovery: the smaller the 
value of γ the more rapid the recovery. The exponential function 
captures the general shape of the recovery curve.  Ui ~N(0,ν2) are 
independent subject-specific random intercepts and Zij ~ N(0,τ2) 
are independent residuals.  Regarding variance (Var), this model 
implied that Var(Yij) = ν2+τ2 and that the correlation between 
pairs of CAP-sym measurements on the same subject was equal to 
ρ where  
ρ = ν2 / (ν2 + τ2). 
The above model was applied to the PASS CAP-sym values. The 
estimated values of the model parameters are shown in table 6.2 
Table 6.2 Parameter Estimates for the Base Non-Linear Model of 
CAP-sym Scores 
Parameter Maximum Likelihood Estimates Standard Error 
α 13.7 0.9 
β 19.0 0.9 
γ 2.2 0.3 
τ2 87.3 5.8 
ν2 87.0 13.0 
A plot of the above model is shown in figure 6.8 and a diagnostic 
plot of the residuals versus fitted values is seen in figure 6.9.. 
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Figure 6.8 Non-linear Model of CAP-sym Scores from Admission to Recovery. 
Dots represent the raw CAP-sym scores and black lines pick out the traces of 8 randomly selected subjects.  The red line shows the 
trajectory of the mean CAP-sym score from the non-linear model (see 6.1.3) using the calculated parameters shown in table 6.2. 
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Figure 6.9 Diagnostic Plot for Initial Model: Residuals vs. Fitted 
The Residual is calculated for all CAP-sym values and these are 
plotted against the values derived from the non-linear model.  No 
systematic change in the distribution of residuals was seen across 
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6.4.3 Incorporating pre-morbid symptom level into the model 
The model described in 6.4.2 did not take into account the 
recorded values for the CAP-sym score which subjects provided to 
represent how they felt 30 days prior to admission.  The model of 
recovery was therefore refined by including these values so that 
recovery became the degree of symptom resolution with respect to 
a pre-pneumonia baseline level of symptoms.  Thus the new model 
was:- 
Yij =  {
                                𝛿 + 𝑈𝑖𝑗 + 𝑍𝑖𝑗: 𝑡𝑖𝑗 < 0
𝛼 +  𝛽 exp (−
𝑡𝑖𝑗
𝛾
) +  𝑈𝑖 +  𝑍𝑖𝑗 ∶  𝑡 ≥ 0
 
Where now  𝛿  is the average pre-pneumonia (t-30) CAP-sym score 
and the other parameters are as in equation (1) (see 6.1.3).  From 
this it can be seen that, if  𝛼  is bigger than 𝛿,  recovery is, on  
average,  only partial, whereas if   𝛼  is smaller than 𝛿, on average 
patients’ long-term state of health is better than their pre-
admission state.  This model is represented schematically in 
figure 6.10 
Figure 6.10 Schematic Representation of Non-linear model of 
CAP-sym Scores  
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6.4.4 Adding covariates to the model 
Next we explored how clinical covariates affected the model.  We 
chose to limit this analysis to an exploration of the degree to 
which the covariates affected the average CAP-sym score after 
recovery i.e. α in figure 6.6. 
In the model formula in 6.4.4 α was replaced with αi :- 
αi = α exp(x1iθ1 + …+ xki θk)               (2) 
where  
i denotes a subject  
θ1,…, θk are parameters   
x1i,   xki are the values of the k covariates for subject i 
 
The covariates fitted to the model were prior statin use, prior 
pulmonary disease, smoking status (coded as 0,1,2 for never, quit 
and active) and age (which was centred at 65 years). 
Table 6.3 Univariate Effects of Covariates on the Non-linear 
Model 
 
From the data in table 6.3 it can be seen that the effect of age was 
to reduce the magnitude of α i.e. as people get older their 
maximum recovery to baseline was greater.  The effect of smoking 
was in the opposite and led to an increase in α from never smokers 
Covariate Maximum Likelihood Estimate p 




Prior Statin Use -0.21 0.045 
Smoking 0.17 0.013 
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to smokers such that smokers had a larger residual level of 
symptoms than non-smokers. 
Finally we performed a multiple regression to adjust each 
covariate for one another.  We used a likelihood ratio test to judge 
the significance of each covariate in the presence of others.  
Results are displayed in table 6.4. 
Table 6.4 Results of Multivariate Analysis of Covariates and 
CAP-sym Recovery 
Covariates Log-likelihood p 
None 2913.4  
Age 2902.7 <0.001 
Age+Smoking 2901.1 0.069 
Age+Smoking+statin 2900.6 0.351 
Age+Smoking+Statin+Pulmonary Disease 2900.6 0.739 
 
On the basis of this analysis we chose a model including the 
effects of age and smoking.  The parameter estimates for this 
model are shown in table 6.5. 
Table 6.5 Parameter Estimates for the Final Non-Linear Model 
of Recovery from CAP 
Parameter Estimate 
α 11.649 
θ  (age) -0.011 














Using the CAP-sym questionnaire we described the symptom 
kinetics of recovery from community-acquired pneumonia (CAP). 
Considering the group as a whole, subjects presented with a high 
burden of symptoms.  These symptoms diminished rapidly over 7 
days, resolved to near baseline by one month and remained at this 
level up to one year.  On a subject by subject basis, patterns of 
recovery varied considerably.  Non-linear modelling and multiple 
regression revealed that age and possibly smoking status 
influenced symptomatic recovery, but with opposite effects.  Older 
people tended to recover more completely and smokers less so. 
Note, however, that the age effect is unequivocally significant 
(p<0.001) whereas the smoking effect, after adjusting for age, does 
not reach the conventional 5% level of significance (p=0.069>0.05) 
6.5.2 What are the strengths of this work? 
This is the first study to model symptomatic recovery from CAP.  
Previous studies have described mean recovery among groups of 
patients at a range of time-points.[53,55,59]  However, most 
doctors are aware that some patients take longer to recover than 
others. And whilst these previous studies enable generalisations 
to be made about large groups of patients, they do not tell us 
about the causal factors involved in differential rates of recovery; 
nor do they help us inform individual patients as to their likely 
recovery trajectory.  This study moves us closer to personalised 
medicine by modelling individual recovery trajectories through 
the random effect term Ui in equation (1) and the covariate 
adjustments in equation (2). The cohort has been shown to be 
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representative (chapter 3) and this enables us to generalise our 
results to similar cohorts and populations.   
6.5.3 What are the limitations of this work? 
6.5.3.1 Exclusions 
The CAP-sym questionnaire requires patients to be able to 
answer questions and as a consequence some of the most sick – 
i.e. those who were expected to die soon after admission or those 
who were intubated – were excluded from the study.  As a 
consequence, this is a study of moderate-to-severe CAP and 
cannot be extrapolated to the most severe cases.  However, 
intubation itself is known to influence recovery and may have 
confounded our attempts to determine CAP-specific effects if these 
patients had been included.[207]  Similarly those who were 
excluded because of cancer would have had their recovery 
confounded by the effects of the cancer.  Larger studies powered to 
investigate differential effects in these sub-groups could confirm 
these effects. 
6.5.3.2 Model parameterisation 
The statistical techniques used in the work were advanced.  As a 
consequence we limited the analysis in several ways.  The final 
model allows covariates to influence alpha – the long-term level of 
symptom recovery  – but not the other recovery parameters e.g. 
rate of recovery (gamma) or peak symptoms (alpha+beta).  
Moreover, in the final model the baseline symptom score, delta, 
with which alpha can be compared is not allowed to depend on 
covariates and so is effectively an average for the group as a 
whole.  This is clearly an un-representative way to parameterise 
the model.  As such the final model is best considered as a proof of 
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principle for the technique and could be refined with further 
work, including investigation of how covariates affect each of the 
parameters in the model. However, a cautionary point is that 
over-elaborate models fitted to sparse data tend to have poor 
predictive performance, hence extension of the model may need 
data form a larger cohort of patients. 
6.5.4 Clinical implications 
The finding, albeit not conventionally significant, that smoking is 
likely to lead to worse symptomatic recovery from CAP enables us 
to make patient-centred decisions and give personalised advice.  It 
delineates a group of patients who may gain greater benefit from 
clinical follow-up and active rehabilitation.  It may also enable 
future research to be focussed on the mechanistic links between 
smoking and symptoms, which may in turn lead to therapeutic 
trials.    
The finding that as you get older you are more likely to fully 
recover from CAP is at first perplexing since ‘traditional’ 
outcomes, such as mortality, are unquestionably worse in the 
elderly.  There are several possible explanations for this result.  
The first is that it may be an artefact of our cohort and study 
design.  It is possible that older people who volunteered for PASS 
were generally fitter than average and therefore predestined to do 
well.  Certainly the in-patient mortality in PASS was lower than 
in some previously reported studies (table 3.5).  Against this is the 
fact that, once cancer and those with terminal disease at 
presentation were accounted for, PASS was similar with respect 
to other outcomes (length of stay mortality and re-admissions) to 
other cohorts (table 3.5 and section 3.1.16).  The age range of 
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PASS was representative of CAP in general and the level of co-
morbidity was high rather than low.  An alternative explanation 
is that this is a true result and reflects something particular 
about how patients report symptoms.  It is possible that the 
elderly are more stoical and under-report symptoms when 
compared with their younger counter-parts.  Several studies have 
reported this phenomenon previously.[208]  This is potentially 
very important as our population is aging and rates of CAP in the 
elderly are high and increasing.[14]  It will be important in future 
studies to carefully link symptoms with physiology and 
biomarkers of inflammation since low levels of reported symptoms 
may mask significant underlying disease.  It may be that in the 
future, as some other authors have suggested, we should 
conceptualise pneumonia as a different disease in the elderly 
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7 DISCUSSION 
7.1 Key findings with reference to the stated aims 
The aim of this thesis was stated in 1.9:-  
‘to explore how efferocytosis and sputum microbiota vary 
depending on the clinical characteristics of patients with CAP and 
to relate these to symptomatic recovery’.   
We found that in a cohort recovering from CAP, symptomatic 
recovery improved as patients got older but was worse in smokers 
than non-smokers. Smoking reduced the rate of efferocytosis but 
statins increased it and efferocytosis increased as BMI increased.  
The cohort had high rates of smoking and consequently high rates 
of underlying lung disease and Haemophilus was the dominant 
bacterial genus identified in the sputum.  The sputum microbiota 
was less diverse when underlying pulmonary disease was present.  
These host-pathogen-symptom interactions are shown 
schematically in figure 7.1. 
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Figure 7.1  Schematic Representation of Host Pathogen Interactions in CAP Recovery 
Solid lines indicate a measured effect and dashed lines indicate a hypothetical interaction. 
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7.2 Strengths of this work 
7.2.1 Efferocytosis 
This is the first study to investigate ex-vivo efferocytosis during 
recovery from CAP.  Patients were representative, alveolar 
macrophages were immediately cultured post-bronchoscopy, 
neutrophils were autologous and cytoplasmically stained rather 
than surface labelled.  Multiple replicate wells enabled us to 
account for the experimental component of stochastic variation in 
the model and multiple regression accounted for confounding 
clinical variables.  This comprehensive range of methodologies has 
not been combined previously in efferocytosis studies and the 
results are robust and novel. 
7.2.2 Sputum microbiota 
This was the largest CAP microbiota study and the first to link 
clinical variables to ecological measures of diversity in acute 
samples.  Sputum samples were rapidly frozen and unadulterated 
by pre-processing prior to DNA extraction.  The DNA extraction 
was mechanical and therefore un-biased and PCRs were 
quadrupled to enhance coverage of rare species.  We removed 
contaminating OTUs and applied a cutting edge compositional 
analysis package.  The size and rigour applied to this analysis 
yielded novel insights into the spectrum of bacrteria in CAP 
sputum and will be highly relevant data on which to base future 
study designs.  
7.2.3 Recovery by CAP-sym score 
This is the first study to create a longitudinal model of 
symptomatic recovery from CAP.  Previous studies of symptom 
recovery have compared mean group symptoms to generalise 
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about recovery at various time points.  This study went further 
and by accounting for repeated measures on the same individual 
and created a model that could be used to explore the influence of 
clinical covariates.  The model has raised important questions 
about the validity of comparing symptoms across the age 
spectrum and has provided useful framework for generating 
future hypotheses. 
7.3 Limitations of this work 
7.3.1 Potential for bias in this work 
7.3.1.1 Low eligibility rates 
PASS limited its recruitment to Monday to Friday 9am to 4pm 
due to resource constraints.  As a consequence a large proportion 
of subjects treated for CAP by the hospitals during the time of 
PASS recruitment were ineligible.  Some of the patients ‘treated 
as CAP’ would not have met our strict definition of CAP but the 
greatest proportion of ineligibility was a consequence of our strict 
adherence to the recruitment of patients early in their admission.  
This was scientifically beneficial but potentially limits the 
applicability of the results if those who could not be recruited 
represented a systematic bias.  It is well known that patients who 
are admitted to hospital at night or at the weekend have worse 
outcomes and PASS in-patient mortality was low when compared 
to the national BTS CAP audits.  However, in most other respects 
PASS subjects were remarkably similar to those audits and other 
published observational studies.  Moreover, when malignancy, 
dementia and those who were moribund at presentation were 
accounted for PASS outcomes were very similar to other cohorts.     
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7.3.1.2 Efferocytosis 
Since all the efferocytosis work was carried out by the author who 
also recruited, bronchoscoped and followed-up the study subjects 
it was predicted that I would have insight into the clinical 
background and recovery rate of the patient.  There were three 
stages at which this knowledge could have introduced bias into 
the assay.  The first was during the ‘wet bench’ section of the 
work.  That involved isolating and culturing alveolar 
macrophages and then co-culturing the macrophages with 
neutrophils.  It was during the co-culture that efferocytosis 
occurred but this process was not amenable to experimental 
influence and so was perceived to have little susceptibility to bias.  
Replicate wells of the efferocytosis experiment generated 
remarkably tight results indicating low levels of experimental 
variation.   The second stage of the assay involved measuring the 
efferocytosis using flow cytometry.  The measurement was 
performed mechanically along pre-set parameters and was 
therefore was not susceptible to researcher bias.  The third stage 
of the assay was the analysis of the output data from the flow 
cytomety work.  This involved a subjective, visual inspection of 
the pattern of the data and was potentially highly susceptible to 
researcher bias.  For that reason the data was batch analysed at 
later date when there was less possibility of researcher recall of 
the recovery characteristics of individual, anonymously coded 
study subjects.  
7.3.1.3 Sputum microbiota 
Regarding the 16S rRNA PCRs and amplicon purification, these 
samples were all anonymised and multiplexed and there was little 
opportunity for the introduction of researcher bias at this stage.  
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Sequencing was performed by an external lab with no prior 
knowledge of the study design and subject characteristics.  
Likewise the assignment of OTU identities and the building of the 
phylogenetic tree that underpinned the data-set were performed 
by a researcher who was entirely removed from all aspects of the 
data other than the sample ID codes.  Thus compartmentalisation 
of the microbiota work and the handling of samples in large 
batches will have effectively blinded the handlers to the data and 
reduced experimental variation.  Two significant and unaccounted 
for areas of bias remain with the sputum microbiota work.  One is 
that half the patients in PASS did not contribute to this data as a 
consequence of not producing sputum.  This is not unusual for 
CAP but does mean that we have only described the microbiota in 
sputum producers and it is possible that non-sputum producers 
have a different spectrum of bacteria especially given the trends 
towards increased rates of pulmonary disease and smoking among 
the sputum producers.  Future studies aimed at identifying the 
spectrum of potential pathogens in CAP will have to specifically 
address the issue of non-sputum production in their design.  The 
second remaining bias in this study is the timing of samples with 
respect to antibiotic.  All the subjects here had received at least 
one dose of antibiotic prior to providing a sputum sample.  This is 
very likely to have altered the results.  The effect of pre-hospital 
antibiotics was investigated in the linear regression and was not 
significant even as a univariate.  Future studies could target 
patients in primary care presenting with CAP whilst antibiotic 
naïve; or in hospital, closely link to the initial triage teams so that 
patients with respiratory tract infections are sampled prior to 
antibiotic.   
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7.3.1.4 CAP-sym bias 
Questionnaire data is prone to intra-subject bias and inter-
observer bias.  However the intra-subject variation was accounted 
for in the statistical modelling and during validation studies the 
CAP-sym questionnaire was shown to have low levels of variation 
between investigators.  
7.3.2 Limitations with respect to the study aims 
It was an ambition of this work to draw direct associations 
between efferocytosis, the bacterial ecology of sputum and patient 
symptoms.  However the study was limited in its scope and 
findings by lower rates of recruitment than expected, the high 
level of comorbidities which rendered most subjects ineligible for 
bronchoscopy and by the fact only half of the subjects could 
produce sputum.  As a consequence the CAP-sym model could not 
incorporate measures of efferocytosis or bacterial diversity as the 
numbers were too small to deliver meaningful answers.  As a 
consequence, as indicated in figure 7.1, associations between 
symptomatic recovery, efferocytosis and bacterial diversity are 
hypotheses rather than direct estimates.  In that diagram I 
hypothesise that the measured negative effect of smoking on 
symptoms may be mechanistically mediated by the measured 
negative effect on efferocytosis.  In a similar fashion it may be 
that the reduced diversity seen in the sputum of those with 
pulmonary disease is mechanistically responsible for some of the 
negative effect of smoking on symptomatic recovery. What I have 
learnt from this study is that to generate enough data to directly 
test these associations would require a study of a different order 
of magnitude – based at multiple sites.  However, the data 
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presented here are the ideal preliminary dataset to support 
applications to fund such ambitious studies.  
7.4 How has this thesis contributed to field? 
There is only a small literature regarding recovery from CAP.  
What studies there are have limited themselves to summary 
descriptions of whole cohorts.  We went further and defined how 
clinical characteristics influence recovery.  Moreover, no prior 
studies have married symptomatic recovery to host or pathogen 
mechanistic factors.  The data presented here pave the way for 
larger future studies aimed at devising pro-recovery strategies 
tailored to the characteristics of individual patients.     
7.4.1 What are the implications for policy and clinicians? 
Current clinical guidelines offer very limited guidance regarding 
the management of recovery from CAP which reflects the limited 
amount of research in this area.  The recently published NICE 
guidelines on pneumonia specifically excluded follow-up and post 
discharge management from their remit although they do specify 
recovery milestones.  However the only specificity associated with 
these recovery targets is the suggestion that those with more 
severe illness may take longer to recover and this is based on 
studies mostly rated low-quality.[10]  The British Thoracic Society 
Guidelines on Pneumonia suggest all patients should have a 
follow-up visit either in hospital or with a GP at 6 weeks.[6]  The 
finding from our study that smoking has a negative impact on 
symptomatic recovery implies a change may be warranted to this 
current ‘one size fits all’ approach to managing the aftermath of 
CAP and that smokers should be treated differently to non-
smokers.  But if smokers deserve special attention what should 
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this be?  Our study was not an intervention study and therefore 
does not provide the definitive answer but rather offers 
hypothesis generating preliminary results which may pave the 
way for further work (see 7.5). 
The overwhelming weight of evidence from previous studies of the 
aetiological causes of CAP suggests that the most common 
bacterial pathogen is Streptococcus pneumonia and this heavily 
influences antibiotic prescribing guidelines.  However, the 
majority of this evidence was derived from studies where the 
detection of bacterial pathogens was limited to culture where 
some bacteria are more easily cultured than others and some 
cannot be cultured at all.   There is therefore an inherent 
detection bias associated with our current understanding of the 
bacterial spectrum of CAP.  Our study suggests that, in a cohort 
with high rates of smoking and lung disease, bacteria of the genus 
Haemophilus are much more abundant in the sputum of patients 
with CAP than was previously thought.  It should be noted that 
this link does not imply causality and future studies would be 
needed to determine this.    
7.5 Ongoing Research 
A number of questions relating to the work described in this 
thesis are currently being pursued.  Collaborative grants are 
being developed to investigate the microbiota of respiratory 
samples from patients with severe CAP that required ventilation 
in intensive care; to refine the CAP-sym model in large more 
diverse cohorts and to generate further insights into the effect of 
statins on macrophages and outcome from CAP.  Another study 
will to explore patients’ experiences of CAP managed by the NHS 
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with the aim of better understanding the processes and 
communication that frustrate or enhance the experience of being 
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8 APPENDIX 1: PASS DOCUMENTATION 
The following pages contain copies of regulatory documentation 
drawn from the ‘Site Master File’ for to the Pneumonia Aetiology 
Study (PASS). 
National Institute of Health Research funding letter regarding 
the Doctoral Research Fellowship that funded PASS p218 
Independent Scientific Review of DRF application p219 -220 
NHS Research Ethics Committee approval for PASS p221 -222 
Front section of contract between funder and sponsor of PASS 
p223 
PASS patient information leaflet (PIL) p224-228 
PASS patient information leaflet for bronchoscopy p229-232 
PASS consultee information leaflet p233-238 
PASS consent form p239 
PASS consultee declaration form p240 
  
 
NIHR Trainees Coordinating Centre  
Leeds Innovation Centre 
103 Clarendon Road 
Leeds LS2 9DF 
Tel: 0113 346 6262 
       Fax: 0113 346 6272 
Email: karen.fernando@nihrtcc.org.uk 
9th September 2010 
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Dr. Dan Wootton 
Specialist Registrar Respiratory and General Medicine 
Department of Respiratory Medicine 
University Hospital Aintree 
Dear Dr. Dan Wootton 
Doctoral Fellowship - awarded August 2010 
Our ref: NIHR-DRF-2010-03-154 
Thank you for accepting your NIHR Fellowship award.  
This is to formally confirm that the NIHR is currently preparing a contract 
between the Department of Health and University Hospital Aintree. This 
contract will support you to start your NIHR DRF on 1st Nov 2010 for a 
duration of 36 months.   
In the meantime we are looking in detail at the finances of your award, the 
original submitted total of which was £223,617. NIHR TCC reserves the 
right to reject any costs that it considers unreasonable or not fully justified. 
We will be in touch if we have any queries. A payment schedule forms part 
of the contract and will set out the dates when your host institution will 
receive payment, quarterly in arrears. Once the contracts have been 
signed, the first payment will be released at the next quarterly payment 
date. 
Individuals can, with the agreement of their employing organizations, 
establish start dates which fall before the formal contracting process is 
complete.   
This award letter is a commitment from the NIHR to support you in a 
Fellowship.   
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Research & Development Directorate 
University Hospital Aintree 
Room 2.06, Clinical Sciences Centre 
Liverpool 
L9 7AL 
R&D Director: Prof Robert Moots 
R&D Deputy Director:  Michelle Mossa 
Tel: 0151 529 5870/1  Fax: 0151 529 5875 
E-mail: michelle.mossa@aintree.nhs.uk  
Pneumonia Aetiology and Severity Study 
(PASS) 
Participant Information Sheet 
We would like to invite you to take part in our research study.  Before you 
decide you should understand why the research is being done and what it 
would involve for you.  Please take time to read the following information 
carefully.  One of our team will go through the information sheet with you 
and answer any questions you have. 
What is the purpose of the study? 
Pneumonia is an infection of the lungs which can be caused by a number of 
different bacteria and viruses.  Traditionally patients have been told by their 
doctor that it takes 6 weeks to fully recover from pneumonia.  It is now clear 
that some patients recover more quickly than this while others take much 
longer.  In this study we want to investigate a group of patients who are 
admitted to hospital with pneumonia and follow their progress over 12 
months to investigate reasons for different patterns of illness.  
It is possible that particular bacteria or viruses or combinations of both lead 
to more severe pneumonia and a more prolonged recovery.  In our study 
we will perform state of the art tests to try to find out if there are differences 
in the organisms present in the lungs of people with different patterns of 
pneumonia illness. We will investigate ways of predicting which patients 
become severely unwell and who takes longer to recover.  For example it 
may be that some people’s genetic make-up predisposes them to slow 
recovery from pneumonia if they have certain bacteria in their lungs.   
Investigating this will involve taking samples and recording clinical 
information at several points during admission and following discharge from 
hospital.   We hope that the information generated by this study will lead to 
the development of new therapies to treat and improve recovery from 
pneumonia in the future. 
Why have I been invited to take part? 
We aim to recruit 400 patients with pneumonia for this study.  Our research 
team works with doctors and a specialist nurse to identify suitable patients 
for the study.  You have been invited to take part because the doctors 
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Research & Development Directorate 
University Hospital Aintree 
Room 2.06, Clinical Sciences Centre 
Liverpool 
L9 7AL 
R&D Director: Prof Robert Moots 
R&D Deputy Director:  Michelle Mossa 
Tel: 0151 529 5870/1  Fax: 0151 529 5875 
E-mail: michelle.mossa@aintree.nhs.uk  
Do I have to take part? 
It is up to you to decide on whether to join the study once you 
understand what it involves.  If you agree to take part we will ask you to 
sign a consent form.  You are free to withdraw at any time without giving 
a reason.  This would not affect the standard of care you receive.  You 
will be able to choose if samples and information collected up to that point 
may be used or should be destroyed. 
What will I have to do? 
This research study involves gathering information about you and your 
symptoms and collecting clinical samples such as blood, sputum and a salt-
water mouthwash.  If you agree to take part in this study, you will be seen by 
a member of the research team on several occasions during your treatment 
in hospital and recovery at home. 
What will happen to me if I take part?  
The research study will run alongside your routine hospital care and you will 
not need to spend any longer in hospital than normal.  Soon after your 
diagnosis of pneumonia a member of the research team will review your 
medical notes and ask you about your symptoms and your past medical 
history.  They will ask to take some clinical samples and table 1 has details 
of when the various samples will be taken.  You will be seen again 
approximately 48 hours later for another review and further samples and 
then again on the day of your discharge.   
 
Following discharge from hospital you will be invited to attend appointments 
1, 6 months and a year later in the out-patient department on convenient 
dates.  At these appointments, a member of the research team may take 
further samples, will question you about your symptoms and may ask you to 
have some breathing tests and an x-ray.  These assessments are designed 
to monitor your recovery in greater detail than is current practice.  We would 
like to phone your GP and then you one year after your admission to 
hospital to review your symptoms and find out about any other medical 
events that have occurred.  If during that phone call you tell us you do not 
want to attend the one year follow-up visit we will offer you the option of 
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Room 2.06, Clinical Sciences Centre 
Liverpool 
L9 7AL 
R&D Director: Prof Robert Moots 
R&D Deputy Director:  Michelle Mossa 
Tel: 0151 529 5870/1  Fax: 0151 529 5875 
E-mail: michelle.mossa@aintree.nhs.uk  
Expenses and payments 
You will receive a modest financial reimbursement for your time and 
inconvenience from participation in the study.  This will be calculated in the 
following way: 
Participation with study procedures during the in-hospital stay. £20 
Participation with the 1 month follow up-visit    £20 
Participation with the 6 month follow up visit    £20 
Participation with the 12 month follow up visit   £10 
 
















Blood samples     
Sputum (phlegm) 
sample 
    
Urine sample     
Mouthwash     
Urine     
What are the possible disadvantages of taking part? 
You will be asked to have additional tests (blood, sputum, mouthwash, 
urine, x-rays and blowing tests) as part of this study.  When you are in 
hospital we will not repeat tests already requested by your team of doctors.  
What are the possible benefits of taking part? 
The study is unlikely to benefit you directly but you will have the reassurance 
of being monitored by pneumonia experts more closely than would normally 
be the case.  A proportion of people who get pneumonia do so because of a 
previously unrecognised abnormality in their lungs and it is possible our in-
depth tests may detect this.   
What will happen if I don’t want to join or carry on with the study? 
Taking part in the study is entirely voluntary.  You are free to withdraw at 
any time and do not have to give a reason for this.  This will have no effect 
on your medical care now or in the future. You will be able to choose if 
samples and information collected up to that point may be used or should 
be destroyed.  
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University Hospital Aintree 
Room 2.06, Clinical Sciences Centre 
Liverpool 
L9 7AL 
R&D Director: Prof Robert Moots 
R&D Deputy Director:  Michelle Mossa 
Tel: 0151 529 5870/1  Fax: 0151 529 5875 
E-mail: michelle.mossa@aintree.nhs.uk  
What if there is a problem? 
If you have a concern about any aspect of this study, you should ask to 
speak to the researchers who will do their best to answer your questions.  If 
you wish to complain formally, you can do this by contacting the Research 
Governance office at Aintree University Hospital.  The contact person is 
Mrs Michelle Mossa 0151 529 5871.  In the unlikely event that you are 
harmed during the research due to someone‘s negligence then you may 
have grounds for a legal action against Aintree University Hospitals NHS 
Foundation Trust. The normal NHS complaints mechanisms will still be 
available to you. 
Will my taking part in this study be kept confidential? 
All information which is collected about you will be kept strictly confidential.  
It will be stored securely within the Aintree University Hospital with 
anonymised samples also being stored at Liverpool School of Tropical 
Medicine.  Access to your personal information collected in the study will be 
restricted to authorised research staff.  
Involvement of the General Practitioner/Family doctor (GP) 
We will write to your GP to tell them that you have been involved in the 
project and will be seen for follow up in our pneumonia clinic and we will 
keep them informed of your recovery. 
What will happen to the samples that I give? 
The samples that you give during this study will be used to find out more 
about the bacteria and viruses that cause pneumonia and how your body 
responds to them.  The samples will be labeled with a code number only. It 
will not be possible for persons outside of the research study to trace these 
samples back to you.  We would also like to keep any excess sample 
material to use in future ethically approved studies that are related to the 
aims of this project.  You could ask for these samples to be destroyed at 
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Room 2.06, Clinical Sciences Centre 
Liverpool 
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R&D Director: Prof Robert Moots 
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Tel: 0151 529 5870/1  Fax: 0151 529 5875 
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What will happen to the results of the research study? 
At the end of the study, we will send you a short report of our findings.  
This will be a summary of all participants’ results and it will not be possible 
to derive any specific information about your tests from this.  The results of 
this research study will be presented at scientific meetings and published in 
medical journals.  
Who is funding the research? 
This study is jointly funded by the Royal Liverpool and Broadgreen 
University Hospitals NHS Trust and the National Institute of Health 
Research.  
 
Who has reviewed the study? 
All research in the NHS is looked at by an independent group of people, 
called a Research Ethics Committee, to protect your interests.  This study 
has been reviewed and given favourable opinion by North Wales Research 
Ethics Committee (Central & East). 
Further information and contact details 
If you have any further questions please contact either of the following 
members of the research team during normal working hours. 
 
 
Dr Dan Wootton (Principle Investigator) 
Tel: 0151 529 5932  Email: dwootton@liverpool.ac.uk 
Dr Stephen Gordon (Chief Investigator) 
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University Hospital Aintree 
Room 2.06, Clinical Sciences Centre 
Liverpool 
L9 7AL 
R&D Director: Prof Robert Moots 
R&D Deputy Director:  Michelle Mossa 
Tel: 0151 529 5870/1  Fax: 0151 529 5875 
E-mail: michelle.mossa@aintree.nhs.uk  
Pneumonia Aetiology and Severity 
Study (PASS) 
Additional Information Sheet for Research Bronchoscopy 
As part of the study we would like to invite you to undergo a test called a 
bronchoscopy.  Before you decide whether to have this test please take 
time to read the following information carefully.  One of our team will go 
through the information sheet with you and answer any questions.  This 
information sheet should be read alongside the Pneumonia Aetiology and 
Severity Study (PASS) Participant Information Sheet. 
 
What is the purpose of this research bronchoscopy? 
After having pneumonia, some patients are fully back to normal quickly 
whilst others take longer to recover.  The removal of infected material and 
damaged lung cells is an important part of recovery from pneumonia and is 
achieved by the lungs’ immune system.  We want to investigate if there is 
any difference in these immune functions between people who recover 
from pneumonia quickly and those who recover more slowly.  As part of the 
research study we plan to collect lung samples from a group of patients 
who have recently been admitted to hospital with pneumonia and the best 
way to do this is via bronchoscopy.  Knowing the reasons why recovery 
from pneumonia is delayed in some people will help us to develop new 
treatments to improve recovery. 
Why have I been invited to take part? 
Previously you agreed to take part in a research study about pneumonia.  
During the study some patients will be classified as having ‘rapid recovery’ 
and others as ‘delayed recovery’.  In order to understand the difference in 
recovery times we are inviting all study participants to have a bronchoscopy 
so we can investigate differences between the two groups.  
What are the possible benefits to me of taking part? 
In a few people the research bronchoscopy may identify an unexpected 
abnormality in the lungs.  This is more likely if you smoke.  If this occurs 
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Will I get paid for taking part? 
You will be offered £100 as reimbursement and for any inconvenience as a 
result of the bronchoscopy.  
Do I have to take part? 
It is up to you to decide whether to join this part of the study.  If you agree 
to take part we will then ask you to sign a consent form but after signing 
you remain free to change your mind at any point before the bronchoscopy 
without giving a reason.  Declining to have a bronchoscopy does not affect 
your participation in any other aspect of the study or the standard of 
medical care you receive. 
What is a bronchoscopy? 
A bronchoscopy involves passing a thin, flexible tube called a 
bronchoscope through the nose or mouth and into the breathing tubes 
(bronchi).  We will take samples from the lungs to investigate their functions 
and the bronchoscope contains a video camera so we can look at the 
breathing tubes.  One of the samples we take is called a ‘lavage’ and 
involves passing some salty water into the breathing tubes.  The water is 
then gently sucked back up and is sent for analysis.  Another sample is 
obtained using a tiny brush which is passed down the bronchoscope to 
remove a small number of cells for analysis.  If we see an unexpected 
abnormality in your breathing tubes we will take samples (biopsies) using 
tiny forceps which are passed through the bronchoscope.  You can’t feel 
biopsies which are standard medical practice when abnormalities are seen 
during any bronchoscopy. 
How long is the test and is there anything I need to do beforehand? 
The test is an out-patient procedure.   You must not eat for 4 hours before 
the bronchoscopy but can have water to drink up to 2 hours prior to the 
bronchoscopy then nothing by mouth for two hours before the 
bronchoscopy.  It takes around 7 minutes to complete the bronchoscopy.  
You then have 2 hours in our recovery area for monitoring. 
What time commitments are involved in this part of the study?  
If you decide to join this part of the study, in addition to the appointments 
described in the main study information sheet, we will ask you to attend 
hospital for the bronchoscopy and we will book a time with you to receive a 
phone call to get your feedback on the procedure. 
What will happen to the samples that I give? 
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The samples that you give will be labelled with an anonymous code and 
stored in secure facilities at Aintree Hospital and the Liverpool School of 
Tropical Medicine.  The bronchoscopy sample will be used to identify lung 
cells and to investigate their function.  They will also be used to look for 
bacteria in the lungs.  Some of the sample volume will also be stored 
anonymously for possible use in future ethically approved studies 
Are there any risks from a bronchoscopy? 
Before the bronchoscopy begins we will place a small needle in the back of 
the hand and will take a blood sample.  This needle can be tender initially, 
like having a blood test, but it is removed soon after the bronchoscopy is 
over.  You will be monitored closely during the bronchoscopy.  A 
bronchoscopy is not painful but can make some people cough while it is 
being carried out.  To reduce the tendency to cough we will use local 
anaesthetic in the nose, the back of the throat and the breathing tubes.  
People are not put to sleep for a bronchoscopy but we will offer you some 
sedation.  The sedation makes some people more relaxed and you may 
want a short sleep when the bronchoscopy is over. Some people who have 
this sedation can’t recall the procedure afterwards. 
If you have the sedative you will not be able to drive home and will need 
another form of transport or someone to pick you up.  We will be happy to 
arrange and pay for a taxi.  If you have had the sedative you should not 
sign legally binding documents or handle heavy machinery until 24 hours 
after the sedative was given.  All patients are monitored for 2 hours after 
the bronchoscopy while the effects of the local anaesthetic and sedation 
wear off and during this time you will not be able to eat or drink. 
The British Lung Foundation describes bronchoscopy as a safe procedure 
(The British Lung Foundation patient information sheet is available on 
request).  Afterwards, most people do not have side-effects but a few 
describe sore throat or hoarseness for a few hours, nasal discomfort or 
rarely a minor nose bleed after the test.  Some get mild discomfort in the 
chest as they breathe but this is easily treated using paracetamol for 24 
hours after the test.   
A member of the study team is available 24 hours a day in the very unlikely 
event of serious problems after the bronchoscopy.  The contact details are 
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Further information and contact details 
If there is anything that is not clear or if you would like more information 
please ask when you meet the study team or by using the contacts at the 
end of this document during normal working hours. 
Dr Sarah Wilks (Clinical Fellow) 
Tel: 0151 529 5886   
Dr Dan Wootton (Principle Investigator). 
Tel: 0151 529 5886  Email: dwootton@liverpool.ac.uk  
Dr Stephen Gordon (Study Chief Investigator) 
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Pneumonia Aetiology and Severity Study 
(PASS) 
Consultee Information Sheet 
 
We feel your relative / friend is unable to decide for him/herself whether to 
participate in this research. 
To help decide if he/she should join the study, we’d like to ask your opinion 
whether or not they would want to be involved.  We’d ask you to consider 
what you know of their wishes and feelings, and to consider their interests.  
Please let us know of any advance decisions they may have made about 
participating in research.  These should take precedence. 
If you decide your friend/relative would have no objection to taking part we 
will ask you to read and sign the consultee declaration on the last page of 
this information leaflet.  We’ll then give you a copy to keep.  We will keep 
you fully informed during the study so you can let us know if you have any 
concerns or you think you relative / friend should be withdrawn.   
If you decide that your friend / relative would not wish to take part it will not 
affect the standard of care they receive in any way. 
If you are unsure about taking the role of consultee you may seek 
independent advice. 
We will understand if you do not want to take on this responsibility. 
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What is the purpose of the study? 
Pneumonia is an infection of the lungs which can be caused by a number of 
different bacteria and viruses.  Traditionally patients have been told by their 
doctor that it takes 6 weeks to fully recover from pneumonia.  It is now clear 
that some patients recover more quickly than this while others take much 
longer.  In this study we want to investigate a group of patients who are 
admitted to hospital with pneumonia and follow their progress over 12 
months to investigate reasons for different patterns of illness.  
It is possible that particular bacteria or viruses or combinations of both lead 
to more severe pneumonia and a more prolonged recovery.  In our study 
we will perform state of the art tests to try to find out if there are differences 
in the organisms present in the lungs of people with different patterns of 
pneumonia illness. We will investigate ways of predicting which patients 
become severely unwell and who takes longer to recover. For example it 
may be that some people’s genetic make-up predisposes them to slow 
recovery from pneumonia if they have certain bacteria in their lungs.   
Investigating this will involve taking samples and recording clinical 
information at several points during admission and following discharge from 
hospital.   We hope that the information generated by this study will lead to 
the development of new therapies to treat and improve recovery from 
pneumonia in the future. 
Why have I been invited to take part? 
We aim to recruit 400 patients with pneumonia for this study.  Our research 
team works with doctors and a specialist nurse to identify suitable patients 
for the study.  You have been invited to take part because the doctors 
looking after you think you have pneumonia.  
Do I have to take part? 
It is up to you to decide on whether to join the study once you 
understand what it involves.  If you agree to take part we will ask you to 
sign a consent form.  You are free to withdraw at any time without giving 
a reason.  This would not affect the standard of care you receive.  You 
will be able to choose if samples and information collected up to that point 
may be used or should be destroyed. 
What will I have to do? 
This research study involves gathering information about you and your 
symptoms and collecting clinical samples such as blood, sputum and a salt-
water mouthwash.  If you agree to take part in this study, you will be seen by 
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a member of the research team on several occasions during your treatment 
in hospital and recovery at home. 
What will happen to me if I take part?  
The research study will run alongside your routine hospital care and you will 
not need to spend any longer in hospital than normal.  Soon after your 
diagnosis of pneumonia a member of the research team will review your 
medical notes and ask you about your symptoms and your past medical 
history.  They will ask to take some clinical samples and table 1 has details 
of when the various samples will be taken.  You will be seen again 
approximately 48 hours later for another review and further samples and 
then again on the day of your discharge.   
 
Following discharge from hospital you will be invited to attend appointments 
1 and 6 months and a year later in the out-patient department on convenient 
dates.  At these appointments, a member of the research team may take 
further samples, will question you about your symptoms and may ask you to 
have some breathing tests and an x-ray.  These assessments are designed 
to monitor your recovery in greater detail than is current practice.  Finally we 
would like to phone your GP and then you one year after your admission to 
hospital to review your symptoms and find out about any other medical 
events that have occurred.  If during that phone call you tell us you do not 
want to attend the one year follow-up visit we will offer you the option of 
going through the symptom questionnaire over the phone.   
 
Expenses and payments 
You will receive a modest financial reimbursement for your time and 
inconvenience from participation in the study.  This will be calculated in the 
following way: 
Participation with study procedures during the in-hospital stay. £20 
Participation with the 1 month follow up-visit    £20 
Participation with the 6 month follow up visit    £20 
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Tel: 0151 529 5870/1  Fax: 0151 529 5875 
E-mail: michelle.mossa@aintree.nhs.uk  
 
 
















Blood samples     
Sputum (phlegm) 
sample 
    
Urine sample     
Mouthwash     
Urine     
 
What are the possible disadvantages of taking part? 
You will be asked to have additional tests (blood, sputum, mouthwash, 
urine, x-rays and blowing tests) as part of this study.  When you are in 
hospital we will not repeat tests already requested by your team of doctors.  
 
What are the possible benefits of taking part? 
The study is unlikely to benefit you directly but you will have the reassurance 
of being monitored by pneumonia experts more closely than would normally 
be the case.  A proportion of people who get pneumonia do so because of a 
previously unrecognised abnormality in their lungs and it is possible our in-
depth tests may detect this.   
 
What will happen if I don’t want to join or carry on with the study? 
Taking part in the study is entirely voluntary.  You are free to withdraw at 
any time and do not have to give a reason for this.  This will have no effect 
on your medical care now or in the future. You will be able to choose if 
samples and information collected up to that point may be used or should 
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University Hospital Aintree 
Room 2.06, Clinical Sciences Centre 
Liverpool 
L9 7AL 
R&D Director: Prof Robert Moots 
R&D Deputy Director:  Michelle Mossa 
Tel: 0151 529 5870/1  Fax: 0151 529 5875 
E-mail: michelle.mossa@aintree.nhs.uk  
What if there is a problem? 
If you have a concern about any aspect of this study, you should ask to 
speak to the researchers who will do their best to answer your questions.  If 
you wish to complain formally, you can do this by contacting the Research 
Governance office at Aintree University Hospital.  The contact person is 
Mrs Michelle Mossa 0151 529 5871.  In the unlikely event that you are 
harmed during the research due to someone‘s negligence then you may 
have grounds for a legal action against Aintree University Hospitals NHS 
Foundation Trust. The normal NHS complaints mechanisms will still be 
available to you. 
Will my taking part in this study be kept confidential? 
All information which is collected about you will be kept strictly confidential.  
It will be stored securely within the Aintree University Hospital with 
anonymised samples also being stored at Liverpool School of Tropical 
Medicine.  Access to your personal information collected in the study will be 
restricted to authorised research staff.  
Involvement of the General Practitioner/Family doctor (GP) 
We will write to your GP to tell them that you have been involved in the 
project and will be seen for follow up in our pneumonia clinic and we will 
keep them informed of your recovery. 
What will happen to the samples that I give? 
The samples that you give during this study will be used to find out more 
about the bacteria and viruses that cause pneumonia and how your body 
responds to them.  The samples will be labeled with a code number only. It 
will not be possible for persons outside of the research study to trace these 
samples back to you.  We would also like to keep any excess sample 
material to use in future ethically approved studies that are related to the 
aims of this project.  You could ask for these samples to be destroyed at 
any time now or in the future. 
What will happen to the results of the research study? 
At the end of the study, we will send you a short report of our findings.  
This will be a summary of all participants’ results and it will not be possible 
to derive any specific information about your tests from this.  The results of 
this research study will be presented at scientific meetings and published in 
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University Hospital Aintree 
Room 2.06, Clinical Sciences Centre 
Liverpool 
L9 7AL 
R&D Director: Prof Robert Moots 
R&D Deputy Director:  Michelle Mossa 
Tel: 0151 529 5870/1  Fax: 0151 529 5875 
E-mail: michelle.mossa@aintree.nhs.uk  
Who is funding the research? 
This study is jointly funded by the Royal Liverpool and Broadgreen 
University Hospitals NHS Trust and the National Institute of Health 
Research.  
 
Who has reviewed the study? 
All research in the NHS is looked at by an independent group of people, 
called a Research Ethics Committee, to protect your interests.  This study 
has been reviewed and given favourable opinion by North Wales Research 
Ethics Committee (Central & East). 
Further information and contact details 
If you have any further questions please contact either of the following 
members of the research team during normal working hours. 
 
 
Dr Dan Wootton (Principle Investigator) 
Tel: 0151 529 5886  Email: dwootton@liverpool.ac.uk 
Dr Stephen Gordon (Chief Investigator) 








Pneumonia Aetiology and Severity Study (PASS) 
 






1. I confirm that I understand the participant information sheet dated 
________ for the above study. I have had the opportunity to consider 
the information, ask questions and have had these answered 
satisfactorily. 
 
2. I understand that my participation is voluntary and that I am free to 
withdraw at any time without giving any reason, without my medical 
care or legal rights being affected. 
 
3. I understand that my medical notes and data collected during the study 
may be looked at by individuals from the Liverpool School of Tropical 
Medicine, from Aintree University Hospitals NHS Foundation Trust or 
from regulatory authorities.  I give permission for these individuals to 
have access to my records. 
  
4. I agree to the use of my samples as described in the patient information 
leaflet. 
 
5. I agree to the storage and use of my samples in future ethically-
approved research studies. 
 
6. I agree to my GP being informed of my participation in the study. 
 
7. I agree to take part in the above study.     
 
   
 
Name of patient  Signature  Date  
 
 
Name of person taking consent  Signature  Date  
 
When completed: 1 copy for participant; 1 copy for study case report file; 1 
copy to be kept in medical notes.  
Use patient label 
Patient name: 
Date of Birth:  
Hospital number: 
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Consultee Declaration Form 
 
Pneumonia Aetiology and Severity Study (PASS) 
 








1. I ............................................................ have been consulted about 
..................................’s participation in this research project. I have had the 
opportunity to ask questions about the study and understand what is involved.  
 
2. In my opinion he/she would have no objection to taking part in the above study. 
 
3. I understand that I can request he/she is withdrawn from the study at any time, 
without giving any reason and without his/her care or legal rights being 
affected. 
 
4. I understand that relevant sections of his/her care record and data collected 
during the study may be looked at by responsible individuals from University 
Hospital Aintree, Liverpool School of Tropical Medicine or from regulatory 
authorities, where it is relevant to their taking part in this research. 
 
5. I agree to their GP being informed of their participation in the study. 
 
   
 
Name of Consultee   Signature   
 Date  
 
 
Relationship to participant  Signature   
 Date  
 
 
Person undertaking consultation  Signature   
 Date  
(designation e.g. researcher) 
 
When completed: 1 copy for participant; 1 copy for study case report 
file; 1 copy to be kept in medical notes. 
 
Use patient label 
Patient name: 
Date of Birth:  
Hospital number: 
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9 APPENDIX 2: EFFEROCYTOSIS EXPERIMENT 
STANDARD OPERATING PROCEDURE (SOP) 
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SOP: Tuesday Lab procedures. 
 Non-stock reagents:-  
 15ml media (= IMDM with 10% human AB serum)









 Lysis buffer http://www.biolegend.com/rbc-lysis-buffer-10x-1498.html 
 APC labelled annexin V, 7AAD, annexin binding buffer 
http://www.bdbiosciences.com/documents/BD_Reagents_AnnexinV_Product
InfoSheet.pdf 
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Day before use study numbers to label the following for each subject: 
 (PEN) 5x orange sealed sputum pots numbered 1-5 with study number 
 (PEN) 3x 50 ml falcons with study number 
 (PEN) four 0.5ml eppendorfs V / 7 / V7 / U for fresh neuts 
 (PEN) four 0.5ml eppendorfs V / 7 / V7 / U for fresh HAMs 
 (cryo-lables) One 3ml cryo-vial labelled WB 
 (Cryo-labels) Three 50ml falcons SN 
 (cryo-lables) Ten 1.5ml cryo-vials SN  
 2 Cyto-spin slides – fresh HAMs and fresh neuts 
1. Prepare two falcons containing 40ml ½ x Hepes buffered saline ( = 30ml 
H2O and 10ml 2x Hepes buffered saline.  
2. Prepare 10ml 1x lysis buffer 
  = 9ml H2O and 1mL 10x lysis buffer 
3. Morning of Bronch - put water bath on and warm the saline for BAL 
 Place UpCell 48 well plate in incubator 
 Get ice in Yeti and place 5 labelled orange pots on ice. 
 Place the 5 pre-labelled 50ml falcons on ice with four 50ml falcons for 
every subject 
 Turn on a refrigerated centrifuge and refrigerate to 4oC 
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 BAL Processing 
Processing BAL should be cold throughout - preserve phenotype/prevent HAMs 
adhering to plastic 
Please complete the BAL record sheet as you go along 
1. Filter contents of BAL pots though separate 100 micron filters into 3 cold, 
labelled, 50ml falcons. 
2. Take 3ml of the whole BAL and place in the 3.5ml cryo-vial labelled WB.  
3. Place WB cryo-vials on ice prior to transfer to -80 
4. Pool rest of BAL, record volume (plus 3mls), divide into 3 cold 50ml 
Falcons. 
5. Spin the BAL at 2000rpm for 10 mins at 2-8 degrees (brake on). 
6. Divide supernatant between 3 50ml falcons labelled SN (supernatant).  
7. Remove ten 1ml aliquots of SN (supernatant) and place in cryo-vials 
labelled SN 
8. Place falcons and cryo-vials of SN on ice prior to transfer to -80 
9. Re-suspend the cell pellets in 1ml cool complete media, combine and 
make up to 10ml. 
10. Count cells using haemocytometer (10µl cells + 10µ trypan blue); count 
trypan stained cells. 
11. Pellet and re-suspend in warm CM @ 1x106 cells/ml 
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12. Take 100µL aliquot of cells into an eppendorf, add 150µl PBS/EDTA and 
run cyto-spin 
13. Take four x 100µL aliquots and place in the four epindorfs (V/7/V7/U) and 
add 500µl PBS. 
14. Pellet in micro-fuge (hinges out) at 450rcf for 4mins 
15. Meanwhile add 500µl cell suspension to 13 wells of the 48 well UpCell 
plate and label then place plate in incubator – note the time it goes into 
incubator 
16. Remove supernatant from eppendorfs, re-suspend in 500µl PBS and re-
pellet 
17. Repeat above then re-suspend in 100µl binding buffer to each 
18. Add 5µl annexin V APC and or 5µl 7aad to relevant samples  
19. Vortex and place in dark (room temp) for 15 mins 
20. Meanwhile open up flow database  
21. create new / disc D / dan wootton /databases /  name = “today’s date 
HAMs”)  
22. load protocol (file /protocol / load / disc D / dan wootton / protocols / 
fresh HAM apoptosis)  
23. add 400µl binding buffer then analyse 
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 Venesection 
1. Using a green needle with a monovette adaptor, 36 ml blood is drawn 
into 4 x 9ml EDTA monovettes (BD Vacutainer®, BD Becton 
Dickinson UK Limited, Oxford, UK) in endoscopy recovery post 
brochoscopy. 
2. The blood should then be used as soon as possible – within two hours. 
3. Allow blood to settle at 18-22 degrees (i.e. the time it takes to get it to the 
lab) 
4. If there is a likely delay in analysis then neutrophils are best left to wait as 
whole blood in the EDTA tube rather than being separated then waiting. 
 Neutrophil separation 
This protocol is derived and adapted from local protocols and with 
reference to the polymorph-prep manufacturers SOP.  Other than 
centrifugation, all aspects of this protocol are carried out in a class II 
bio-safety cabinet and, unless otherwise specified, all substrates and 
reagents are used at room temperature.  
 
Warm the ½ x Hepes Buffered Saline (Serum free IMDM, IMDM with 5% AB 
serum 
1. Place 9ml polymorphprep (used 1:1 with blood @ room temp) into each 
of four plain 20 ml universal tubes. 30ml, polystyrene, screw-top, 
universal containers - henceforth referred to as ‘universals’  
2. With a 10ml serological pipette, take blood from monovettes and layer 
over polymorphprep Spin @ 2000rpm for 35 mins, room temp, break off 
(takes 50 mins). 
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This was a slightly faster spin than some methods report and was 
optimised following our groups anecdotal finding that the blood of 
patients with symptoms suggesting active inflammation would fail to 
separate with lower rcf. 
3. Take neutrophil layer (down to the RBC layer) and add the cells from 2 
tubes to each falcon containing HBS (This step represents returning 
the neutrophils to physiological osmolality). 
4. Pellet cells by spinning at 2000 rpm at room temp. for 10 mins (brake on). 
5. Carefully remove supernatant from pelleted neutophils. 
6. Add 1ml lysis buffer) to each tube, combine and add another 4ml.  
7. Place on ice for 3 mins with a quick vortex every minute. 
8. Make up to 50ml with serum free IMDM and spin at 2000 rpm to pellet. 
9. Remove supernatant, re-suspend in 1ml serum free IMDM and make up 
to 10ml. 
10. Count with haemocytometer. 
11. Divide the 10ml of cell suspension between two falcons labelled stained 
and unstained.  Into the unstained falcon place the minimum volume of 
cell suspension to ensure there will be at least 10 million cells left after 
recovering from the culture flask. 
12. Make each falcon up to 20ml with IMDM and pellet.  
13. Take off supernatant from the cells in the tube labelled stained and re-
suspend cells in 5ml serum free IMDM  
14. Add 10µL DMSO to 50µg Cell Tracker ( = 10mM) 
15. Add the 10µL of Cell Tracker solution to the 5ml of cells (= 20µM) 
16. Incubate in the falcon for 15mins at 37 degrees 
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17. Meanwhile take off the supernatant from the unstained cells and re-
suspend in 1ml serum free IMDM then add 4 ml Serum free IMDM then 
add 35 ml IMDM with 5% serum – place in a labelled 75cm2 culture flask 
and transfer to the incubator. 
18. Add 35ml IMDM with 5% serum to the stained cells and count using a 
haemocytometer 
19. Take four appropriate 1x105 aliquots into four 1.5ml epindorfs labelled V, 
7, V7, U  
20. Add 500µL PBS to each epindorf and pellet at 450rcf in microfuge for 4 
mins 
21. Meanwhile take 1x105 cells for a cytospin. 
22. Transfer the remaining cell suspension in a 75cm2 culture flask and 
culture for 20 hours. 
23. Meanwhile wash the cells in the eppendorfs twice with 500µL PBS 
24. Resuspend in 100 µL 1x binding buffer 
25. Add 5 µL annexin V APC and 5µL 7AAD to the relevant tubes, vortex and 
place in dark for 15mins 
26. Meanwhile stain the cytospin  
24. Open flow database: create new / disc D / dan wootton /databases /  
name = “today’s date neuts” 
27. Load protocol: file /protocol/ load /disc D /dan wootton /protocols 
/neutrophils 
28. Add 400 µL 1x binding buffer to each epindorf and analyse on flow 
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SOP: Wednesday lab procedures. 
 
1. First make Crystal Violet Quenching Solution 
This is derived from the method published in: 
Hallden G et al.  Quhenching of intracellular autofluorescence in alveolar 
macrophages permits analysis of fluorochrome labelled surface antigens by flow 
cytometry.  Journal of Immunological Methods.  1991 142;207-214 
The idea is to create a super-saturated solution of crystal violet by heating and 
then to remove any precipitate that emerges on cooling by filtration. 
The solution should be created on the day of use as the crystal violet will 
precipitate out over time leaving the remaining solution in a less potent 
quenching state. 
1. Take a standard bijou and place on scales 
2. Zero scales and add approx 10mg crystal violet (Sigma-Aldrich 61135-25G) 
3. Add an appropriate volume of PBS to create a solution of 1mg/ml 
4. Place the bijou in a heated sonication bath set at 65 degrees 
5. Sonicate and heat until the crystal violet has completely dissolved 
6. Allow the solution to cool before use 
7. Just before use – pass through a filter 
2. Efferocytosis 
Warm serum free IMDM, warm IMDM with 10% AB serum 
 Harvest the neutrophil suspension from flask to a 50ml falcon (pipette up 
and down gently). 
 To remove more neutrophils from culture flask spray bottom with 10ml 
IMDM (no serum), remove and add to the falcon. 
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 Wash twice with 50ml warm (37 degrees) IMDM (no serum), 1500rpm 5 
mins – each time re-suspend in 1ml IMDM gently to avoid clumping the 
cells. 
 Count final suspension using haemocytometer. 
 Re-suspend at 5x106/mL in serum free IMDM. 
 Take four 20µL into four epindorfs labelled V/7/V7/U add 500µL PBS to 
each and spin at 450rcf in the microfuge for 4 mins 
 Take 20µL and place in cytospin with 180µL PBS EDTA and start  
 Meanwhile remove media from macrophages and rinse macrophages 
with 500µL warm IMDM (serum free) to remove non-adherent cells. 
 Add 0.5ml (2.5 x 106) neutrophils to each well of macrophages and 
incubate for 90 mins at 37 degrees. 
 Wash the cells in the epindorfs twice with 500µL PBS 
 Add 100µL 1x binding buffer to each  
 Add 5µL annexin V or 7AAD to each as appropriate and place in dark for 
15 mins 
 Stain cytospin 
25. Open flow database: create new / disc D / dan wootton /databases /  
name = “today’s date efferocytosis” 
 Take neutrophil suspension from each well of macrophages and wash 
twice with 1ml warm Ca Mg free HBSS 
 Add 500µL Ca Mg free HBSS and place plate on water ice for 15 mins. 
 Label  flow tubes 
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 Remove all the fluid from each well by forceful pipetting and transfer to 
1.5ml epindorfs 
 Pellet 
 Add 100 µL PBS to each epindorf 
 Add 100 µL crystal violet to each epindorf, vortex and after 30 seconds 
add 1ml PBS 
 Pellet and wash three times with 1ml PBS 
 Resuspend in 500µL PBS/BSA and analyse 
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10 APPENDIX 3: TOP 20 OTU TABLE 
The following pages contain counts for each of the top 20 (by 
abundance) OTUs for each sequenced PASS sputum sample. 
In the final column of the final table are the sums for each OTU in 
these 76 samples and these values are those used in figure 5.3 
A note on interpretation: the data presented in these tables are 
from the rarefied data-set (see 5.3.13.2).  That is, they do not 
represent the true number of reads of each OTU sequenced in 
each sample, but rather the number of reads that were obtained 
by using the softwear package Phyloseq to randomly choose 549 
(rarefaction level) reads from each sample.  Moreover, because 
only 20 OTUs (from a total of 774 OTUs) are displayed here 
extreme caution must be taken making comparisons between 
samples; for the reasons explained in 5.3.13.3 it would be 
statistically inadmissible to attempt meaningful inferences of 
relative abundance from these tables.
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OTU_name 1323.t1.s 9385.t1.s 7905.t1.s 3466.t1.s 7401.t1.s 5902.t1.s 1249.t1.s 4661.t1.s 9012.t1.s 9934.t1.s 
Lactobacillus_2187 32 0 0 0 0 0 0 0 0 0 
Prevotella_2758 2 37 7 4 1 1 0 2 1 1 
Aggregatibacter_3926 0 2 1 0 0 0 0 3 18 3 
Leptotrichia_2233 0 3 1 15 0 4 5 2 12 0 
Haemophilus_4739 4 0 0 8 65 0 1 20 39 35 
Prevotella_433 9 0 2 3 3 2 5 20 0 2 
Escherichia-shigella_1216 0 0 0 0 0 0 0 0 0 0 
Klebsiella_1954 0 0 0 0 0 0 0 0 0 0 
Moraxella_2510 0 0 20 0 0 0 0 0 0 0 
Pseudomonas_3976 0 0 0 0 0 0 0 0 0 0 
Granulicatella_740 0 0 1 3 3 2 55 45 7 14 
Neisseria_4683 1 37 18 18 2 0 1 3 56 22 
Prevotella_956 21 82 37 47 11 14 12 17 40 10 
Fusobacterium_1252 20 10 2 56 51 27 16 74 64 63 
Actinobacillus_419 9 39 38 0 0 46 0 74 34 4 
Streptococcus_1024 57 20 11 19 1 76 14 50 3 29 
Streptococcus_3600 131 2 6 108 17 16 3 0 3 1 
Streptococcus_4318 12 0 39 13 11 9 31 8 28 34 
Veillonella_1328 27 176 307 37 37 262 141 48 89 16 
Haemophilus_617 11 1 0 1 0 4 1 45 5 116 
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OTU_name 5031.t1.s 1197.t1.s 1673.t1.s 7094.t1.s 6056.t1.s 7646.t1.s 4462.t1.s 9571.t1.s 3107.tuk.s 5898.t1.s 
Lactobacillus_2187 0 0 0 0 1 0 65 0 4 0 
Prevotella_2758 0 3 2 5 3 0 0 71 0 41 
Aggregatibacter_3926 0 0 0 17 0 0 0 0 0 0 
Leptotrichia_2233 0 6 27 1 0 2 0 2 0 28 
Haemophilus_4739 0 0 0 20 0 0 0 45 0 0 
Prevotella_433 0 0 21 0 2 4 0 0 0 5 
Escherichia-shigella_1216 0 0 0 0 0 0 0 0 0 0 
Klebsiella_1954 0 0 0 0 0 0 0 0 0 0 
Moraxella_2510 528 6 0 0 0 0 2 0 0 0 
Pseudomonas_3976 0 0 0 0 0 0 0 2 0 0 
Granulicatella_740 0 1 1 0 0 1 0 42 0 0 
Neisseria_4683 0 0 182 35 123 0 0 1 0 0 
Prevotella_956 1 6 7 19 28 3 0 0 0 63 
Fusobacterium_1252 0 0 57 98 31 27 16 21 0 16 
Actinobacillus_419 0 0 0 0 0 0 0 78 0 10 
Streptococcus_1024 4 2 2 0 16 8 0 55 0 52 
Streptococcus_3600 0 5 2 5 17 38 158 18 7 0 
Streptococcus_4318 0 0 7 26 160 6 69 5 15 22 
Veillonella_1328 1 91 13 66 39 217 5 89 2 204 
Haemophilus_617 14 403 0 40 0 0 2 8 484 0 
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OTU_name 7290.t1.s 7556.t1.s 9969.t1.s 3556.t1.s 1387.t1.s 6636.t1.s 5621.t1.s 8163.t1.s 8228.t1.s 1603.t1.s 
Lactobacillus_2187 0 0 0 0 0 22 100 1 0 0 
Prevotella_2758 13 0 0 2 12 0 0 35 1 1 
Aggregatibacter_3926 0 5 0 0 20 1 0 0 1 115 
Leptotrichia_2233 3 18 0 32 3 0 0 5 0 2 
Haemophilus_4739 0 0 0 22 21 0 0 1 0 5 
Prevotella_433 14 18 23 3 0 26 0 4 1 0 
Escherichia-shigella_1216 0 0 0 0 0 0 0 0 0 0 
Klebsiella_1954 0 0 34 0 0 0 0 0 0 0 
Moraxella_2510 0 0 0 25 9 0 0 0 0 0 
Pseudomonas_3976 0 0 0 0 0 0 0 0 0 0 
Granulicatella_740 66 0 0 66 2 0 2 0 6 4 
Neisseria_4683 0 106 0 22 0 0 0 0 112 8 
Prevotella_956 47 6 1 3 0 1 0 57 22 16 
Fusobacterium_1252 114 7 0 7 0 4 0 13 176 43 
Actinobacillus_419 0 0 0 0 54 0 0 2 1 25 
Streptococcus_1024 20 112 3 18 83 0 111 29 5 5 
Streptococcus_3600 9 93 0 12 7 19 0 81 0 2 
Streptococcus_4318 2 5 38 75 142 275 16 6 17 2 
Veillonella_1328 2 9 197 40 35 42 145 131 95 23 
Haemophilus_617 0 5 46 3 82 1 1 2 0 102 
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OTU_name 2123.t1.s 8420.t1.s 6835.t1.s.A 7554.t1.s 6406.t1.s.A 4897.t1.s 0414.t1.s 5974.t1.s 5600.t1.s 2671.t1.s 
Lactobacillus_2187 0 0 0 0 0 0 0 0 0 0 
Prevotella_2758 2 4 4 0 0 3 0 5 0 0 
Aggregatibacter_3926 0 22 0 0 0 1 0 0 0 0 
Leptotrichia_2233 1 0 1 81 0 2 1 5 0 0 
Haemophilus_4739 0 13 0 0 0 4 3 2 0 0 
Prevotella_433 1 9 4 2 0 42 6 10 0 151 
Escherichia-shigella_1216 9 0 0 0 0 0 0 0 0 0 
Klebsiella_1954 0 0 0 0 0 0 0 1 0 0 
Moraxella_2510 0 0 0 0 0 0 0 0 0 0 
Pseudomonas_3976 0 0 0 0 499 0 1 0 0 0 
Granulicatella_740 3 10 0 0 0 3 6 58 0 48 
Neisseria_4683 0 1 0 0 0 6 33 0 0 0 
Prevotella_956 31 5 14 0 0 12 1 24 0 2 
Fusobacterium_1252 1 60 5 50 0 127 1 22 0 0 
Actinobacillus_419 61 25 0 0 0 0 0 80 0 0 
Streptococcus_1024 24 0 0 0 5 16 11 25 1 20 
Streptococcus_3600 44 5 1 3 34 0 2 8 0 13 
Streptococcus_4318 184 27 5 0 0 9 91 50 6 132 
Veillonella_1328 18 38 101 4 0 19 3 129 0 0 
Haemophilus_617 0 0 380 215 0 0 358 1 539 0 
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OTU_name 3149.t1.s 9120.t1.s 2738.t1.s 9219.t1.s 6874.t1.s 9622.t1.s 3371.t1.s.A 9988.t1.s 1571.t1.s 1172.t1.s 
Lactobacillus_2187 0 0 0 44 16 0 0 0 0 0 
Prevotella_2758 1 0 0 0 0 2 0 5 0 0 
Aggregatibacter_3926 0 0 0 0 0 0 0 0 0 0 
Leptotrichia_2233 0 0 0 0 0 1 0 16 0 0 
Haemophilus_4739 0 0 0 0 0 0 0 6 0 1 
Prevotella_433 0 1 0 0 0 3 47 1 0 0 
Escherichia-shigella_1216 0 0 0 2 2 0 0 7 0 0 
Klebsiella_1954 0 0 0 10 0 399 0 0 0 0 
Moraxella_2510 0 1 0 1 0 0 1 0 40 0 
Pseudomonas_3976 0 0 0 0 0 0 0 0 0 216 
Granulicatella_740 0 0 4 11 1 0 0 20 17 0 
Neisseria_4683 0 0 0 0 0 0 0 0 9 0 
Prevotella_956 1 0 0 27 13 1 27 117 0 0 
Fusobacterium_1252 0 0 0 0 1 33 23 0 0 0 
Actinobacillus_419 0 0 0 0 0 0 133 1 217 0 
Streptococcus_1024 4 0 6 1 0 0 4 148 1 0 
Streptococcus_3600 0 0 7 130 229 1 2 8 1 0 
Streptococcus_4318 199 72 4 15 145 0 139 28 175 329 
Veillonella_1328 2 2 17 119 96 1 27 66 0 0 
Haemophilus_617 334 464 500 3 0 2 52 1 36 0 
 
  
     256 
 
OTU_name 5432.t1.s 0001.t1.s 6257.t1.s 8902.t1.s 5318.t1.s 5813.t1.s 8305.t1.s 5316.t1.s 2780.t1.s 6016.t1s 
Lactobacillus_2187 0 1 0 0 0 2 0 8 0 0 
Prevotella_2758 7 3 0 2 29 19 2 9 0 0 
Aggregatibacter_3926 8 0 0 26 0 0 0 0 2 0 
Leptotrichia_2233 0 0 0 19 17 15 0 3 2 5 
Haemophilus_4739 0 0 0 9 3 1 40 0 19 0 
Prevotella_433 4 20 0 0 2 3 2 0 0 0 
Escherichia-shigella_1216 0 3 0 0 0 0 1 0 0 0 
Klebsiella_1954 0 0 0 0 0 0 0 0 0 0 
Moraxella_2510 0 0 0 0 0 0 0 0 19 0 
Pseudomonas_3976 0 0 0 0 0 0 0 0 0 0 
Granulicatella_740 0 0 0 18 1 1 66 0 54 0 
Neisseria_4683 27 0 0 5 42 8 1 13 46 22 
Prevotella_956 66 0 0 7 145 71 3 55 2 0 
Fusobacterium_1252 16 11 2 22 5 1 6 0 0 0 
Actinobacillus_419 0 0 0 9 3 0 258 0 0 0 
Streptococcus_1024 127 2 3 41 3 14 3 58 41 9 
Streptococcus_3600 2 1 1 0 12 23 0 47 14 15 
Streptococcus_4318 5 9 0 193 2 7 103 90 100 137 
Veillonella_1328 55 38 1 111 167 209 2 56 39 18 
Haemophilus_617 13 396 513 3 22 2 1 0 13 324 
 
  
     257 
 
OTU_name 1664.t1.s 5700.t1.s 3925.t1.s 4238.t1.s 0657.t1.s 3824.t1.s 4254.t1.s 8560.t1.s 6076.t1.s 1913.t1.s 
Lactobacillus_2187 0 1 7 0 0 0 37 0 0 0 
Prevotella_2758 0 0 0 0 0 1 0 0 1 0 
Aggregatibacter_3926 0 0 0 0 0 0 0 0 0 2 
Leptotrichia_2233 0 0 0 0 0 0 0 1 5 35 
Haemophilus_4739 0 0 31 0 0 0 0 6 0 2 
Prevotella_433 0 20 0 0 0 2 11 0 0 0 
Escherichia-shigella_1216 428 0 0 34 0 0 25 0 0 0 
Klebsiella_1954 1 0 0 5 0 0 50 0 0 0 
Moraxella_2510 0 0 3 0 0 4 0 0 0 0 
Pseudomonas_3976 0 0 0 0 0 0 0 0 0 0 
Granulicatella_740 58 36 0 3 49 8 0 0 0 1 
Neisseria_4683 0 2 0 49 64 0 0 0 1 61 
Prevotella_956 0 1 0 1 24 74 0 0 0 0 
Fusobacterium_1252 0 4 0 0 1 1 66 0 0 5 
Actinobacillus_419 0 0 0 0 106 0 0 5 0 13 
Streptococcus_1024 0 10 90 8 177 0 0 0 76 19 
Streptococcus_3600 26 26 140 73 2 223 1 8 396 0 
Streptococcus_4318 0 0 32 3 26 10 2 1 0 84 
Veillonella_1328 20 17 51 0 56 185 4 114 1 107 
Haemophilus_617 0 331 155 362 0 3 0 394 38 56 
 
  
     258 
 
OTU_name 1357.t1.s 4454.t1.s 1420.t1.s 5276.t1.s 8041.t1.s 6867.tuk.s Row_sum 
Lactobacillus_2187 0 1 0 0 0 0 272 
Prevotella_2758 0 0 0 4 0 0 223 
Aggregatibacter_3926 0 0 5 3 0 113 351 
Leptotrichia_2233 0 0 2 5 2 0 324 
Haemophilus_4739 0 0 17 0 0 0 378 
Prevotella_433 0 0 0 0 0 0 476 
Escherichia-shigella_1216 0 0 0 0 1 0 512 
Klebsiella_1954 0 0 0 0 0 93 593 
Moraxella_2510 0 1 0 0 0 0 124 
Pseudomonas_3976 0 0 0 0 0 4 720 
Granulicatella_740 0 0 32 1 0 2 787 
Neisseria_4683 0 0 22 0 1 0 819 
Prevotella_956 0 0 31 1 5 0 1205 
Fusobacterium_1252 0 0 0 9 2 0 1221 
Actinobacillus_419 0 0 169 0 0 1 1407 
Streptococcus_1024 0 0 10 20 6 19 1668 
Streptococcus_3600 0 4 38 0 0 0 2050 
Streptococcus_4318 0 0 56 15 58 14 3320 
Veillonella_1328 0 2 34 6 3 0 3797 
Haemophilus_617 547 541 0 0 461 0 7486 
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